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Abstract 
EphB4 is a member of the largest family of receptor tyrosine kinases, the Eph 
receptors. These receptors are involved in many developmental processes (neural and 
cardiac) and tumour biology.  The sole ligand for EphB4 is ephrin-B2, itself one of a 
family of cell surface-tethered ephrin ligands that normally interact with their Eph 
receptors from a neighbouring cell.  In a manner unique to the Eph receptor tyrosine 
kinases and their ephrin ligands, interaction propagates signals into both the receptor 
expressing and the ligand expressing cells in a process called bidirectional signalling 
– forward into the receptor expressing cell and reverse into the cell that expresses the 
ligand. 
EphB4 is increased in many cancers of epithelial and haematological origin and 
has diverse roles in tumour initiation and progression. In prostate cancer (PCa), EphB4 
is over-expressed in 66% of prostate cancer clinical samples where it contributes to 
increased tumour cell growth, migration and invasion. Interestingly, EphB4 is poorly 
phosphorylated in cancer cells and cancer cells often express little to no ligand 
suggesting that tumour promoting EphB4 signalling pathways are independent of 
interaction with its ligand ephrin-B2.  Indeed acute stimulation of over-expressed 
EphB4 with excess soluble ligand activates ligand-dependent signalling pathways 
linked to tumour suppression.  
Recent data suggests the cellular responses to EphB4-ephrin-B2 interactions are 
cell-type specific.  For example, activation of ephrin-B2 expressed on endothelial cells 
with either soluble recombinant human EphB4 ectodomain or from cancer cells 
expressing an EphB4 mutant protein incapable of forward signalling correlates with 
increased tumour angiogenesis.  This would suggest that a mechanism that facilitates 
both ligand-independent forward signalling of the EphB4 in the cancer cell and the 
receptor-mediated activation of reverse signalling through the ligand on endothelial 
cells might contribute to tumourigenesis.  Several groups have now identified Eph 
receptors as substrates for various cancer-associated proteases and prior to the 
commencement of this project another research project that was developing an in silico 
screening technique to identify  substrates of the PCa-associated serine protease 
Kallikrein-related peptidase 4 (KLK4) identified murine ephrin-B2 as a possible 
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substrate of KLK4.  This led to the hypothesis of this study - that protease regulation 
of EphB4-ephrin-B2 interaction is required for their tumour promoting functions and 
human KLK4 was used as a model protease in the research aims designed to explore 
this.  These research aims included 1) using recombinant proteins to determine whether 
KLK4 could in fact cleave ephrin-B2 – both murine and human, 2) determining 
whether EphB4 was also a target for KLK4 and other proteases in the prostate cancer 
cell,  and 3) determining the consequences of KLK4 cleavage and release of a 
potentially biologically active intracellular fragment.  The potential release of an 
extracellular fragment was not explored here but is also potentially biologically 
relevant.  
The first research chapter describes experiments that confirm recombinant 
murine ephrin-B2 can be cleaved by recombinant human KLK4 and N-terminal 
sequencing then confirmed an in silico-predicted KLK4 cleavage site was present in 
the extracellular domain between residues arginine 178 and asparagine 179. 
Interestingly, similar experiments using recombinant human ephrin-B2 protein 
showed that human ephrin-B2 was cleaved less efficiently than murine ephrin-B2 and 
this was proposed to be due to amino acid differences at the corresponding primary 
cleavage site. Cleavage of ephrin-B2 proteins were also tested using the closely related 
Kallikrein protease members (KLK2 and KLK3/PSA) but these were clearly less 
efficient at cleaving ephrin-B2. A consideration from these observations is that as 
murine ephrin-B2 is a substrate of human KLK4, with human ephrin-B2 being less so, 
and this could impact the responses that are elicited from their interactions in in vivo 
mouse xenograft models where human prostate cancer cells that secrete human KLK4 
would interact with stromal mouse ephrin-B2 and potentially stimulate signalling 
pathways that are different to those in a human clinical setting where human ephrin-
B2 is not cleaved as efficiently. 
In the second research chapter in this study, the proteolysis of EphB4 as a means 
of regulating the EphB4-ephrin-B2 interaction was explored. Our laboratory has 
developed an overexpression model to study EphB4 in PCa using the cell line 22Rv1 
(22Rv1-B4) and identified the presence of novel EphB4 fragments. Using EphB4-
specific antibodies directed to either the C- or N-terminus of the protein we predicted 
these were the result of sequential specific proteolytic cleavage events releasing both 
an extracellular fragment (ECD – 70 kDa) and then as a consequence an intracellular 
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fragment (ICD – 47 kDa) was generated from the remaining 50 kDa intracellular 
fragment. The presence of different cleavage fragments present in prostate cancer cell 
lines that endogenously over-express EphB4 suggest that there might be several 
proteases that can target and cleave EphB4 but it was determined that KLK4 could 
mediate the first cleavage event and this was therefore used as a model protease to 
explore the consequences of protease cleavage of EphB4 in more detail.  The primary 
cleavage site targeted by KLK4 in EphB4 was determined by N-terminal sequencing 
to be in the extracellular domain (after R508), consistent with the identified fragments 
(70 and 50 kDa). The second fragment of 47 kDa was lost upon γ-secretase inhibition 
suggesting that the production of the 47 kDa ICD was due to the action of this 
intramembrane protease. The ICD fragment was not sent to the proteasome therefore 
might have a function in PCa. From this work, it was concluded that EphB4 is a 
substrate for protease cleavage in prostate cancer cells, the first time this has been 
reported, and that cleavage of the extracellular domain using proteases like KLK4 
leads to a second cleavage event that generates an intracellular fragment that might 
have a biological function that contributes to PCa. 
The aim of the final research chapter was to determine the function of the 
protease released ICD fragment in PCa.  Subcellular fractionation of the KLK4-
positive PCa cell line LNCaP and KLK4 treated 22Rv1-B4 cells identified the ICD in 
different compartments within the cells including the nucleus suggestive of a potential 
function in the regulation of gene expression. Inhibition of importins using a specific 
inhibitor prevented nuclear localisation and confirmed the nuclear localisation 
sequence within this fragment retained its function. Over-expression of the 
intracellular fragment in DU145 and PC3 cells resulted in changes to the cellular 
morphology of these cells.  PC3 cells over-expressing the ICD were found to have a 
higher migratory and proliferative capacity and although the DU145-ICD cells also 
had a higher migratory capacity, proliferation of these cells was not increased by ICD 
over-expression. Markers of epithelial to mesenchymal plasticity were explored by 
qRT-PCR due to the changed cellular morphology of these cells. DU145-ICD cells 
appeared more mesenchymal and lost CHD1 expression compared to parental cells, 
although a reduction in the levels of the CHD1 transcriptional regulators SNAI1and 
SNAI2 would suggest that this is not a classical EMT response.  PC3-ICD cells had 
increased CHD1 and lower levels of SNAI1 and SNAI2 which might suggest these cells 
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could be in an amoeboid transition of undergoing MET. Interestingly, over-expression 
of the ICD fragment in both cell lines increased expression LEF1, a transcription factor 
that has been linked to androgen-independent prostate cancer. This further supports a 
hypothesis of a link between the production of the ICD EphB4 fragment and prostate 
cancer progression and this should be explored further using clinical prostate cancer 
samples. 
These studies provide the first evidence of proteolytic regulation of EphB4 in 
PCa whereby the PCa-associated protease KLK4 cleaves the ectodomain of EphB4 
leading to a subsequent second intracellular cleavage by γ-secretase, releasing a 
potentially bioactive nuclear fragment. Understanding the functions of the released 
EphB4 fragments will determine whether the development of strategies for inhibition 
of proteolysis and/or nuclear translocation may prove to be a potential novel avenue 
for anti-cancer therapies. 
In summary, both EphB4 and ephrin-B2 can be cleaved by the prostate cancer 
associated protease, KLK4 and this may regulate the interaction between them to elicit 
differing biological responses which could contribute to the initiation or progression 
of prostate cancer.   
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1.1 BACKGROUND 
Globally, Australia and New Zealand have the highest estimated incidence of cancer with 
the age-standardized rate of 366 people per 100,000 (Ferlay et al., 2015). This alarming statistic 
is mainly due to the improved detection of prostate cancer (PCa), which now comprises over a 
third of the above incidence rate when compared with the diagnosis of other cancers (Ferlay et 
al., 2015). Recent Australian statistics show that PCa is the most commonly diagnosed cancer 
in men and the main reason for these statistics is the advent of prostate specific antigen (PSA) 
testing (AIHW, 2014). PSA is a serine protease produced normally in the prostate and 
compartmentalised to the glandular system.  When the tissue architecture of the prostate is 
disrupted as cancers develop and invade, PSA can leak into the blood stream where it is 
identified (Fuhrman-Luck et al., 2014). Measuring PSA however, is not a diagnostic test for 
prostate cancer and a diagnosis of the disease is only after a biopsy of the prostate tissue is 
examined histologically (Fine et al., 2012). Also, the PSA test isn’t particularly sensitive or 
specific enough to detect all clinically relevant PCa and PSA screening often leads to the biopsy 
and treatment of clinically insignificant tumours which will not be the primary cause of death 
in the patient (Heidenreich et al., 2011; Vickers et al., 2009; Wilt et al., 2013). Although PCa 
has a five-year survival rate approaching 100 % when the disease is localized to the prostate, 
late-stage metastatic disease that has spread to other organs including bone has limited 
treatment options and is the main cause of mortality (AIHW, 2014; De Bono et al., 2011; Xue 
et al., 2012). Clinically significant aggressive prostate cancer is currently one of leading causes 
of death from cancer for males in Australia (AIHW, 2014). Therefore, it is critical that new 
options for treatment are developed that can help these patients. Before we can do this 
effectively, we need to understand the molecular mechanisms, which regulate the progression 
from localised to metastatic disease. 
The largest family of receptor tyrosine kinases (RTKs) are the Eph receptors (EphR) with 
14 human members that, together with their ligands the ephrins, play important roles in 
cell/tissue boundary formation during embryonic development (Cayuso et al., 2015). The Eph 
family is further divided into two classes - the EphA subclass with nine members and the EphB 
subclass with 5 members, based on sequence homologies and specificities of ligand 
interactions. The ephrin ligands are also divided into two subclasses with 6 ephrin-A members 
and 3 ephrin-B members (Pasquale, 1997). Interestingly, and unlike other ligands for receptor 
tyrosine kinases that are soluble growth factors, the ephrin ligands are membrane bound to the 
outside surface of the expressing cells, with the ephrin-As attached via a glycosylphosphatidyl-
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inositol (GPI) linker and the ephrin-Bs anchored by a single, hydrophobic transmembrane 
domain. As both receptor and ligand are membrane bound, for signalling to occur 2 cells (one 
expressing the receptor and one expressing the ligand) must interact closely and this leads to 
signal propagation in both cell populations (Pasquale, 2008). This is called bidirectional 
signalling – forward into the receptor-expressing cell and reverse into the ligand-expressing 
cell. The consequences of Eph-ephrin interactions and bidirectional signalling include 
regulation of cellular morphology, migration, adhesion and repulsion processes that are also 
important to the initiation and progression of cancer (Pasquale, 2010).  
EphB4 is a member of the Eph family and is often over-expressed in many epithelial 
cancers including PCa (Alam et al., 2008; Ferguson et al., 2014; Hasina et al., 2013; Hasina et 
al., 2012; Kumar et al., 2007; Kumar et al., 2006; Lee et al., 2005; Stephenson et al., 2001; 
Tan et al., 2011; Xia et al., 2005a). EphB4 has been shown to have various roles in cancer both 
in vitro and in vivo such as in the initiation of tumours from precancerous lesions, driving 
tumour growth, migration and invasion as well as helping tumour cells to metastasise to other 
sites (Ferguson et al., 2014; Héroult et al., 2010; Lee et al., 2005; Liersch‐Löhn et al., 2015; 
Liu et al., 2013b; Noren et al., 2004). Therefore, it has the potential to be a druggable target 
with agents that block EphB4 in cancer such as kinase inhibitors, monoclonal antibodies and 
soluble proteins currently being developed (Dimasi et al., 2015; Kertesz et al., 2006; 
Stephenson et al., 2015; Werner et al., 2015; Yang-Kolodji et al., 2014). There is growing 
evidence however that kinase activity of EphB4 is tumour suppressive and therefore kinase 
inhibitors may not be effective against EphB4 (Herington et al., 2014; Noren et al., 2007; 
Rutkowski et al., 2012). EphB4 has been shown to be involved in tumourigenesis, however 
some conflicting data suggests that EphB4 can be a tumour suppressor and is down-regulated 
in some cancers (Chen et al., 2008; Noren et al., 2007). Our laboratory has reconciled this 
conflicting data by showing that EphB4 has a dual function in both tumour promotion and 
tumour suppression that is regulated by receptor over-expression and the absence (tumour 
promotion) or presence (tumour suppression) of ephrin-B2 (Rutkowski et al., 2012). In a model 
of PCa, overexpression of EphB4 led to tumourigenesis however, treatment with soluble 
ephrin-B2-Fc protein, which induced receptor signalling resulted in tumour suppression 
(Rutkowski et al., 2012). It is still not well understood how forward signalling of EphB4 
regulates these opposing roles in cancer and more research is needed to clarify the differences 
between tumour promoting ligand-independent signalling and tumour suppressive ligand-
dependent signalling. 
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It will also be important to understand reverse signalling through the EphB4 ligand 
ephrin-B2. Ephrin-B2 is the sole physiologically relevant ephrin ligand of EphB4 and normally 
their interaction regulates how the vascular system develops through positioning of endothelial 
cells (Gale et al., 2001; Gerety et al., 1999; Wang et al., 1998). Experiments where either 
Ephb4 or Efnb2 are knocked out in mice result in phenocopied abnormalities in vasculogenesis, 
cardiac morphogenesis and embryonic lethality (Adams et al., 1999; Gerety et al., 1999). 
Further studies have also determined that ephrin-B2 is an important mediator of angiogenesis, 
and activation of reverse signalling with soluble EphB4 ectodomain correlated with endothelial 
cell proliferation and vascular remodelling (Wang et al., 1998). Angiogenesis is an important 
hallmark of tumour development and ephrin-B2 could be contributing to cancer through its 
roles in angiogenesis and might be a useful target for anti-angiogenic therapies (Holopainen et 
al., 2011; Sawamiphak et al., 2010).  
Important to understanding the contribution of both EphB4 forward signalling and 
ephrin-B2 reverse signalling to prostate cancer will be clarification of how the interaction 
between these two binding partners is regulated.  It has been shown that in many normal cells, 
and particularly during tissue boundary formation in embryogenesis, the interaction between 
Eph receptors and ephrin ligand results in repulsion of the two cells and the high affinity 
interaction must be broken.  There are many mechanisms that can do this including activation 
of proteases that target either the receptor or the ligand.  Several proteases are altered in prostate 
cancer tissues, PSA itself is a serine protease, and the aim of the research described in this 
thesis is to explore the contribution of protease cleavage of EphB4 and ephrin-B2 to prostate 
cancer promotion and therefore whether this might identify new options for targeted therapies.  
1.2 CONTEXT  
PCa is the most commonly diagnosed cancer in men in Australia and if we are to 
effectively treat this disease we must understand the important processes that lead to its 
development and progression in more detail. EphB4 and ephrin-B2 are both implicated in 
prostate cancer initiation and tumour angiogenesis and are therefore potential targets for the 
development of novel anti-prostate cancer therapeutics. Preliminary data has shown that EphB4 
can be proteolytically cleaved by a prostate cancer associated serine protease Kallikrein 
Related Peptidase 4 (KLK4) and this may be an important process that contributes to the 
regulation of EphB4-ephrin-B2 interactions and their cancer promoting functions.  
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1.3 RESEARCH HYPOTHESIS AND AIMS  
Hypotheses:  
The hypothesis of this study is that protease regulation of EphB4-ephrin-B2 interactions 
is required for their tumour promoting functions. 
To test this hypothesis the overall aim of the study was to use KLK4 to proteolytically 
cleave both ephrin-B2 and EphB4, using recombinant and prostate cancer cell-expressed 
proteins, and determine the consequences of this for prostate cancer cell growth and migration 
in vitro.  
Specific aims included- 
1. Using recombinant proteins to determine whether KLK4 can cleave ephrin-B2. 
2. Investigating protease regulation of EphB4 exogenously and endogenously expressed 
by PCa cell lines. 
3. Determining the consequences of KLK4 cleavage of EphB4 expressed on the surface 
of PCa cells and in particular the release of a biologically functional intracellular 
fragment. 
1.4 SIGNIFICANCE  
Significant data links the function of EphB4 and ephrin-B2 to prostate cancer. How this 
interaction is regulated to allow ligand-independent signalling of EphB4 that is tumour 
promoting whilst at the same time stimulating ephrin-B2 reverse signalling that contributes to 
tumour angiogenesis is not clear.  It is expected that protease activity plays a key role. 
Understanding these processes is likely to identify new options for the development of anti-
prostate cancer therapies for example by inhibiting the protease activity, by blocking ephrin-
B2 signalling events and by activating ligand-dependent EphB4 signalling. This thesis provides 
novel data adding to our knowledge of the molecular mechanisms that drive PCa and our search 
for options that will lead to treatments that prolong the overall survival of PCa patients.  
1.5 THESIS OUTLINE 
Chapter 1: General Introduction 
This Chapter introduces prostate cancer as a clinical problem in Australia and introduces 
two key proteins that are important in the development of prostate cancer, the receptor tyrosine 
kinase EphB4 and its ligand ephrin-B2.  This work is to explore the role of protease regulation 
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of these two proteins and to understand the consequences of this to prostate cancer 
development. The hypothesis and aims of the study are outlined and the clinical significance 
for prostate cancer explained. 
Chapter 2: Published literature review and up to date literature review 
Chapter 2 contains a literature review that was published by Biochimica et Biophysica 
Acta (BBA)-Reviews on Cancer in the first year of my candidature.  
Lisle, J. E., Mertens-Walker, I., Rutkowski, R., Herington, A. C., & Stephenson, 
S.-A. (2013). Eph receptors and their ligands: promising molecular biomarkers 
and therapeutic targets in prostate cancer. Biochimica et Biophysica Acta (BBA)-
Reviews on Cancer, 1835(2), 243-257. 
 
More recent data concerning EphB4 in cancer and prostate cancer has been added to this 
Chapter and a review of ephrin-B2 in cancer is also included. 
Chapter 3: Studies exploring ephrin B2 cleavage by the serine protease Kallikrein-4 
 
Chapter 3 details biochemical experiments that show ephrin-B2 can be cleaved by KLK4 
and this work was published in Experimental Cell Research. 
 
Lisle, J. E., Mertens-Walker, I., Stephens, C. R., Stansfield, S. H., Clements, J. A., Herington, 
A. C., & Stephenson, S. A. (2015). Murine, but not human, ephrin-B2 can be efficiently cleaved 
by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer. 
Experimental cell research, 333(1), 136-146. 
 
Chapter 4: Kallikrein-related Peptidase 4 Initiates Cleavage of the Tumour-promoting 
Receptor Tyrosine Kinase, EphB4, at the Surface of Prostate Cancer Cells 
Preliminary data from my Honours work identified cleavage of EphB4 in a prostate 
cancer over-expression model.  This chapter explores prostate cancer-related protease cleavage 
of EphB4 using several PCa cell lines that express EphB4 both endogenously and exogenously. 
Biochemical assays using recombinant EphB4 and KLK4 proteins show that EphB4 may be a 
substrate for KLK4 in the prostate cancer setting.  N-terminal sequencing was used to map the 
cleavage site to the extracellular domain, and this matched the predicted consensus sequence 
for KLK4.  A second cleavage event that followed after KLK4 cleavage was also studied and 
attributed to the action of -secretase. (This work is under preparation for journal submission) 
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Chapter 5: Localisation and functions of the intracellular domain fragment of EphB4 in 
prostate cancer 
KLK4 cleavage removes the extracellular domain of EphB4 but leaves the C-terminal 
intracellular fragment retained in the membrane. This fragment is further cleaved by -
secretase, which releases most of the intracellular part of EphB4 into the cytosol.  This chapter 
describes experiments that sought to determine the potential function of this intracellular 
fragment (ICD) using exogenous over-expression in two prostate cancer cell lines and 
characterisation of these using various in vitro cell behaviour assays.  (This work is under 
preparation for journal submission) 
Chapter 6: Conclusions and Future Directions 
In this chapter, the results of each of the three studies will be described and are explained 
in the context of prostate cancer and future experiments that will help clarify the importance of 
protease activity in the regulation of the EphB4-ephrin-B2 interaction In addition, potential 
roles and experiments to test a possible function for the released extracellular fragment, which 
was not explored here, will be outlined. 
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2.1 GENERAL INTRODUCTION 
In 2013, I published a review entitled “Eph receptors and their ligands: promising 
molecular biomarkers and therapeutic targets in prostate cancer” in Biochimica et Biophysica 
Acta (BBA) - Reviews on Cancer as first author with co-authorship from several members of 
the Eph Receptor biology group, Cancer Research program, QUT.  This review describes how 
Eph Receptors and their ligands, ephrins are often implicated in both the initiation and 
progression of prostate cancer and because of this may find future application as both 
diagnostic and prognostic biomarkers for prostate cancer. It also reviews the literature reporting 
that Eph receptors are often found in circulating tumour cells and exosomes, which due to ease 
of isolation, are showing promise in the biomarker field. This review also describes the 
significant collection of experiments that demonstrate how to effectively target Eph receptors 
in new anti-cancer therapies for the treatment of prostate cancer.  
2.1.1 The Prostate  
Located below the bladder and surrounding the urethra, the prostate is a walnut sized 
organ that is involved in the secretion of fluids during ejaculation which support the viability 
and motility of sperm (Kumar et al., 1995). It is comprised of four zones; the peripheral zone, 
central zone, transition zone, and the anterior fibromuscular stroma (Figure 2.5) (McLaughlin 
et al., 2005). The transition zone surrounds the urethra whilst the central zone envelopes the 
ejaculatory ducts. The top anterior of the prostate contains the anterior fibromuscular stroma, 
a region of stroma with no glandular tissue (McLaughlin et al., 2005). The peripheral zone 
makes up more than 70% of the glandular architecture of the prostate and surrounds the central 
and transition zones of the prostate (McLaughlin et al., 2005). This is the zone where most 
prostate cancers arise (McNeal et al., 1988). 
2.1.2 Prostate Cancer Prevalence in Australia  
Prostate cancer (PCa) remains the most commonly diagnosed male cancer and in 
Australia and according to predictions there is expected to be an estimated 17,050 new cases 
this year alone (AIHW, 2014). Ninety-three percent of men with this disease will survive 5 
years after diagnosis as this cancer is often caught relatively early due to PCa screening 
programs in Australia (AIHW, 2014). However, approximately 3,390 Australian men will still 
die from the advanced stages of this disease, with PCa having the 2nd highest mortality rate for 
cancers in males (AIHW, 2014). Diagnosis and treatment of prostate cancer imposes a 
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significant burden on our health system (Roehrborn et al., 2011). This highlights a significant 
and complex health problem that will only get worse with an ageing population. 
 
 
 
 
 
 
Figure 2-1: Diagrammatic depiction of the prostate.  
The anterior fibromuscular stroma is shown in purple. The central zone which surrounds the 
ejaculatory ducts is shown here in blue whilst the transitional zone which envelopes the urethra 
is the green shape. The peripheral zone depicted with yellow is where most prostate cancers 
occur. Derived from (De Marzo et al., 2007).  
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2.1.3 Progression of Prostate Cancer  
Prostate cancer arises when the epithelial cells lining the glandular tissue of the prostate 
become unresponsive to growth arrest or apoptotic signals and normal cellular processes are 
subverted (Ricke et al., 2012). At this early stage, the cells are dependent on androgens for 
growth, are confined to the prostate and can be treated effectively by first line options such as 
androgen-deprivation therapy and/or radical prostatectomy (Feng et al., 2013; Warde et al., 
2012; Wilt et al., 2012). 
As the disease progresses the tumour epithelial cells lose their reliance on androgens for 
growth (described as androgen independence or castrate resistant prostate cancer), and further 
transform through the gain of several genetic alterations targeting subsets of tumour suppressor 
genes and oncogenes that allows the tumour cells to spread outside the prostate (metastasize) 
and form secondary tumours in other tissues including the bone, lung and brain (Grasso et al., 
2012). At this stage, the disease is incurable and existing treatments are ineffective and mainly 
palliative. Therefore, it is essential to both discover new targets for the development of novel 
therapies, particularly for treatment of advanced stages of PCa, and to determine which patients 
have a poorer prognosis and will need to be more aggressively treated.  
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2.2  PUBLISHED LITERATURE REVIEW 
Keywords: Eph receptors, ephrin ligands, prostate cancer, biomarkers, therapeutic targets, 
exosomes 
2.2.1 Abstract 
Although at present, there is a high incidence of prostate cancer, particularly in the 
Western world, mortality from this disease is declining and occurs primarily only from 
clinically significant late stage tumours with a poor prognosis. A major current focus of this 
field is the identification of new biomarkers which can detect earlier, and more effectively, 
clinically significant tumours from those deemed “low risk”, as well as predict the prognostic 
course of a particular cancer. This strategy can in turn offer novel avenues for targeted 
therapies. The large family of Receptor Tyrosine Kinases, the Ephs, and their binding partners, 
the ephrins, have been implicated in many cancers of epithelial origin through stimulation of 
oncogenic transformation, tumour angiogenesis, and promotion of increased cell survival, 
invasion and migration. They also show promise as both biomarkers of diagnostic and 
prognostic value and as targeted therapies in cancer. This review will briefly discuss the 
complex roles and biological mechanisms of action of these receptors and ligands and, with 
regard to prostate cancer, highlight their potential as biomarkers for both diagnosis and 
prognosis, their application as imaging agents, and current approaches to assessing them as 
therapeutic targets. This review demonstrates the need for future studies into those particular 
family members that will prove helpful in understanding the biology and potential as targets 
for treatment of prostate cancer.  
2.2.2 Introduction 
Oncogenesis is established when normal cellular processes such as cell growth, 
movement, metabolism and apoptosis are corrupted (Hanahan et al., 2011). These changes in 
cellular biology are often used as biological indicators of cancer. It is only in recent years that 
the measurable markers of these changes, termed biomarkers, have been used to provide 
diagnostic or prognostic information valuable in the improvement of detection, monitoring and 
treatment of tumours (Reed et al., 2010).  
Prostate cancer (PCa) remains the most common cancer of Western males. Currently, 
worldwide, there is a decreasing trend in mortality for those with PCa (Jemal et al., 2011). This 
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may be due to better screening of those at risk with diagnostic markers such as prostate Specific 
Antigen (PSA).  However, there is much controversy in the field as to whether this has led to 
the over-diagnosis of indolent cancers which will not be the primary cause of mortality of those 
with this disease (Barry, 2009). Mortality has also declined due to better treatment options for 
those with localized disease. However, there are significant adverse effects associated with 
these treatments such as erectile, bowel and urinary dysfunction (Jemal et al., 2011). Therefore, 
there is a requirement for better clinical tools that are able to circumvent unnecessary medical 
intervention for tumours that are better suited to an "active surveillance" strategy (Singer et al., 
2012).  
Conversely, there are few prognostic markers that are able to selectively predict clinically 
significant tumours with a poor prognosis (Kristiansen, 2012). These malignancies are more 
likely to progress and lead to mortality and will need to be treated more assertively (Reed et 
al., 2010). However, existing treatments for the advanced stages of the disease are often not 
effective, with treatment options primarily being palliative and rarely affecting a cure when the 
disease progresses and becomes castration resistant or when metastasis, often to the bone, 
occurs (Siegel et al., 2012). Thus, it is critical to identify and to treat earlier those patients who 
are at risk of these more aggressive cancers. 
The inherent complexities in the prediction of the course of a particular prostate tumour 
are compounded by the current lack of knowledge of the cellular mechanisms that determine 
its progression. A family of proteins termed the Eph receptors and their ligands, the ephrins, 
have been shown to be dysregulated and required for the establishment and progression of 
many different cancers (see reviews (Herath et al., 2010; Kaenel et al., 2012; Li et al., 2012)). 
They also show promise as biomarkers in many cancers, both in diagnosis and determining the 
prognosis for a particular tumour. This review will discuss this unique family of receptors and 
ligands and demonstrate their potential attractiveness as both molecular biomarkers and 
targeted therapeutics for PCa. 
2.2.3 Eph Receptors and Ephrin Ligands: 
2.2.3.1 Family members and nomenclature 
The Eph receptors are the largest family of Receptor Tyrosine Kinases (RTKs) and 
include 14 human type 1 transmembrane protein members (Eph, 1997; Pasquale, 1997) (Figure 
2.1: A and B). They are divided into two subgroups designated EphA and EphB based on both 
sequence homologies and their ability to bind their ligands, the ephrins (Pasquale, 1997) 
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(Figure 2.1: B). The EphA subclass includes nine members (EphA1-A8, EphA10) and the 
EphB subclass includes five members (EphB1-B4, EphB6).  
 
 
Figure 2-2: Introduction to the Eph receptor family. 
(A) Protein domain structure of a typical Eph receptor. (B) Members of the Eph family: There 
are 9 EphA receptors and 5 EphB receptors. Their ligands, the ephrins comprise the 5 ephrin-
As and 3 ephrin-Bs.  (C) Bi-directional Signalling: Shown here is a heterotetramer which 
comprises 2 Eph receptors on one cell and 2 ephrin ligands on another cell. Forward signalling 
is then initiated into the receptor expressing cell and reverse signalling occurs in the ligand 
expressing cell. 
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Uniquely, the ligands to these receptors are also associated with the plasma membrane 
of expressing cells, which is unlike other RTKs whose ligands are soluble proteins. The ephrin 
ligands are also divided into two subclasses based on the type of cell membrane attachment. 
The ephrin-As include 6 members (A1-A6) which are attached to the membrane via a 
glycosylphosphatidyl-inositol (GPI) linker and generally interact with EphA receptors. The 
ephrin-Bs are all type 1 transmembrane proteins, being anchored into the cell membrane by 
their single, hydrophobic transmembrane domain. Ephrin-Bs include three members (B1-B3). 
A particular feature of this family of RTKs is the promiscuous nature of Eph-ephrin interactions 
between these subclasses. For example, EphA4 can bind several ephrin-Bs and the EphB2 
receptor can interact with ephrin-A5 in addition to all three ephrin-B ligands(Himanen et al., 
2004; Kullander et al., 2002). The exception to this, however, is EphB4 whose sole 
physiologically relevant ligand is ephrin-B2 (Brambilla et al., 1995; Sakano et al., 1996). 
2.2.3.2 Eph receptor and ephrin structure 
Eph receptors share a common protein structure important to their biological functions 
(Figure 2.1: A). The extracellular domain is comprised of a globular domain and a cysteine-
rich domain which are both involved in ligand binding, and two fibronectin type III repeats that 
are thought to stabilize the dimerization of Eph receptors that is needed for activation of 
intracellular signalling cascades (Pasquale, 2005). As Eph receptors are type 1 transmembrane 
proteins they include a transmembrane domain between the extracellular and intracellular 
region of the molecule. The intracellular domain of Eph receptors is comprised of a tyrosine 
kinase domain, through which intracellular signalling cascades are activated, a sterile alpha 
motif (SAM) and a PDZ (Post synaptic density protein PSD-95 Discs large and Zona occludens 
tight junction protein) binding domain, the latter two of which are thought to interact with 
cytoskeletal and other intracellular proteins (Pasquale, 2005). Ephrin-B ligands also have a 
PDZ domain and conserved intracellular tyrosine residues for signalling (Lin et al., 1999). 
2.2.3.3 Bi-directional signalling  
As the Eph receptors and their ligands are both membrane bound, normally on separate 
cell types, and have the capacity to propagate signals, activation of normal signalling requires 
cell to cell contact in trans ie contact between separate cells expressing either receptor or 
ligand. This results in bi-directional signalling which is forward into the Eph-expressing cell 
and reverse into the ephrin-expressing cell (Figure 2.1C). Forward signalling through the Eph 
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receptor-expressing cell causes trans-phosphorylation of tyrosine residues in the kinase 
domain, allowing interactions with other intracellular signalling molecules containing Src 
homology 2 domains and initiation of signal transduction (Himanen et al., 2003). Reverse 
signalling occurs through the ephrin-expressing cell and can result in phosphorylation of Src 
kinases and subsequent activation of cellular signalling pathways through SH2-containing 
adaptor proteins such as Grb4 (Cowan et al., 2001; Palmer et al., 2002). Examples of signalling 
cascades that are initiated or inhibited through Eph/ephrin signalling include activation of the 
small GTPases of the Rho family to regulate cytoskeletal behaviour, and regulation of the 
mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinase (ERK) 
pathway (Bush et al., 2010; Penzes et al., 2003; Shamah et al., 2001). Activation of signalling 
pathways by Ephs and ephrins is complex and is highly context dependent, even among the 
same subclasses of receptors/ligands, and also differs significantly in cancer. Signalling will 
be briefly discussed in the context of cancer in section 2.2.5 and Figure 2.2.  
Bi-directional signalling requires the formation of at least two receptors and two ligands 
in a heterotetrameric structure (Himanen et al., 2001).This is a highly orchestrated response 
which starts with the association of an Eph and ephrin in a 1:1 high-affinity interaction between 
the Eph globular domain and a conserved Eph-binding domain on the ephrin. Additional 
protein interfaces in these domains such as the cysteine rich domain and two fibronectin type 
III repeats then tether dimers laterally so that each ephrin binds two Ephs and each Eph binds 
two ephrins, leading to the assembly of these heterotetramers. Co-expression of Eph receptors 
and their ligands on the same cell, a signalling interaction known as in cis, has been shown to 
inhibit Eph/ephrin signalling, although this is somewhat controversial as there is no evidence 
that ephrin-As can laterally associate with their receptors (Carvalho et al., 2006; Yin et al., 
2004).  
2.2.4  Roles of Eph Receptors and Ephrin Ligands 
2.2.4.1 Cell adhesion and cell repulsion  
The consequences of Eph-ephrin interaction and bi-directional signalling are either 
repulsion or adhesion of the two cells and this depends on several factors.  The most well 
described response that occurs when Eph receptors and their ligands interact is cell repulsion.  
Disruption of cell contact due to separation of the high affinity interaction between the Eph 
receptor and the ephrin can occur as a result of subsequent endocytosis of the whole receptor-
ligand complex into either cell via a mechanism that is dependent on Rac signalling (Pitulescu 
et al., 2010; Zimmer et al., 2003). A second mechanism includes extracellular proteolysis of 
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either receptor or ligand to terminate the interaction and thus signalling. This mechanism has 
been well characterized by Janes et al. (2005) who showed that A Disintegrin and 
Metalloproteinase 10 (ADAM10) associates with EphA3 in the plasma membrane. Upon 
ephrin-A5 binding to EphA3, a conformational change reveals an ADAM10 recognition motif 
in ephrin-A5 resulting in cleavage of ephrin-A5. Proteolysis leads to endocytosis of cleaved 
ephrin-A5 into the EphA3 expressing cell, repulsion between the two cells and prevention of 
ligand signalling (Janes et al., 2005). In contrast, adhesion occurs when there are low levels or 
poor activation of Eph forward signalling, as seen where kinase dead mutants or receptors with 
a truncated cytoplasmic domain switch from cell repulsion to cell adhesion activity (Holmberg 
et al., 2000). The controlled regulation of cell adhesion and repulsion is important as Eph 
signalling is crucial to many processes in development and, if dysregulated, can lead to 
undesired cellular consequences.   
2.2.4.2 Ephs/ephrins as effectors of development  
Signalling by Ephs has been shown to stimulate intracellular signalling cascades that 
produce cellular responses that alter morphology, mobility, migration, adhesion and repulsion 
(Lai et al., 2004; Penzes et al., 2003; Sahin et al., 2005; Shamah et al., 2001; Yamazaki et al., 
2009). The consequences of this signalling are important in embryonic development and 
maintenance of adult tissues. One of the main roles for Ephs and their signalling partners is 
cell/tissue boundary formation. This is particularly important as the segregation of cell 
populations drives many facets of embryogenesis. An example of this is found in mouse 
embryos, where EphB2 and EphB3 prevent intermingling of the proliferating epithelial cells 
of the gastrointestinal crypts and the differentiated cells of the villi through interaction with 
ephrin-B2 and subsequent repulsion of the two cell populations (Batlle et al., 2002).  
Eph receptors and their ligands are essential for axon guidance and neuronal 
development. Ephrin-B1 and ephrin-B2 are found in the neural crest cells and motor axons and, 
through the regulation of migration of crest cells to somite boundaries, contribute to neural 
crest formation (Wang et al., 1997). If ephrin-B1 is deleted or mutated this results in neural 
crest defects and incomplete body closure (Davy et al., 2004). Eph and ephrins also regulate 
synaptogenesis by stabilizing axon/dendrite contacts, controlling synaptic retraction and 
maturation (Ethell et al., 2001; Fu et al., 2006; Segura et al., 2007).  
Another critical process that is regulated by the interplay between Ephs and ephrins is 
angiogenesis and cardiovascular development. The key members involved are ephrin-B2, 
which is mainly expressed on arterial endothelial cells, and EphB4 which has a venous type 
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expression pattern (Gerety et al., 1999; Wang et al., 1998). Experiments where either EPHB4 
or ephrin-B2 genes were knocked out in mice resulted in phenocopied abnormalities in 
angiogenesis, cardiac morphogenesis and embryonic lethality, showing these proteins are 
essential for the development of a functional cardiovascular system (Adams et al., 1999; Gerety 
et al., 2002; Gerety et al., 1999). Ephrin-B2 is also an important mediator of angiogenesis and, 
when activated by EphB4, correlates with endothelial cell proliferation and vascular 
remodelling (Wang et al., 1998). These examples demonstrate the key roles that Ephs and their 
ligands play in cellular and tissue development. 
2.2.4.3 Eph and ephrins in the development of the prostate  
Prostate development begins in the anterior urogenital sinus (UGS) (Marker et al., 2003). 
The UGS, comprised of epithelial cells, undergoes an outgrowth of budding tips which invade 
the surrounding mesenchyme. This mesenchymal region is important as it regulates the 
surrounding prostate epithelia through paracrine signalling. This signalling co-ordinates 
prostate organogenesis through induction of epithelial bud formation, eliciting prostatic bud 
growth and ductal branching, and promoting the differentiation of the secretory epithelia in 
response to androgens and other molecular factors such as the Wnt pathway (Prins et al., 2008).  
There have been extensive studies of the role of Eph/ephrin signalling in development, 
organogenesis and maintenance of adult tissues, with the prostate being no exception (Andres 
et al., 2003; Kouros‐Mehr et al., 2006; Miao et al., 2009b). Through transcriptional profiling, 
the EphB3 gene was identified in the ventral mesenchymal pad (Vanpoucke et al., 2007).  Both 
EphB3 and ephrin-B1 were also found to be expressed during ventral prostate (VP) 
development of rodents, with EphB3 showing the highest expression during peri-puberty 
(Ashley et al., 2010). In vitro organ culture of the VP in the presence of clustered ephrin B1-
Fc and testosterone resulted in significant increases in organ area, branching and proliferation 
of the surrounding VP epithelium (Ashley et al., 2010). However, incubation with EphB3-Fc 
receptor reduced organ size and reduced budding (Ashley et al., 2010). Transcriptomic analysis 
has suggested that several Eph receptors are regulated by the androgen receptor during prostate 
development. EphA7, EphB1 and EphB2 genes are suppressed in development after addition 
of androgens (Schaeffer et al., 2008). Reactivation of embryonic genes is common in PCa and 
the same study demonstrated that EphA5, EphB1 and EphB2 genes were highly enriched in 
PCa. This suggests that genes that have important roles in prostate development may become 
reactivated and their normal roles subverted in PCa. These results also demonstrate that highly 
orchestrated Eph/ephrin signalling plays a role in the early development of the prostate.  
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The role of Eph/ephrin signalling in maintenance of adult tissues such as the colon and 
mammary glands has been well studied (Andres et al., 2003; Kouros‐Mehr et al., 2006; Miao 
et al., 2009b), however this is less so for the prostate. In a single study of healthy human tissues 
with real-time PCR EphA3, EphA7, ephrin-A1, ephrin-B1 and ephrin-B2 mRNA transcripts 
were shown to be highly expressed in prostate tissue (Hafner et al., 2004). Further study is 
warranted into the roles of the above Ephs and their binding partners in the adult prostate as 
they also play roles in oncogenic transformation. 
2.2.5 Ephs and Ephrins in Cancer:  
During development Ephs and ephrins are highly expressed both at the mRNA and 
protein level, but in adult tissues are often lowly expressed (Hafner et al., 2004). During 
tumourigenesis, however, Eph and ephrins are often either re-expressed, often at high levels, 
or down-regulated, making them attractive targets for diagnostic or prognostic biomarkers of 
cancer.  
There have been many reports that suggest tumours with a higher expression of Ephs and 
lower expression of their ephrin ligands are more aggressive with a corresponding association 
with higher clinical stages and/or grades of human cancers. Thus, particular Ephs have been 
recognized as attractive candidates for prognostic biomarkers and potential targets for 
therapeutic intervention. Representative examples, illustrating the important relationship 
between over-expression of the Eph receptors and cancer progression, are listed in Table 2.2.  
In some instances Eph receptors can be down-regulated in cancer through mutations or 
epigenetic silencing and their lack of expression correlates with poor prognosis and metastasis 
in certain tumours. Examples of these contrasting relationships are listed in Table 2.3. In 
addition to significant alterations in the receptors, similar contrasting observations have been 
reported for several of the ephrins – some being down-regulated, some being up-regulated and 
often being correlated with prognostic indicators. Again several examples are listed in Table 
2.4. The data in Tables 2.2-2.4 and Figure 2.2 clearly suggest that the role that Eph and ephrins 
play in cancer is complex and needs to be examined carefully in a cell/tumour-dependent 
context.  
Cancer cells rely on intracellular signalling and the Eph receptors and their ligands have 
been implicated in modulating the myriad of signalling pathways and cellular processes that 
are subverted in cancer. Figure 2.2 illustrates the major signalling pathways that are potentially 
implicated in Eph/ephrin tumour promotion. It should be noted that not all such pathways have 
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been specifically demonstrated in cancer cells, but their demonstrated functional outcomes are 
clearly relevant in the cancer context.  
Examples of tumour promoting signalling include increasing migration by destabilizing 
adheren junctions, through activation of RhoA GTPases in both EphA and EphB subclasses 
(Fang et al., 2008; Yang et al., 2006). EphA signalling can also promote migration and invasion 
of cancer cells through activation by Akt (Miao et al., 2009a). EphB receptors can activate Akt, 
and primarily lead to survival of cancer cells and evasion of cell death (Maddigan et al., 2011). 
In colon cancer EphB2 forward signalling can increase proliferation through cyclin D1 
(Genander et al., 2009), whilst in glioma EphB2 activates RRAS which leads to increased 
invasion and reduced proliferation (Nakada et al., 2005). These examples highlight the 
differences in signalling outcomes dependent on cancer cell context. Selected examples of 
ephrin reverse signalling in cancer have shown that it can transform cells through Src activation 
and promote invasion through Rac1 (Campbell et al., 2006; Merritt et al., 2011; Nakada et al., 
2006).These examples are highly simplified and representative of Eph/ephrin signalling in 
cancer. More comprehensive reviews on Eph/ephrin signalling in cancer can be found in 
references (Kandouz, 2012; Pasquale, 2010). 
 
2.2.6 Eph receptor and ephrin ligand expression and roles in Prostate Cancer 
Several Eph receptors and ephrin ligands have been reported to be relevant in PCa. These are 
summarized below. 
2.2.6.1 Eph receptors: 
EphA1: 
In an early study which examined transcript expression in xenografts of the PCa cell line 
CWR22,.the EphA1 gene was found to be expressed at the mRNA level using degenerate  
primers which enriched for RTKs (Robinson et al., 1996). However, another pilot study of the 
expression of Eph/ephrin family members in PCa revealed that in more aggressive PCa cell 
lines there was a loss of expression of EphA1 in the cell lines NPTX (normal prostate 
epithelium) and CPTX (primary prostate tumour), isolated from the same individual, the 
expression of EphA1 was highest in NPTX with a decrease in CPTX (Fox et al., 2006). In other 
cancers there is often loss of EphA1 and this would correlate with the above findings (Herath 
et al., 2009). Expression of EphA1 at the protein level in PCa has not yet been determined and 
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Table 2-1: Examples of Eph receptors that are highly expressed in cancer and correlate with prognosis 
Eph Receptor/ Cancer type mRNA/ Protein Prognostic Indication Reference 
EphA2    
Lung Non-Small Cell 
carcinoma (NSCLC) 
protein advanced stage; increased brain metastases and poorer 
survival   
(Brannan et al., 2009; Kinch et 
al., 2003b) 
Hepatocellular mRNA; protein decreased differentiation state and poor survival (Cui et al., 2010) 
Epithelial Ovarian mRNA; protein increased metastases and poor survival  (Han et al., 2005; Meade-Tollin et 
al., 2007) 
Endometrial protein poor survival (Merritt et al., 2011) 
Breast mRNA poor survival (Martin et al., 2008) 
Astrocytoma mRNA; protein increased pathological grade (Li et al., 2007) 
Glioma protein increased histological grade and poor survival (Li et al., 2010) 
Prostate Protein increased pathological grade (Zeng et al., 2003)  
EphA3    
Gastric mRNA; protein increased histological grade and poor survival  (Xi et al., 2012b) 
Colorectal protein increased histological grade, metastases and poor survival (Xi et al., 2011) 
EphA4    
Gastric mRNA; protein poor survival (Oki et al., 2008) 
EphA7    
Glioblastoma Protein poor survival  (Wang et al., 2008) 
EphB3    
NSCLC mRNA; protein increased histological grade and metastases (Ji et al., 2011) 
EphB4    
Bladder mRNA; protein increased histological grade  (Xia et al., 2006) 
Ovarian protein increased histological grade, ascites and poor survival (Kumar et al., 2007) 
Head & neck squamous cell mRNA; protein increased histological grade and lymph node metastases (Masood et al., 2006) 
Prostate protein increased histological grade/Gleason score (Lee et al., 2005) 
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Figure 2-3: Potential Eph/ephrin tumour promoting signalling pathways.  
Major signalling pathways only are shown, together with their demonstrated, cancer-relevant, 
functional outcomes. Not all pathways have been specifically demonstrated in cancer cells. 
Pathways are shown following activation of reverse signalling for (A) ephrin A ligands and (B) 
ephrin B ligands in tumour-associated cells such as endothelial cells, leading to increased 
angiogenesis.  Ligand-independent forward signalling pathways eliciting tumour-promoting 
actions in cancer cells are shown in (C) for EphA receptors and (D) for EphB receptors. 
Pathways indicated by the asterisk (*) in (C) and (D) are those known to be inhibited by ligand 
binding leading to tumour suppression. EMT = epithelial to mesenchymal transition.  
represents phosphorylation on specific tyrosine/ serine/threonine residues that determines 
which pathways are activated.   represents expression and/or function of proteases (MMP, 
ADAMs) that are involved in regulation of ephrin B and EphA function, respectively. Figures 
are adapted from (Pasquale, 2010; Xi et al., 2012a). 
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Table 2-2: Examples of ephrin ligands that have prognostic significance in cancer 
 
Ephrin/ Cancer type mRNA/Protein Prognostic Indication Reference 
 
Up-Regulated 
  
Increased levels correlate with 
 
Ephrin-A1    
Melanoma Protein poor survival (Straume et al., 2002) 
Gastric adenocarcinoma Protein increased TNM 
stage and lymph node metastasis 
(Yuan et al., 2009) 
Hepatocellular carcinoma mRNA; protein (in serum of HCC patients) - potential biomarker (Cui et al., 2010) 
Ovarian mRNA poor survival (Herath et al., 2006) 
Ephrin-A4    
Osteosarcoma Protein (Increased cytoplasmic location) - aggressive histopathological 
type, stage, metastasis and poor survival) 
(Abdou et al., 2010) 
Ephrin-A5    
Ovarian mRNA poor survival (Herath et al., 2006) 
Ephrin-B2    
Glioma Protein increased histological grade and poor survival (Tu et al., 2012) 
Ovarian mRNA; protein increased histological grade and poor survival (Alam et al., 2008) 
Uterine cervical mRNA; protein increased histological grade and poor survival (Alam et al., 2009) 
 
Down regulated 
 
 Reduced levels correlate with  
Ephrin-A1    
Glioma Protein poor prognosis for high grade tumours  (Li et al., 2010) 
Prostate mRNA 
mRNA; protein 
higher Gleason score; 
bone metastases cf liver and lymph node metastases 
(Larkin et al., 2011) 
(Morrissey et al., 2008) 
Ephrin-A5    
Prostate Protein (in serum of advanced stage prostate cancer patients) - 
decreased survival 
(Kälin et al., 2011) 
Chondrosarcoma mRNA; protein higher clinical grade (Kalinski et al., 2009) 
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this would be more indicative of the role that the loss of EphA1 plays in the progression 
from normal to cancerous prostate.  
EphA2:  
EphA2 is one of the most extensively studied Eph receptors in PCa. Early studies 
identified EphA2 protein over-expression in PCa cell lines which are more transformed and 
have higher metastatic potential (Walker‐Daniels et al., 1999). Clinical prostate samples 
examined with Immunohistochemistry (IHC) showed weak or negative staining of EphA2 in 
the epithelial and basal cells of benign prostate and more intense staining of EphA2, and a 
higher percentage of EphA2 positive cells, in prostate carcinoma (Walker‐Daniels et al., 1999). 
However, this study did not determine if EphA2 over-expression occurs early in PCa 
development or was more involved in metastatic potential. Additional IHC studies were 
performed with a larger number of samples of benign prostate tissue, high grade PIN (prostatic 
intraepithelial neoplasia) and prostatic adenocarcinomas from radical prostatectomy. The 
percentage of cells staining positively with EphA2 was highest in prostatic adenocarcinoma 
(85%) and high-grade prostatic intraepithelial neoplasia (67%), whereas it was low in benign 
prostatic epithelium (12%). Staining was seen only within the epithelial cells and not in 
surrounding tumour-proximal stroma. Therefore, higher expression of EphA2 is related to 
oncogenic transformation and as intensity of staining was significantly higher in PIN, which is 
a precursor to PCa, than in benign glands this indicates that EphA2 over-expression is an early 
event in PCa linked to its progression (Zeng et al., 2003).  
Several studies have indicated that EphA2 may be tumour suppressive or tumour 
promoting depending on both ligand-dependent and -independent and kinase-dependent or -
independent factors. Largely, it is thought that the over-expression of EphA2 contributes to 
PCa through lack of ephrin binding, which is believed to be tumour suppressive. Lack of ephrin 
binding occurs in cancer as cells do not form the stable cell-to-cell contacts needed for bi-
directional signalling (Hanahan et al., 2011). This is most evident in studies where EphA2 has 
been stimulated by its ligand ephrin-A1. In both the immortalized benign prostate epithelial 
cell line pRNS-1-1 and the PCa cell line PC3, stimulation with a clustered (active), soluble 
form of ephrin-A1 inhibited the activation of the Ras/extracellular signal-regulated kinase 1/2 
(ERK1/2) signalling cascade, thereby leading to a decrease in proliferation (Miao et al., 2001). 
The study by Miao et al. (2000) showed that stimulation by ephrin-A1 inhibited Integrin-
mediated cell adhesion and inactivated focal adhesion kinase (FAK) through rapid recruitment 
of the protein tyrosine phosphatase SHP2, which ultimately led to cell rounding and decreased 
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migration (Miao et al., 2000). In PCa there is often a loss in the tumour suppressor phosphatase 
and tensin homolog (PTEN) which in turn activates the Akt-mTORC1 pathway (Salmena et 
al., 2008; Trotman et al., 2003). Stimulation of EphA2 by ephrin-A1 in the PTEN null PCa cell 
line, PC3, inhibits the Akt-mTORC1 pathway through activation of a phosphatase, which 
dephosphorylates Akt leading to a decrease in migration and cell growth (Miao et al., 2009a; 
Yang et al., 2011).This indicates that stimulation of EphA2 by its ligand is mainly tumour 
suppressive.  
Other studies have shown kinase-dependent or -independent roles for EphA2 in PCa. 
PC3 cells exogenously over-expressing dominant-negative EphA2 kinase mutants or mutants 
lacking the cytoplasmic domain, showed that kinase activity is needed for ephrin-A1 mediated 
cell rounding, inhibition of migration and adhesion (Taddei et al., 2009). Wild type expression 
of EphA2 in PC3 cells injected into rodents showed a higher number of bone metastases than 
the EphA2 kinase mutants or the mutants lacking the cytoplasmic domain (Taddei et al., 2009). 
This indicates that both ligand-dependent and -independent and kinase-dependent and -
independent mechanisms may be involved in EphA2 signalling.   
EphA2 also aids in metastatic potential in PCa cells by increasing cell migratory activity, 
thereby facilitating cells to migrate from the primary tumour and disseminate into other tissues 
(Taddei et al., 2011). Therefore, the targeting of EphA2 may offer opportunities for PCa 
prevention and treatment. 
Despite extensive study of EphA2 and its effects in prostate cancer cell lines there 
remains only a single study reporting on the association of expression levels with 
clinicopathological parameters in prostate cancer (Zeng et al., 2003). Its potential as a 
prognostic indicator therefore needs further examination. 
EphA3: 
  In a microarray study EphA3  has been found to be upregulated in PCa cells that are androgen-
independent compared with those dependent on androgens (Singh et al., 2008). A study of 
AMP-activated protein kinase (AMPK) also showed that inactivation of this protein led to 
transformation of PCa cell lines and an upregulation of EphA3 mRNA (Zhou et al., 2009). This 
means that AMPK may regulate EphA3 and therefore, after transformation of PCa cells, EphA3 
may have an oncogenic role. However, the role of EphA3 in PCa is uncertain and therefore 
needs to be evaluated further.  
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EphA4: 
 cDNA microarray analysis identified EphA4 as a gene that was upregulated in the 
transition from PIN to PCa (Ashida et al., 2004). Analysis by IHC showed that EphA4 protein 
was strongly expressed in PCa epithelial cells compared with weak or no staining in the PIN 
or normal prostate cells from the same patient. In the same study, EphA4 was then knocked 
out using siRNA which led to a significant decrease in cell viability and colony formation, 
suggesting a tumour promoting role in PCa (Ashida et al., 2004). In another study  stimulation 
of EphA2 and EphA4 by ephrin-A1 and ephrin-A5 resulted in inhibition of migration of PC3 
cells, which suggests that these two receptors, once activated, induce contact inhibition of 
locomotion (Astin et al., 2010). These studies indicate that EphA4 over-expression is tumour-
promoting in transformed cells, however this may be controlled in early PCa by the presence 
of its ligand which is lost in the transition from normal prostate to cancerous prostate. EphA4 
may also be regulated by the PCa-associated receptor ERBB3/HER3 (Soler et al., 2009). When 
ERBB3/HER3 was knocked down, the EphA4 gene was also down regulated suggesting a 
functional linkage between the two receptors. 
 
EphA5: 
 Transcriptomic analysis has revealed that the EphA5 gene is down regulated in radical 
prostatectomy patients who have high grade PCa with a Gleason score of 8 (Ross et al., 2011). 
In high grade breast cancer the EphA5 gene promoter is hypermethylated in 64% of tumours 
but only 28% of matched normal breast tissue (Fu et al., 2010) . Methylation results in a loss 
of EphA5 at both the gene and protein level and is significantly associated with higher 
clinicopathologic tumour grade, lymph node metastases, and PR-negative status (Fu et al., 
2010). These observations support a critical role for EphA5 in cancer progression in a majority 
of tumours.  Its role in PCa and potential as a biomarker should be further investigated.   
 
EphA6:  
EphA6 has also been shown to be one of the down regulated genes in intact orthotopic 
tumours from the androgen-independent PCa cell line LNCaP-19 (Jennbacken et al., 2009). 
This suggests that EphA6 may have a tumour suppressive role in the prostate which is then lost 
when it is down regulated. This finding, however, must be confirmed with additional studies 
of this receptor. 
EphA7:  
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In the study performed by Guan et al. (2009) EphA7 mRNA and protein were shown to 
be down regulated in PCa. IHC demonstrated that EphA7 protein expression is high in the 
normal prostate and that when it progresses to cancer EphA7 expression is lost. This is due to 
hypermethylation of the EphA7 promoter and this correlates with higher Gleason scores of 7-
10. Exogenous over-expression of EphA7 protein in the cell line DU145 resulted in inhibition 
of colony formation, suggesting a role for EphA7 as a tumour suppressor (Guan et al., 2009). 
However, another study indicated that the loss of EphA7 is not an early event in PCa as EphA7 
has been shown to be in primary tumours but not in lymph or bone metastases (Oudes et al., 
2005). Interestingly, since EphA7 is regulated by androgens and expressed in the development 
of the prostate one might speculate that it plays a role in tissue maintenance that is subverted 
in PCa. 
EphA10:  
EphA10 is the most recent addition to the Eph family (Aasheim et al., 2005). Recent 
evidence shows that a single nucleotide polymorphism (SNP) (rs731174) in an intron of the 
EphA10 gene may interact with other SNPs that are implicated in PCa risk (Tao et al., 2012). 
Thus, it may be prudent to perform further research into this receptor with regards to its role in 
PCa. 
EphB2:  
EphB2 may also be a tumour suppressor in PCa as it has been shown to be commonly 
mutated and inactivated in PCa. Huusko et al. (2004) showed by nonsense-mediated decay 
microarray analysis that missense and nonsense mutations occurred more frequently in samples 
from metastatic PCa. These mutations were often located in the kinase domain and when wild-
type EphB2 was over-expressed in DU145 cells, which do not express functional EphB2, the 
growth and colony formation of these cells was suppressed (Huusko et al., 2004). Another 
germline nonsense mutation termed K1019X (3055A>T) has been identified more frequently 
in African Americans than in Caucasian men. Individuals with the T allele have a significantly 
increased risk of PCa which aligns with the higher incidence and mortality from the disease in 
African Americans (Jemal et al., 2010; Kittles et al., 2006). Further analysis of EphB2 
mutations in sporadic PCa in African American men revealed other SNPs associated with PCa 
risk and also some that tended to provide a protective effect against PCa (Robbins et al., 2011).  
EphB3: 
 EphB3 gene expression using both microarrays and RT-PCR has been found to be 
elevated in PCa tissue compared with adjacent prostate epithelium.  However, a functional role 
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has not been elucidated (Chaib et al., 2001). Given its role in the development of the prostate 
this finding warrants further investigation.  
EphB4:  
EphB4 has been extensively studied in PCa where it is often over-expressed. Several 
studies have linked the over-expression to the development and progression of PCa. In 2005, a 
pilot study by Lee et al. (2005) found that in 66% (8/15) of clinical PCa samples EphB4 protein 
was over-expressed with a trend toward increased EphB4 immunoreactivity being associated 
with higher grades of disease (Lee et al., 2005). It was also suggested that EphB4 expression 
was an early event in PCa progression as EphB4 was expressed in foci of both prostatic 
intraepithelial neoplasia (PIN) and high grade PCa from the same patients. This was supported 
by another study in the same year that showed (41/62) (66%) of PCa samples examined were 
positive for EphB4 protein (Xia et al., 2005b). Their study of PCa cell lines showed that the 
EPHB4 locus on chromosome 7q22 is amplified, illustrating one potential mechanism by which 
EPHB4 mRNA and protein is over-expressed in prostate cancers. Knockdown of EPHB4 
mRNA and protein in PC3 cells via an siRNA approach resulted in an 80% reduction in cell 
viability, a 7.9 fold increase in apoptosis and an 88% reduction in tumour cell migration and 
invasion. In addition to these  in vitro studies, anti-sense knockdown of EPHB4 in vivo in a 
PCa xenograft model resulted in a 72% reduction in growth of tumours (Xia et al., 2005b).  
These data highlight the critical role that over-expressed EphB4 plays in prostate (and other) 
cancers. 
The role of EphB4, however, in prostate cancer is highly dependent on the relative levels 
of expression of its sole physiological ligand, ephrin-B2. Indeed, EphB4 has been shown to 
have contrasting functions in PCa – driving signalling pathways leading to either tumour 
promotion (regulated by its over-expression in a ligand-independent manner) or tumour 
suppression (regulated by the presence of its ligand ephrin-B2) (Figure 2.2) (Rutkowski et al., 
2012). When EphB4 was exogenously over-expressed in the PCa cell line 22Rv1 (22Rv1-B4), 
these cells showed increased migration, invasion and anchorage-independent growth. 
Treatment with the clustered recombinant form of the ligand (ephrin-B2-Fc) decreased cell 
growth, invasion, migration, and colony formation and led to apoptosis in the EphB4 over-
expressing cells (Rutkowski et al., 2012). This suggests that EphB4 has numerous cancer 
promoting roles that can be overcome through treatment with its ligand and that this may be an 
attractive target for anti-cancer therapeutics (Section 2.2.8). 
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2.2.6.2 Ephrins:  
While several ephrins have been shown to be implicated in various cancers, there is little 
evidence for critical roles in PCa for most of the ephrins. Only ephrin-A1 and -A5 have been 
implicated to date. It also needs to be noted that ephrins are expressed on some non-epithelial 
cells – endothelial cells in particular – and there is little evidence reported of the influence of, 
or changing expression of, ephrins in such non-epithelial cell types in prostate cancer.  
Ephrin-A1:  
Ephrin-A1 mRNA, extracted from micro-dissections of pathologist-confirmed prostate 
cancer tissue, has been shown to be significantly negatively correlated with Gleason score, 
being high for scores <7 and lower for Gleason scores >7 (Larkin et al., 2011). As indicated 
above, stimulation of EphA2 with ephrin-A1 is tumour suppressive therefore it is logical to 
find it down regulated in more aggressive PCa. 
 
Ephrin-A5:  
Proteomic analysis of the cell culture medium of LNCaP cells exposed to androgens 
showed that the ephrin-A5 protein was increased indicating that it is regulated by androgens 
(Martin et al., 2004). This is further evidenced by a retrospective study of patients with 
metastatic castration-resistant PCa where it was found that lower serum levels of ephrin-A5 
correlated with a shorter predicted survival time (Kälin et al., 2011). These studies show that 
as the tumours progress to a castration-resistant state ephrin-A5 is lost and this may indicate 
that it is a good prognostic marker to determine if a cancer will progress to the metastatic and 
currently incurable castration-resistant stage.  
 
2.2.7  Eph Receptors as Biomarkers  
2.2.7.1 Identification of circulating tumour cells 
The development of methods to isolate disseminating tumour cells from the peripheral 
blood of cancer patients holds great promise for diagnosis, prognosis and monitoring of 
treatment. Such methods need to be sensitive enough to identify a single tumour cell in a 
background of millions of normal haematopoietic cells and specific enough to identify it as an 
actual tumour originating cell. The most established methods for isolation of tumour cells from 
fluid samples use density-gradient centrifugation, where tumour cells are separated from blood 
cells due to their different buoyant density, and immuno-magnetic enrichment which uses 
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antibodies specific to tumour cell surface proteins immobilized on magnetic beads (Pantel et 
al., 2012). Novel methods designed to automate tumour cell enrichment using immuno-
magnetic approaches include CellSearch (FDA-approved and in clinical trial), the CTC chip 
and the epithelial immunospot (EPISPOT) assay. These have already shown promising results 
(Alix-Panabières et al., 2005; Alix-Panabières et al., 2009; de Bono et al., 2008; Nagrath et al., 
2007). Adaptation of these techniques for the identification of circulating prostate cancer cells 
will rely on the identification of tumour specific markers - both proteins and mRNA transcripts 
- that can be used to capture and discriminate tumour cells from normal cells (Kruck et al., 
2012). Important to this will be ensuring that selected markers are more highly expressed in 
PCa cells when compared with normal cells and that quantitative RT-PCR assays are used with 
validated minimum expression values.  Also of great importance will be the selection of 
markers that remain expressed in PCa cells that have undergone epithelial to mesenchymal 
transition (EMT), a complex process associated with the de-differentiation of cells, loss of 
adhesion and increased motility that is required for metastasis.  
Given their common over-expression on PCa cells, Eph receptors may prove to be useful 
for both immuno-magnetic isolation of circulating cells and for the identification of those cells. 
The ephrin mimetic peptide YSAYPDSVPMMS (YSA), which binds to Eph receptors over-
expressed on the surface of cancer cells, has been used to label magnetic CoFe2O4 nanoparticles 
(Scarberry et al., 2008). These YSA-labeled magnetic nanoparticles were used successfully to 
isolate ovarian cancer cells from the peritoneal cavity of mice by application of a magnetic 
field to both the abdomen of the mice and to peritoneal fluid. A model circulatory system, 
driven by a peristaltic pump, also demonstrated that a dialysis-like approach combined with 
magnetic isolation may be used to remove EphA2 positive cells from the circulation suggesting 
that this approach may find application in the clearing of tumour cells from the circulation. 
In studies to develop immunobead RT-PCR for the detection of circulating breast and 
head and neck tumour cells, EPHB4 gene expression was confirmed to be specific for the 
tumour cells and expressed at a sufficiently high level that it was sensitive enough to detect a 
single tumour cell in 100 peripheral blood mononuclear cells (PBMNCs) using a single round 
of RT-PCR (Raynor et al., 2002; Raynor et al., 2009; Stuart et al., 2009). Although not yet 
reported, it is likely that EphB4 will also be expressed in circulating PCa cells and will prove 
to be useful in the identification of these in peripheral blood and bone marrow.  
Expression of genes whose protein products contribute to survival of the circulating cell, 
allow attachment to the endothelial cell wall, and/or facilitate extravasation, will be particularly 
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useful biomarkers because it is likely that within the population of circulating cells, these are 
the ones that have the potential to form a metastatic deposit.  Tumour cells retain expression of 
EphB4 receptors in the circulation, engage with ephrin-B2 positive endothelial cells in the 
arterial endothelium and adhere (Héroult et al., 2010). Activation of reverse signalling in 
ephrin-positive endothelial cells promotes the proliferation and survival of the endothelial cells 
and thereby promotes angiogenesis (Noren et al., 2004). Eph receptor signalling has also been 
linked to mesenchymal to epithelial transition (MET), an important process required for 
formation of a metastatic deposit. Although part of a normal developmental process, studies of 
somite morphogenesis in zebrafish show that ephrin stimulation of Eph receptor positive cells 
(EphB4/ephrin-B2 and EphA4/ephrin-A) results in a mesenchymal to epithelial transition 
(Barrios et al., 2003). Although the expression of PCa over-expressed Eph receptor proteins on 
the surface of circulating cells from patients with disseminating prostate cancer has not yet 
been explored, several studies have identified functions of these Eph receptor proteins that 
would suggest the identification of Eph positive cells would in fact be a valuable indicator of 
metastatic potential. 
 
2.2.7.2 Eph and ephrins on circulating tumour cells as biomarkers to predict prostate 
cancer metastatic potential.  
Identification of EphB4 positive disseminated PCa cells in the circulation may also prove 
to be highly predictive of metastasis to the bone. Bone is the most frequent site of prostate 
carcinoma metastasis and prostate cancers produce predominantly osteoblastic bone 
metastases. Interactions between EphB4 and ephrin-B2 and EphA2 and ephrin-A2 have been 
shown to be required for normal bone homeostasis.  Osteoclasts express ephrin-B2 and 
osteoblasts EphB4, and interaction between these two cells via EphB4 and ephrin-B2 has been 
shown to suppress bone reabsorption (ephrin-B2 reverse signalling inhibits osteoclast 
differentiation) and enhance bone formation (Otaki et al., 2012; Zhao et al., 2006) (Figure 2.3). 
The opposite is true of ephrin-A2 where reverse signalling into osteoclasts enhances 
osteoclastogenesis and EphA2 forward signalling into osteoblasts suppresses osteoblastic bone 
formation and mineralization (Irie et al., 2009). 
Given that reciprocal expression of an Eph receptor and its ephrin ligand has already been 
shown to facilitate adherence between the two cells (Héroult et al., 2010), it is possible that 
EphB4 positive PCa cells can adhere to ephrin-B2 positive osteoclasts, stimulate ephrin-B2 
reverse signalling, and therefore block bone reabsorption. However, it is likely that the role of 
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EphB4 and ephrin-B2 in PCa bone metastases is more complicated than this simple hypothesis. 
Ephrin-B2 expression is induced in osteoblasts by parathyroid hormone, a Ca2+-regulating 
hormone often elevated in the serum of men with PCa (Allan et al., 2008). Furthermore, over-
expression of ephrin-B2 in bone marrow mesenchymal stem cells (BMSCs) promotes their 
differentiation into vascular endothelial cells (Xu et al., 2008). Interactions between other Eph 
receptors and ephrin ligands are also likely to be involved. Tissue microarray analysis of PCa 
metastatic foci showed that ephrin-A1 gene expression is decreased in bone metastases 
(Morrissey et al., 2008). 
2.2.7.3  Eph receptor expression in exosomes 
Most cells, from both normal physiological and pathological tissues, release exosomes – 
nanosized (30-100 nm) cup-shaped membrane vesicles derived from the endosome(Ludwig et 
al., 2011; Trams et al., 1981). Several studies have now demonstrated that they contain an array 
of cytosolic and membrane proteins, DNA, and functional RNA molecules, including mRNA 
and microRNAs, derived from the parental cell (Fleissner et al., 2012; Peters et al., 2011; 
Valadi et al., 2007). These vesicles can fuse with neighbouring cells and deliver their cargos 
to target cells and thereby influence target cell function. Already described functional 
mechanisms include (i) stimulation of surface molecules on recipient target cells by molecules 
that require clustering (for example in lipid rafts) on the exosomes (de Gassart et al., 2003), 
(ii) transfer of membrane receptors through fusion of theexosome with the membrane of the 
target cell (Peinado et al., 2012), and (iii) transfer of cytoplasmic signalling molecules, 
including DNA and RNA, again via membrane-exosome fusion (Balaj et al., 2011; Miranda et 
al., 2010).  
Exosomes from tumour cells play multiple roles in tumour growth and metastasis including 
suppression of the immune response, modulation of angiogenesis and the stroma and, through 
this, promotion of metastasis by conditioning the pre-metastatic niche, the site of future 
metastatic deposits (Kaplan et al., 2005). Identification of exosomes from the circulation, 
seminal fluid and urine could be used to identify PCa patients with an increased risk of 
metastatic spread (Mitchell et al., 2009). Furthermore, characterization of the process of 
exosome production itself, and how exosomes interact with target cells in the pre-metastatic 
niche, could yield new targets for anti-metastatic therapy. Proteomic profiling has identified 
ligands ephrin-B1, ephrin-B2, and receptors EphA2-8 and EphB1-4 in exosomes from a colon 
cancer cell line (Choi et al., 2011) but given that the molecular content of exosomes reflects 
their cell of origin, it is likely that PCa cell derived exosomes will also be Eph and ephrin  
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Figure 2-4: Diagrammatic representation of the interactions between ephrin ligands (eB2, 
eA2) and Eph receptors (EB4, EA2) in the bone environment.  
(A) normal functions of specific interactions between ephrin expression on osteoclasts and Eph 
receptors on osteoblasts. eB2/EB4 interaction leads to suppressed bone reabsorption and 
enhanced bone formation, whereas the opposite is seen for eA2/EA2 interaction. (B) circulating 
prostate cancer cells, over-expressing EphB4, could home to bone, interact with eB2 on 
osteoclasts and inhibit bone reasorption. Locally produced PTHrP in bone acts 1) on osteoblasts 
to increase ligand ephrin-B2 which can then interact in trans with EphB4 receptors on adjacent 
osteoblasts to stimulate bone formation, and 2) on bone marrow stem cells to induce 
differentiation into endothelial cells and enhance angiogenesis. 
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positive and we have preliminary data (unpublished) that supports this hypothesis. 
2.2.8 Therapeutic Targeting of Eph Receptors on Prostate Cancer Cells 
Eph receptors are promising targets for the development of new anti-prostate cancer 
therapies but the success of these will rely on understanding the biology of the particular 
receptor in both cancer and normal cells. In prostate cancers, where over-expression causes the 
activation of ligand-independent pathways, therapies that activate ligand-like signalling may 
be particularly effective. Studies have shown that over-expression of receptors including 
EphA2 and EphB4 on the surface of cultured human PCa cells (PC3, LNCaP, DU145, 22Rv1) 
leads to activation of ligand-independent pathways that promote oncogenic and metastatic 
phenotypes (Miao et al., 2001; Rutkowski et al., 2012; Walker‐Daniels et al., 1999). 
Stimulation of over-expressed EphB4 using soluble ephrin-B2 ligand reverses this, proving 
that normal ligand-dependent signalling is tumour suppressive (Astin et al., 2010; Miao et al., 
2001; Rutkowski et al., 2012). Clearly, mechanisms that reactivate ligand-dependent signalling 
will be useful in these cases and currently several different approaches are in development 
(illustrated in Figure 2.4).   
 
2.2.8.1 Soluble Ephs and ephrins 
Several groups have tested soluble forms of ephrin ligands for their ability to stimulate Eph 
receptor activation and thereby exert an anti-oncogenic effect.  For example, treatment of 
EphB4 positive tumour cells with soluble ephrin-B2-Fc protein, clustered using an anti-Fc 
antibody, caused EphB4 tyrosine phosphorylation and inhibited cell proliferation (Rutkowski 
et al., 2012). Similarly, the ephrin-A1 ligand exerts anti-oncogenic effects in tumour cells 
through activation and down-regulation of the EphA2 receptor (Wykosky et al., 2007). 
Expression of soluble ephrin-A1 in EphA2 over-expressing glioblastoma cells resulted in a 
substantial decrease in EphA2 levels and significantly reduced cell proliferation and migration 
(Wykosky et al., 2007). Expression of soluble ligands from adenoviral vectors may prove to 
be a useful approach for new therapies. This approach was tested by Noblitt et al. (2004) who 
demonstrated that over-expression of ephrin-A1-Fc from a human adenoviral type 5 vector in 
the breast cancer cell line MDA-MB-231 caused increased EphA2 activation and degradation, 
decreasing tumour cell viability in anchorage-independent soft agar assays and, importantly, 
prevented tumour formation in xenograft models (Noblitt et al., 2004). 
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In vivo experiments have shown that soluble forms of both Eph receptors and ephrin 
ligands have biological effects on tumour cells. Noren et al. (2004) reported that the 
ectodomain of a signalling-defective form of EphB4 (no forward signalling) made tumour 
xenografts grow more rapidly because it exerted an attractive effect on endothelial cells, 
promoting their survival and proliferation and therefore promoting angiogenesis in the tumour 
mass (Noren et al., 2004). Supporting this result were experiments using soluble ephrin-B2 
extracellular domain (Kimura et al., 2009). Injection of soluble ephrin-B2 into EphB4 positive 
head and neck squamous cell carcinoma xenografts suppressed xenograft growth by 
stimulating blood vessel maturation and stabilization, preventing leakage and further vessel 
formation. Furthermore, a soluble monomeric derivative of the extracellular domain of EphB4  
(sEphB4) blocks activation of EphB4 and ephrin-B2 adhesion, inhibits endothelial cell tube 
formation in vitro and inhibits the angiogenic effects of various growth factors (VEGF and 
bFGF) in vivo  (Kertesz et al., 2006).  Ephrin-A1 has also been used in molecularly targeted 
therapies by conjugating with a derivative of the Pseudomonas endotoxin A, PE38QQR 
(Wykosky et al., 2007). Ephrin-A1-PE38QQR was cytotoxic to EphA2-positive prostate 
cancer-derived cell lines through induction of caspase-dependent apoptosis and this correlated 
with a rapid decreased in EphA2 protein levels.  
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Figure 2-5:  Potential therapeutic approaches to target Eph receptors in cancer.  
 
(A) Targeting Eph receptors for which ligand stimulation mediates tumour suppression; (B) 
targeting Eph receptors for which ligand stimulation mediates tumour promotion. Examples of 
each approach are discussed in Sections 2.2.8-2.2.9. In (A) ligand mimetics activate and 
phosphorylate the Eph receptor, stimulating both tumour suppressing signalling pathways 
(asterisked in Figure 2.2) and causing receptor internalisation which leads to Eph degradation. 
In (B) where ligand stimulation leads to tumour promotion, blockade of these pathways can be 
affected using an ephrin antagonist peptide or blocking activation of the receptor by a small 
molecule kinase inhibitor.  
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2.2.8.2  Ephrin mimetics 
An early strategy used phage display libraries to identify peptide sequences that bound 
with high affinity to the ligand-binding interfaces on the EphA2, EphA4 and EphB4 ligand 
binding domains (Koolpe et al., 2005; Koolpe et al., 2002; Murai et al., 2003). Peptides that 
both inhibited receptor activation by ephrins or behaved as ephrin mimics, promoting receptor 
activation and downstream signalling, were identified. Experiments using soluble ephrin ligand 
to reconstruct forward signalling have shown that effective signalling is only achieved when 
the soluble ligand is clustered.  Monomeric forms of the ligands are normally antagonists. How 
monomeric peptides that mimic ligands can therefore activate (transphosphorylate) receptors 
is unclear but it is possible that this is via activation of an associated but distinct allosteric site 
through specifically induced conformational changes (Koolpe et al., 2002). 
2.2.8.3 Small molecule inhibitors 
Another approach that has shown promise for targeting receptor tyrosine kinases is use 
of small molecule drugs that block tyrosine kinase activity, receptor autophosphorylation and 
activation of downstream signalling (Gallick et al., 2012; Sonpavde et al., 2006). Small 
molecules that block ligand-independent tumour promoting activities of Eph receptors may 
find application in the treatment of cancers that over-express a particular Eph receptor. Several 
small molecule inhibitors have been identified and most occupy the ATP binding pocket but 
show broad specificity targeting different families of tyrosine kinases (Caligiuri et al., 2006; 
Karaman et al., 2008; Kolb et al., 2008). Two derivatives of 2–5-dimethylpyrrolyl benzoic acid 
that selectively inhibit ligand binding to EphA2 and EphA4 and prevent ligand-dependent 
phosphorylation have been identified (Noberini et al., 2008). Molecules such as these, that 
block ligand binding to the EphA2 and EphA4 receptors, may be more suitable for application 
in therapies for conditions where receptor activation contributes to the pathology.  
Interestingly, these compounds were found to selectively inhibit EphA2-mediated retraction of 
cell periphery in PC3 prostate cancer derived cells and they may therefore also find application 
in cases where EphA2 is highly activated to promote tumourigenesis. 
Petty et al. (2012) have used an in silico screening method to identify small molecule 
agonists of EphA2 and EphA4 that interact with the extracellular ligand-binding domain (Petty 
et al., 2012). One of these, a quinazoline-based compound doxazosin was marketed as 
Cardura®, an α1-adrenoreceptor antagonist for treating hypertension and for improving 
urination in patients with an enlarged prostate from benign prostatic hyperplasia. An indication 
that doxazosin may be effective against prostate cancer had already been demonstrated by 
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experiments which showed that doxazosin treatment of LNCaP cells induced apoptosis through 
changes in the expression of genes involved in cell-cycle regulation, DNA replication and 
repair, and cell adhesion (Arencibia et al., 2005). Agonist activity was demonstrated through 
inhibition of downstream Akt and ERK kinase activities similar to that induced by ligand 
stimulation (Petty et al., 2012). Petty et al. then performed pre-clinical testing of doxazosin as 
an anti-prostate cancer agent (Petty et al., 2012). For these experiments they used PC3 cells in 
which the tumour suppressor gene DAB2IP had been knocked down, as this is reported to 
confer highly migratory and metastatic properties both in vitro and in vivo (Xie et al., 2010; 
Xie et al., 2009). These PC3-DAB2IP knock-down cells were injected orthotopically into the 
prostate glands of nude mice and tumours allowed to establish for 3 days before systemic 
treatment with a daily injection of 50 mg/kg doxazosin for 10 days.  In this model, doxazosin 
reduced distal metastasis and prolonged survival of recipient mice, thereby identifying 
doxazosin as a small molecule agonist of EphA2 capable of inhibiting malignant behaviour of 
PCa cells in vivo. 
Small molecule inhibitors are also in development for targeting EphB4. These include 
the XL647 multi-targeted tyrosine kinase inhibitor (Pietanza et al., 2012) that also inhibits 
EphB4 kinase activity and 4-amino-5-(3-chloro-4-fluoro-phenyl)-7-aryl-thieno[3,2,c]pyridine 
derivatives (Miyazaki et al., 2007) that block the ATP binding pocket of EphB4. Another 
EphB4-specific Novartis compound NVP-BHG712 inhibits EphB4 kinase activity and VEGF-
mediated blood vessel formation in vivo (Martiny-Baron et al., 2010). To our knowledge, no 
studies of these inhibitors have been undertaken to date in prostate cancer. 
2.2.8.4 Monoclonal antibodies 
Monoclonal antibodies targeting receptor tyrosine kinases have proven useful in the 
treatment of several cancers (Scott et al., 2012). In many cases, the antibodies block the ligand-
receptor interaction, inhibit ligand-induced receptor signalling and increase both down-
regulation and internalization of the receptor (Belleudi et al., 2012; Rowinsky et al., 2007; 
Vincenzi et al., 2008).  This may also prove to be a suitable strategy to target Eph receptors for 
which ligand-dependent signalling promotes oncogenesis (for example, EphB2 in colon and 
gastric cancers).  
For treatment of cancers promoted by Eph receptors with ligand-independent signalling 
functions, ligand-blocking antibodies may in fact prove detrimental. The alternative would be 
to use antibodies that activate ligand-like signalling pathways.  Monoclonal antibodies 
targeting both EphA2 and EphB4 have been developed and tested in xenograft studies and are 
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providing encouraging data for the application of these in anti-PCa strategies. Carles-Kinch et 
al. (2002 & 2003) developed antibodies targeting the extracellular domain of EphA2 and 
selected these for their abilities to inhibit metastatic behavior of breast cancer cells. Treatment 
with these EphA2 monoclonal antibodies increased EphA2 phosphorylation and degradation 
(Carles-Kinch et al., 2002; Kinch et al., 2003a). The potential for EphA2 specific antibodies to 
deliver chemotherapeutic agents to tumour cells has also been explored. In many cases the 
efficacy of these would be enhanced by internalisation of the antibody-chemotherapeutic 
immuno-conjugate and subsequent detachment of the chemotherapeutic. Indeed, an EphA2 
monoclonal antibody, 1C1, that induces rapid tyrosine phosphorylation, internalization and 
degradation of the EphA2 receptor, when coupled to the microtubule inhibitor monomethyl 
auristin phenylalanine (MMAF) via a non-cleavable maleimidocaproyl linker, stimulated 
caspase-mediated cell death and inhibited tumour growth in vivo (Jackson et al., 2008).  
Similarly, two antibodies targeting extracellular epitopes of EphB4 inhibit the growth of 
established xenograft tumours of several epithelial cancers, including prostate (Krasnoperov et 
al., 2010). The first of these antibodies, MAb131, recognises an epitope in the fibronectin type-
III domain 1 and is reported to inhibit human endothelial tube formation in vitro (Krasnoperov 
et al., 2010). In vivo treatment with this antibody correlated with a reduction in EphB4 level 
and a 43.1% increase in TUNEL positive cells, indicating increased apoptosis (Krasnoperov et 
al., 2010). The second antibody, MAb47, targets the second fibronectin type-III domain of both 
human and murine EphB4.  In vivo, this antibody did not alter EphB4 receptor levels, but 
inhibited angiogenesis, correlating with a 44% reduction in blood vessel density and, 
consequently, a reduction in the growth of EphB4-positive and EphB4-negative tumours in a 
mouse subcutaneous xenograft model. When applied in combination with bevacizumab, a 
humanized monoclonal antibody that targets a second angiogenesis related protein - vascular 
endothelial growth factor A (VEGF-A) - MAb47 enhanced the anti-tumour activity and 
induced tumour regression (Krasnoperov et al., 2010).  
The anti-EphA3 monoclonal antibody IIIA4 binds to a conformation-specific epitope in 
the ephrin-binding domain of EphA3 (Vearing et al., 2005). This epitope is adjacent to the low-
affinity ephrin binding site known to be involved in heterotetramerisation between two EphA3 
receptors and two ephrin-A5 ligands. Binding of IIIA4 to EphA3 results in a conformational 
change in the EphA3 protein which facilitates assembly of EphA3 with ephrin-A5 ligand into 
signalling clusters. Addition of IIIA4 together with ephrin-A5 enhances signalling and results 
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in contraction of the cytoskeleton and cell rounding. Interestingly, pre-clustered antibody was 
also effective in activating EphA3 signalling (Vearing et al., 2005). 
EphA4-specific antibodies may also find application for the treatment of EphA4 positive 
prostate cancers. Although not yet described in the general scientific literature, a patent 
describing antibodies to EphA4 for treatment of pancreatic cancers has been filed (Nakatsuru 
et al., 2011). Kinch et al.(2009) have also reported in the patent literature that antibodies to 
EphA4 can reduce the anchorage-independent growth of EphA4-expressing cells and decrease 
cell-ECM attachment to induce cell rounding (Kinch et al., 2009). 
2.2.9 Eph Receptors as Targets for Prostate Cancer Specific Imaging Agents  
Given their increased expression levels in tumour cells, it is likely that several Eph 
receptors will prove to be useful targets to improve tumour imaging but, to date, in vivo imaging 
of tumours using Eph receptors as the target protein has been explored by only a few groups.  
The EphA2-specific antibody 1C1 was labelled with copper molecules (64Cu) through 
the chelating agent 1,4,7,10-tetraazacyclododecane N,N′,N″,N″′-tetraacetic acid (DOTA) (Cai 
et al., 2007). This was tested as an imaging agent using eight different tumour models of cell 
lines with varying levels of EphA2 positivity and demonstrated a linear correlation when used 
for positron emission tomography (PET) imaging (Cai et al., 2007).   
Vearing et al. (2005)  have coupled the EphA3-specific antibody IIIA4 to 111Indium for 
gamma camera imaging and found that it retains immunoreactivity with the EphA3 expressing 
target cells in xenograft models (Vearing et al., 2005). The 111In-IIIA4 Ab conjugate is stable 
for approximately 48 h in the circulation and there was significant uptake and retention in the 
tumour mass over this time. Whole-animal images showed that there was no 111In- IIIA4 
deposition in other organs, such as liver or spleen. 
More recently, Mamat et al.(2012) attached a fluorine-18-containing radiotracer to a 
high-affinity benzodioxolylpyrimidine EphB4 kinase inhibitor and tested the potential of this 
as a molecular imaging agent for use in positron emission tomography (PET). Although the 
inhibitor was stable in vivo and retained its function as an EphB4 and Src inhibitor, there was 
no substantial accumulation in the EphB4 over-expressing cells compared to the control cells 
(Mamat et al., 2012). 
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2.2.10   Conclusion 
The family of Eph receptors and their ephrin ligands has well described effects during 
development and in tumours in the adult. Their mechanisms of action are complex, in part due 
to significant promiscuity in their relative binding interactions. Nonetheless, in cancers in 
general, and prostate cancer in particular, there are several observations that suggest that 
specific members of this large family play important roles in tumour promotion and/or tumour 
regression. With prostate cancer over-expressing particular Eph receptors, some with 
correlations with stage of disease, it is evident that future studies on the identified differentially-
expressed genes and signalling pathways will not only be helpful in understanding the biology 
of prostate cancer progression, but may well provide new opportunities for identification and 
imaging of diagnostic and/or prognostic biomarkers, as well as novel therapeutic targets for 
late-stage, castrate-resistant forms of the disease, for which there are no current effective 
therapies. 
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2.3 Literature Review Update 
In this section, a more detailed update of EphB4 and ephrin-B2 literature, with regards 
to cancer in general and prostate cancer has been included to complement the published review. 
2.3.1 EphB4 
EphB4 is a type I transmembrane protein and member of the B subclass of the Eph family 
of receptors. It was independently discovered in the same year in mouse mammary cells, 
CD34+ human bone marrow cells and in a human hepatocellular carcinoma cell line hence the 
former name hepatoma transmembrane kinase (Htk) (Andres et al., 1994; Bennett et al., 1994). 
Analysis of EphB4’s 987 amino sequence and protein domain structure revealed that it was 
close in homology to the Eph family of receptor tyrosine kinases and it was subsequently 
renamed erythropoietin producing hepatocellular receptor B4 (Bennett et al., 1994; Pasquale, 
1997). The EPHB4 gene is situated on Chromosome 7q22 and is highly expressed at the mRNA 
levels in the placenta, foetal heart, brain, lung, liver, kidney but its expression lowers or 
becomes absent in these tissues in the adult (Bennett et al., 1994; Hafner et al., 2004). In 
contrast to other Eph receptors it has only one preferred ephrin ligand, ephrin-B2 (Chrencik et 
al., 2006; Sakano et al., 1996). The main role of EphB4 in embryonic development is to 
regulate angiogenesis and the formation of the cardiovascular system (Adams et al., 1999; 
Erber et al., 2006; Gerety et al., 1999; Kim et al., 2008; Wang et al., 1998). Expression of 
EphB4 on endothelial and endocardial cells designates it to be of venous identity whilst ephrin-
B2 expression on endothelial cells signifies it to be arterial in origin and nature. Lack of these 
proteins in mouse embryos leads to inappropriate intermingling and remodelling of these cell 
populations which results in cardiac defects, defective circulation, arteriovenous 
malformations and embryonic lethality (Gerety et al., 1999). EphB4 also has roles in 
differentiation of stem cell populations through interaction with ephrin-B2 expressing cells and 
subsequent bi-directional signalling. An example of this is when EphB4 expressing 
hematopoietic stem cells (HSC) interact with ephrin-B2 expressing bone marrow stromal cells, 
which causes the HSC to differentiate into mature erythroid cells (Suenobu et al., 2002; Wang 
et al., 2002). The interaction and bi-directional signalling between EphB4 and ephrin-B2 also 
regulates bone homeostasis and remodelling. EphB4 expressing osteoblasts, which are the bone 
forming cells, interact with the ephrin-B2 expressing osteoclasts which degrade bone, resulting 
in activation of either bone development or degradation forming a balance between the 
functions of either cell (Zhao et al., 2006). EphB4 also stimulates osteogenic differentiation of 
mesenchymal stem cells (MSC) through ephrin-B2 interaction and cross talk with the Wnt 
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pathway (Zhang et al., 2015). If EphB4 signalling is unchecked it can result in several non-
cancer pathologies related to uncontrolled angiogenesis such as increased microvessel density 
in pterygium and haemorrhagic cerebral arteriovenous malformation (Bai et al., 2014; Xue et 
al., 2014). Therefore, EphB4 regulates many important developmental processes through its 
interaction with ephrin-B2. 
2.3.2 EphB4: an attractive anti- cancer target  
EphB4 is required for many developmental processes but in the adult is lowly expressed. 
In cancer however, EphB4 is often increased and dysregulated (Chen et al., 2013; Guijarro-
Muñoz et al., 2013; Hasina et al., 2013; Li et al., 2013; Liu et al., 2013a; Tu et al., 2012) (Table 
2.4). The first evidence that linked EphB4 to cancer was its discovery in a hepatocellular cancer 
cell line HEP3B and in the same study found to be expressed at the mRNA level in several 
other cancer cell lines such as breast and colon (Bennett et al., 1994).  
Hyperplasia in tissues is often thought to precede cancer. EphB4 may be involved in 
cancer initiation as it is often found increased in these pre-neoplastic tissues (Hasina et al., 
2013; Lee et al., 2005; Liersch‐Löhn et al., 2015). Transgenic mice where both Ephb4 and 
Neu/HER2 are overexpressed at puberty formed more tumours in the epithelial cells of the 
mammary glands compared to either EphB4 or HER2 overexpression alone, and these tumours 
metastasised to the lung (Munarini et al., 2002). Further studies with the same  model showed 
that overexpression of EphB4 lead to an increase in luminal and progenitor cells in mammary 
epithelial cells and this lead to alterations in the tissue architecture such as increased ductal 
branching (Kaenel et al., 2014) . Furthermore, they showed that there was increased 
angiogenesis in these mice with increased vascularisation compared to wild type mice which 
suggests a transformative potential (Kaenel et al., 2014). Another study of gastroesophageal 
cancer found that EPHB4 mRNA was significantly increased in pre-neoplastic lesions 
compared to normal tissue providing evidence for EPHB4’s potential to be a tumour initiator 
(Liersch‐Löhn et al., 2015). Atypical hyperplastic endometrium is more likely to become 
cancerous compared to simple hyperplasia and a study by Berclaz et al. (2003) showed that 
more cells expressed membrane associated EphB4 in the glandular epithelial cells of atypical 
hyperplasia than simple hyperplasia (Berclaz et al., 2003). These results demonstrate that 
EphB4 overexpression may occur early in the progression from precancerous tissues to cancer 
and may contribute to cancer initiation.  
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Numerous studies have found that EphB4 is over-expressed in many epithelial tumours 
and this suggests a role in many different cancers (Table 2.4). Often there is little to no 
expression of EphB4 in the normal tissue or adjacent stroma surrounding the tumour (Kumar 
et al., 2009; Li et al., 2014; Liu et al., 2013a; Liu et al., 2002; Masood et al., 2006; Sinha et 
al., 2006; Stephenson et al., 2001; Tu et al., 2012).  Li et al. (2014) reported that in their cohort 
of 40 patients undergoing radical cystectomy of which 24 cases had normal bladder tissue 
available, 0% of normal urothelium had EphB4 expression at the protein level (Li et al., 2014). 
Conversely 94 % of transitional cell carcinoma samples had EphB4 expression with the same 
trends seen in matched tumour/normal specimens (Li et al., 2014). 
Studies also report that EphB4 is frequently higher in advanced disease versus early 
disease (Kumar et al., 2007; Kumar et al., 2009; Masood et al., 2006; Sinha et al., 2006; Xia 
et al., 2005a; Xuqing et al., 2012). Patients with advanced HNSCC have significantly higher 
EphB4 expression and this correlated with higher stage of disease (Stage III or IV) (Sinha et 
al., 2006). Another example involving colon cancer reported that the intensity of EphB4 
staining at the protein level showed a significant trend towards increasing tumour stage and 
grade (Kumar et al., 2009). In pancreatic cancer EphB4 expression was significantly higher in 
stage III and IV compared to stage I and II as well as is significantly higher in poorly 
differentiated pancreatic cancer versus well differentiated cancers (Liu et al., 2013a).  
Sometimes there is even higher expression in metastatic deposits than the primary tumour 
(Masood et al., 2006; Sinha et al., 2006). In a study by Kumar et al. (2009) all liver and lymph 
metastases from colon cancer patients expressed EphB4 (Kumar et al., 2009). In HNSCC, all 
patients had EphB4 expression in their primary tumours as well as lymph node metastases, 
however when the mean expression of EphB4 was quantified by Western blot analysis, it was 
found that the lymph node metastasis sites had higher EphB4 expression than the primary 
tumour (Sinha et al., 2006).This suggests that as a tumour progresses there is greater 
dysregulation of EphB4 expression or that EphB4 has a role in metastasis. 
The expression pattern where EphB4 is increased has been shown in studies to correlate 
to poor prognosis, with patients who have higher expression of EphB4 having significantly 
lower overall survival (Alam et al., 2009; Brantley-Sieders et al., 2011; Kumar et al., 2007; Tu 
et al., 2012; Wu et al., 2006). An example of this is with cervical cancer where 100 % patients 
express EPHB4 in their tumours and if they are stratified into either low or high EPHB4 
expressing tumours, high EPHB4 expressing tumours had a significantly lower survival rate of 
31% compared to 72% with low expression of EPHB4 over a 36 month   
 Chapter 2: Literature Review 48                
 
Table 2-3: Summary of EphB4 clinical expression in different cancers. 
 
Tumour Protein/mRNA Positive cases/total cases 
(%) 
Method of 
detection 
Prognostic indications of 
high EphB4 
References 
Bladder Protein 32/34 (94) IF increased stage (Li et al., 2014) 
Bladder Protein; 
Protein 
8/15 (53) 
14/15 (93) 
IHC Western 
Analysis 
ND (Xia et al., 2006) 
Breast Protein 7/12 (58) IHC ND (Kumar et al., 2006) 
Breast Protein 88/94 (94) IHC increased stage and grade (Wu et al., 2004) 
Breast Protein 63/126 (50) IHC poor survival (Brantley-Sieders et al., 2011) 
Cervical Protein 86/90 (95) IHC increased stage, tumour 
diameter and MVD 
(Zhang et al., 2007) 
Cervical Protein 62/62 (100) IHC increased stage, lymph 
node metastasis, poor 
survival 
(Alam et al., 2009) 
Colon mRNA; 
Protein 
51/62 (82) 
6/6 (100) 
RT-PCR IHC ND (Stephenson et al., 2001) 
Colon Protein 67/90 (73) IF increased stage and grade (Kumar et al., 2009) 
Colon Protein 20/20 (100) IHC ND (Liu et al., 2002) 
Endometrial Protein 68/68 (100) IHC increased stage,  increased 
grade  and increased depth 
of myometrial invasion 
(Alam et al., 2007) 
Endometrial Protein 20/20 (100) IF increased stage and grade (Takai et al., 2001) 
Endometrial Protein 69/102 (67) IHC ND (Berclaz et al., 2003) 
Gastroesophageal protein 27/31 (87) IHC increased stage (Liersch‐Löhn et al., 2015) 
Glioma Protein 63/96 (65) IHC increased grade and low 
KPS score, poor survival 
(Tu et al., 2012) 
Glioma mRNA 21/23(91) RT-PCR ND (Chen et al., 2013) 
Head and Neck Protein 14/15 (99) IHC increased stage (Ferguson et al., 2014) 
Head and Neck Protein  48/48 (100)  IHC lymph node involvement  (Sinha et al., 2006) 
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The number of cases positive for EphB4 out of the total number of cases examined and the percentage of cases positive is shown in brackets.  The method for 
EphB4 detection, the prognostic indications of high EphB4 and the relevant literature references are indicated.
Tumour Protein/mRNA Positive cases/total cases 
(%) 
Method of 
detection 
Prognostic indications of 
high EphB4 
References 
Head and Neck Protein 37/37 (100) IF increased histological grade, 
stage and lymph node 
metastases 
(Masood et al., 2006) 
Lung  Protein  15/28 (53) IHC increased stage, lymph node 
metastasis and grade 
(Zheng et al., 2012) 
Lung  Protein  ND IHC increased stage  (Ferguson et al., 2013) 
Mesothelioma Protein  12/16 (75) IHC ND (Xia et al., 2005a) 
Mesothelioma Protein  28/39 (72) IHC ND (Liu et al., 2013a) 
Oesophageal mRNA 44/61 (72) RT-PCR ND (Tachibana et al., 2007) 
Oesophageal Protein  190/201(95) IHC increased grade (Hasina et al., 2013) 
Ovarian Protein 92/115 (80) IHC poor survival  (Wu et al., 2006) 
Ovarian  Protein  51/58 (88) IHC ND (Castellano et al., 2006) 
Ovarian Protein  73/85 (86) IHC increased stage, presence of 
ascites, poor survival 
(Kumar et al., 2007) 
Pancreas 
 
mRNA  
Protein 
15/15 (100) 
56/108 (52) 
RT-PCR 
IHC 
increased grade and MVD (Liu et al., 2013a) 
Prostate Protein  41/62 (66) IHC ND (Xia et al., 2005b) 
Prostate Protein  10/15 (66) IHC increased grade (Lee et al., 2005) 
Thyroid Protein 21/21 (100) Western 
Analysis and 
IHC 
lymph node involvement and 
extracapsular spread 
(Sharma et al., 2014) 
Thyroid mRNA 11/16 (69) RT-PCR  ND (Xuqing et al., 2012) 
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period after curative resection of the tumour (Alam et al., 2009). Kaplan-Meier analysis 
of an ovarian cancer cohort showed patients with high EphB4 expression had significantly 
worse median survival (2.58 years) vs low EphB4 expression (7.75 years) with EphB4 
expression being a significant predictor of poor survival (Kumar et al., 2007). Therefore EphB4 
is a non-survival factor in cells that express it and these examples demonstrate the importance 
that EphB4 expression has with regards to patient survival and highlight the potential for it to 
be used to predict prognosis of patient tumours.  
In cancer, amplification of the EPHB4 gene locus could result in EPHB4 up-regulation. 
This is evidenced by Masood et al. (2006) who assessed gene amplification in HNSCC, defined 
as greater than four copies, of the EPHB4 locus and found that 30% tumours had EPHB4 gene 
amplification and that often this gene amplification was limited to higher disease stage 
(Masood et al., 2006). In a comparative genomic hybridization array study of breast cancer,  
the 7q22 site where the EPHB4 locus resides, was amplified in 29% of cases (Somiari et al., 
2004). In oesophageal cancer, 60 % of SCC clinical samples and 62% of adenocarcinoma 
samples had 4-20 copies of the EPHB4 gene (Hasina et al., 2013). Similar trends were seen in 
bladder cancer with 27% of patients possessing 4 or more copies of EPHB4 and squamous cell 
lung carcinoma where 23% had more than 3 copies of EPHB4 and 14% of these having more 
than 10 copies (Ferguson et al., 2013; Xia et al., 2006). 
EphB4 is a transmembrane receptor so it is expected that it will only be in the membrane, 
however in clinical samples the EphB4 protein is also detectable in the cytoplasm and can be 
found in blood vessels, as well as the invasive front of tumours (Alam et al., 2007; Castellano 
et al., 2006; Guijarro-Muñoz et al., 2013; Hasina et al., 2013; Tu et al., 2012). In Glioma, 
EphB4 was not only expressed on the cell membrane of the cancer cells but also in the 
cytoplasm with the highest expression in the tumour cells adjacent to perinecrotic areas of the 
tumour (Tu et al., 2012). In an ovarian cancer study all the histological subtypes demonstrated 
membrane localisation of EphB4 except the clear cell subtype which had cytoplasmic staining 
(Castellano et al., 2006). Wu et al. (2004) also reported that the EphB4 expressed in their breast 
cancer study was largely cytoplasmic and that only 22 of the 88 tumours positive for EphB4 
had membrane staining (Wu et al., 2004). Guijarro-Muñoz et al. (2013) reported that all EphB4 
positive colorectal tumour cells had diffuse cytoplasmic staining with some basolateral 
membrane staining (Guijarro-Muñoz et al., 2013). However Kumar et al. (2009) reported that 
EphB4 staining is only found in the membrane and these differences in cell localisation found 
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in these two studies might reflect that the Guijarro-Muñoz et al. (2013) study involved patients 
who had been treated with chemotherapy and the anti-angiogenic antibody bevacizumab whilst 
the Kumar et al. (2009) study were treatment naive (Guijarro-Muñoz et al., 2013; Kumar et 
al., 2009). Another reason for this discrepancy is that the Guijarro-Muñoz et al. (2013) study 
used a monoclonal antibody directed towards the intracellular domain of EphB4 whilst the 
Kumar et al. (2009) study used a monoclonal antibody which recognises the extracellular 
domain (Guijarro-Muñoz et al., 2013; Kumar et al., 2009). In some cases EphB4 is expressed 
in the vasculature surrounding the tumour and was also found in the cytoplasm of these vascular 
endothelial cells (Alam et al., 2007; Alam et al., 2009; Kumar et al., 2009; Masood et al., 2006; 
Wu et al., 2004). EphB4 has also been found on the invasive front of tumours in clinical 
samples and this suggests that it may have a role in invasion (Masood et al., 2006; Wu et al., 
2004). Masood et al. (2006) found that in the necrotic core of tumours they found reduced 
expression of EphB4 but most of EphB4’s expression was on the leading edge of the tumour 
(Masood et al., 2006). Furthermore they found that EPHB4 specific anti-sense probes showed 
strong EPHB4 expression was seen at the edge of the tumour where tumour cells were most 
metabolically active (Masood et al., 2006). Interestingly, Wu et al. (2004) also found that 
elevated cytoplasmic staining of EphB4 was predominantly in the invasive front suggesting 
that EphB4 may have a differential localisation in cancer although this expression could be due 
to EphB4’s expression in other intracellular membranes (Wu et al., 2004).  
EphB4 could also be used as a marker to predict which patients will respond to a 
particular anti-cancer therapy. In a study investigating predictive biomarkers for treatment 
response to the anti-VEGF monoclonal antibody bevacizumab in metastatic colorectal cancer 
patients, EPHB4 mRNA and protein expression was highest in patients who did not respond to 
bevacizumab treatment (Guijarro-Muñoz et al., 2013). The study also found that in patients 
treated with bevacizumab, the ones with the higher EphB4 expression have significantly lower 
overall survival, with the 6 patients with the highest EphB4 expression succumbing to their 
disease before the conclusion of the study (Guijarro-Muñoz et al., 2013). This outcome was 
specific to bevacizumab treatment response as an independent cohort of patients treated only 
with chemotherapy showed there was no correlation between EphB4 expression, chemotherapy 
response and overall survival in these patients (Guijarro-Muñoz et al., 2013). EphB4 
expression can also predict patient response to chemotherapy (Wu et al., 2006). In a study 
where an ovarian cancer cohort was treated with platinum-based chemotherapy and followed 
up for a median of 71 months the patients with weak expression of EphB4 had significantly 
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higher complete treatment responses than those with strong EphB4 expression (Wu et al., 
2006). These studies suggest a potential for EphB4’s value as a biomarker for treatment 
response that is crucial to avoid unnecessary or unbeneficial treatments for cancer patients.  
EphB4 is commonly dysregulated in cancer but somewhat conflictingly is also reported 
as down-regulated (Batlle et al., 2005; Berclaz et al., 2002; Noren et al., 2006). In 2001, 
Stephenson et al. (2001) reported over-expression of EphB4 in 66% of colon cancer samples 
when compared with matched normal mucosa. This was supported by a study by Liu et al. 
(2002) published not long after. However in 2005, Batlle et al. (2005) reported down-regulation 
of EphB4 in colon cancer and suggested that EphB4 was a tumour suppressor gene. Davalos et 
al. (2006) also showed that there was a trend towards decreasing levels of EphB4 in colon 
cancer progression and explained that this is due to methylation as the promoter of EPHB4 was 
methylated in ∼50% of colorectal tumours in their cohort. They also showed that patients with 
low EPHB4 had a significantly worse prognosis than those with high EPHB4 (Davalos et al., 
2006). However, another study demonstrated with the use of better techniques such as bisulfite 
sequencing and methylation-specific polymerase chain reaction, that the EPHB4 promoter was 
not methylated in colon and ovarian cancer, casting doubt on both the Batlle et al. (2005) and 
Davalos et al. (2006) studies (Wu et al., 2007). More recently however, Kumar et al. (2009) 
showed that EphB4 was over-expressed in all 102 colorectal cancer specimens examined and 
that expression levels correlated with higher tumour stage and grade (Kumar et al., 2009). 
Similar conflicting data is present for studies of breast cancer where EphB4 seems to be down-
regulated (Kumar et al, 2006, Berclaz et al, 2002). EphB4 is expressed in a number of breast 
cancer cell lines where it has been shown that it could be a tumour suppressor through 
activation of the Abl-Crk pathway (Noren et al., 2006). 
In an effort to explain these data, a model for a dual function of EphB4 in both tumour 
promotion and tumour suppression has been proposed (Chen et al, 2008; Pasquale et al, 2010). 
In this model, tumour promotion of EphB4 is a ligand-independent function and the presence 
of ligand regulates signalling pathways that lead to tumour suppression. Several studies support 
this model including those that have shown 1) EphB4 over-expressed in cancers is poorly 
phosphorylated (Noren, Yang, Silldorff, Mutyala, & Pasquale, 2009); 2) stimulation of EphB4 
on cancer cells using soluble exogenous ligand causes cancer cell death (Noren et al., 2006; 
Noren et al., 2004); and 3) an antagonistic peptide that blocked the ephrinB2 binding site of 
EphB4 inhibited cell adhesion (Noren et al., 2009). Furthermore, cancer cells do not form good 
cell-cell contacts that would be required for Eph-ephrin interaction and activation of ligand-
 Chapter 2: Literature Review 54                
 
dependent forward signalling, efficiently. This hypothesis was formally tested in our laboratory 
where we showed that the tumour suppressive or promoting role of EphB4 in both a breast and 
prostate cancer model is highly dependent on the presence or absence of its sole physiological 
ligand, ephrin-B2 (Rutkowski et al., 2012). 
2.3.3 Update to EphB4 in Prostate cancer 
In agreement with the differential localisation of EphB4 in clinical cancer samples 
discussed above our laboratory has found that EphB4 has a differential localisation in prostate 
cancer (Mertens-Walker et al., 2015b). In prostate cancer cell lines EphB4 was localised to not 
only the membrane of cells but also the cytoplasm and the nucleus (Mertens-Walker et al., 
2015b). We identified two functional nuclear localisation signal (NLS) sequences; one being 
in the intracellular domain of EphB4 consisting of the residues RGRLKAPGKKE (key 
consensus residues are in bold) using the NLS prediction program NLStradamus (Mertens-
Walker et al., 2015b). This signal is recognised by the protein importin-α which then transports 
the NLS containing proteins into the nucleus via the nuclear pore complex (Lange et al., 2007). 
Through mutational studies we found both NLS are functional and through CHIP experiments 
discovered that EphB4 could bind DNA. We mapped these sequences to places in the genome 
and found that one of these sequences aligned with Lymphoid enhancer-binding factor 1 
(LEF1) and that EphB4 may regulate LEF1 expression (Mertens-Walker et al., 2015b). 
Following this discovery our laboratory knocked down EphB4 in the prostate cancer cell line 
LNCaP using siRNA and then performed microarray analysis to determine of there were any 
other genes that EphB4 could regulate besides LEF1. After EphB4 knockdown, Integrin β8 
(ITGB8) was the most significantly down regulated gene with a fold change of -29.4 compared 
to non-silencing siRNA control(Mertens-Walker et al., 2015a). This was then confirmed both 
at the mRNA and protein level with Western analysis showing that if EphB4 is silenced in 
LNCaP, ITGB8’s expression decreased concurrently. Importantly, in the prostate cancer cell 
line 22Rv1, where there is no expression of ITGB8 at the protein level, expression is switched 
on when EphB4 is overexpressed (Mertens-Walker et al., 2015a).   
Prostate cancer often metastasises to the bone and involves a complicated interplay 
between prostate cancer cells, stromal cells, osteoblasts, osteoclasts and hematopoietic stem 
cells (Ibrahim et al., 2010). Recently Özdemir et al. (2014) identified EphB4 as unregulated in 
a gene signature of the osteoblastic bone metastasis-associated stroma transcriptome (OB-
BMST) (Özdemir et al., 2014). This study used xenografted prostate cancer cells which form 
osteoblastic lesions in mouse bone and defined the response of the bone-specific stroma to 
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these cells in order to elucidate why prostate cancer cells exhibit osteotropism (Özdemir et al., 
2014). They highlighted EphB4’s role as an upstream regulator in this gene signature and its 
potential as an activator of the canonical TGF-β pathway as well as speculated that because of 
the known roles of EphB4/ephrin-B2 in bone homeostasis and angiogenesis, which were 
common themes is this gene signature, it suggests an important link between EphB4’s role in 
development and potential role in bone metastasis of prostate cancer (Özdemir et al., 2014).  
2.3.4 ephrin-B2  
The ephrins are a family of 9 proteins and the ligands of the Eph receptors (Pasquale, 
1997). They are divided into two subclasses based on sequence homologies which translate to 
the structure of the proteins and in particular how they are attached to the cell surface – the six 
ephrin-A ligands are cell attached through GPI links and the three ephrin-B ligands, via a single 
hydrophobic transmembrane sequence. Interaction of ephrins with Eph receptors is 
promiscuous in particular within the ephrin-A subclass (Pasquale, 1997).  
Ephrin-B2 is the sole ligand for EphB4 but itself can interact with several other EphB 
and EphA receptors including EphB1, EphB2 and EphA4, (Himanen et al., 2001; Qin et al., 
2010; Smith et al., 1997).  The gene for EFNB2 is located on 13q33 and encodes a 333 amino 
acid protein with an extracellular receptor binding domain, a single transmembrane sequence 
and an intracellular domain that can be phosphorylated at the C-terminal PDZ domain 
following binding to the receptor (Bennett et al., 1995; Brückner et al., 1997; Cerretti et al., 
1995; de Fatima et al., 1994; Holland et al., 1996; Torres et al., 1998). This initiates the events 
of signalling described as reverse signalling and ultimately activates processes that cause 
repulsion of the receptor-expressing and ligand-expressing cells (Gale et al., 1997). 
 During development, expression on arterial angioblasts, endothelial cells (ECs) and 
perivascular mesenchymal cells supports a hypothesis that ephrin-B2 is involved in 
vasculogenesis and lymphogenesis (Adams et al., 1999; Gerety et al., 2002; Wang et al., 1998). 
Knock-out mouse studies confirmed an essential role for Efnb2 in development of the mouse 
vascular system and as this phenocopied Ephb4 knockout, this suggested that it was in fact the 
interaction of EphB4 and ephrin-B2 that was required (Adams et al., 1999; Gale et al., 2001). 
Interestingly, EphB4 and ephrin-B2 are reciprocally expressed in the vascular system – ephrin-
B2 is expressed by arterial endothelial cells and EphB4 by venous ECs (Adams et al., 1999). 
During vasculogenesis, ephrin-B2 reverse signalling regulates endothelial tip cell guidance and 
this is in part through the regulation of VEGFR2 internalization (Sawamiphak et al., 2010; 
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Wang et al., 2010b). Ephrin-B2 is also involved in the developing nervous system in several 
direct and indirect ways. For example, ephrin-B2 is required for vascularisation of the neural 
tube, can induce neural stem cell quiescence and mediates axon guidance in the retina (Lewis 
et al., 2015; Ottone et al., 2014; Wang et al., 1998; Williams et al., 2003). Loss of ephrin-B2 
also leads to defects in populations of cranial and trunk neural crest cells and to defective somite 
development (Davy et al., 2007). These examples highlight the important role ephrin-B2 has 
in development particularly with regards to vascular and neuronal development. 
2.3.5 ephrin-B2 in cancer 
Ephrin-B2 may also be involved in tumour initiation with a similar role to its binding 
partner EphB4. In gastroesophageal cancer, EFNB2  mRNA is significantly overexpressed in 
both preneoplastic tissues and tumours compared to normal tissue (Liersch‐Löhn et al., 
2015). This suggests that EFNB2 upregulation gives these preneoplastic cells the capacity to 
become cancerous and continues to play a role after tumour initiation.  
Increased levels of ephrin-B2, both at the mRNA and protein levels have been 
identified in clinical samples of many different cancer types such as colon, bladder, thyroid, 
gastroesophageal, ovarian, mesothelioma, breast and prostate (Alam et al., 2007; Alam et al., 
2008; Kataoka et al., 2002; Liu et al., 2002; Nakada et al., 2010; Sharma et al., 2014; 
Tachibana et al., 2007; Xia et al., 2006; Xia et al., 2005a). In colon cancer EFNB2 mRNA 
expression was found in both normal mucosa and cancer tissue however IHC analysis 
revealed higher protein expression in the tumour tissue compared to normal mucosa (Liu et 
al., 2002). EFNB2 is significantly increased in glioblastoma compared to normal brain 
surrounding the tumour (Nakada et al., 2010). Additionally Nakada et al. (2010) found that 
those patients with higher EFNB2 expression had significantly shorter survival than patients 
with low EFNB2 expression and  ephrin-B2 was highly phosphorylated in these patients 
suggesting activation of ephrin-B2 (Nakada et al., 2010). In both endometrial, uterine and 
ovarian tumours both EFNB2 mRNA and ephrin-B2 histoscores have been observed to 
significantly increase with clinical stage (Alam et al., 2007; Alam et al., 2008). As with 
EphB4, patient prognosis was poor with high ephrin-B2 expression (Alam et al., 2007; Alam 
et al., 2008). Furthermore in endometrial and uterine cancer EFNB2 mRNA expression and 
histoscores also significantly increased with histological grade and depth of myometrial 
invasion (Alam et al., 2007). This suggests that ephrin-B2 expression may be a good marker 
for determining the prognosis for a particular tumour and that the role of ephrin-B2 in these 
tumours may include invasion into surrounding tissues.  Further evidence by a study into 
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oesophageal SCC showed EFNB2 mRNA expression significantly correlated with the number 
of lymph node metastases and in thyroid cancer increased levels of ephrin-B2 significantly 
correlated to lymph node involvement (Sharma et al., 2014; Tachibana et al., 2007).  
The role of ephrin-B2 in pathological settings such as cancer may reflect its functions 
during development. For example, expression of ephrin-B2 has been shown to increase in adult 
neovascularization sites including during tumour angiogenesis and its role may include its 
interaction with EphB4 and this will be further discussed in the next section of this chapter 
(Masood et al., 2005; Noren et al., 2004).  
 
2.3.6 Angiogenesis can be regulated by the interaction between the extracellular domain 
of EphB4 and ephrin-B2 
Studies have shown that not only does EphB4-ephrin-B2 signalling have a role in 
developmental angiogenesis but this signalling also occurs in cancer to promote angiogenesis 
in the surrounding tumour endothelium (Noren et al., 2004). This was explored through 
engineering breast cancer cells to express a fusion protein of the EphB4 extracellular domain 
(ecd) with green fluorescent protein [replacing the intracellular domains (EphB4ΔC-EGFP)], 
which is capable of stimulating reverse signalling into ephrin-B2 ligand expressing cells but 
cannot activate forward signalling into the tumour cells (which would be tumour suppressive) 
(Figure 2.6A). In a mouse xenograft model using this cell line there was an increase in tumour 
volume and angiogenesis associated with an increased size in blood vessels and haemoglobin 
concentration in EphB4ΔC-EGFP tumours versus control cells. Green fluorescent EphB4-ecd 
tumour cells were also seen to reside close to endothelial cells that were ephrin-B2 positive 
suggesting that they were interacting (Noren et al., 2004). In vitro the EphB4ΔC-GFP cells 
were also able to attract HUVEC (Human umbilical vein endothelial cells) and induce these 
cells to proliferate and invade more, characteristics that are key angiogenic factors. The soluble 
EphB4 ectodomain fused to human Fc (EphB4-Fc) also exerted a pro-angiogenic effect 
suggesting that the ectodomain of EphB4 could be a mediator of ephrin-B2 reverse signalling 
which stimulates angiogenesis (Noren et al., 2004) (Figure 2.6B). 
In the experiment described above, the EphB4ΔC-GFP protein is expressed on the 
surface of the tumour cells and is therefore likely to be clustering on the surface to facilitate 
formation of the heterotetrameric signalling complexes. Interestingly, studies have shown that 
soluble, monomeric EphB4 extracellular domain (sEphB4) can prevent reverse signalling 
 Chapter 2: Literature Review 58                
 
through ephrin-B2 because it cannot dimerise and therefore cannot form the required 
heterotetramer (Kertesz et al., 2006; Martiny-Baron et al., 2004; Scehnet et al., 2009). Martiny-
Baron et al. (2004) first studied this in the melanoma cell line A375 by transfecting cells to 
stably express and secrete a soluble form of the extracellular domain of EphB4 (Figure 2.6C). 
When compared with parental A375 cells, EphB4-ecd expressing A375 cells did not form 
compact 3D spheroids, an in vitro characteristic where formation of more spheroids indicates 
more metastatic potential (Martiny-Baron et al., 2004). Although Martiny-Baron et al. (2004) 
stated that the EphB4 was monomeric, they did not formally determine whether this was the 
case.  Noren et al. (2004) found that ephrin-B2 stimulation and subsequent EphB4 activation 
has negative effects on cell proliferation and tumour progression and although reporting that 
A375 cells are ephrin-B2 positive, Martiny-Baron et al. (2004)  did not explore further whether 
this effect was mediated through ephrin-B2 blockade and/or alterations to EphB4 signalling 
(Martiny-Baron et al., 2004; Noren et al., 2004).  
A second study from Kertesz et al. (2006), which also explored the function of a soluble 
monomeric form of the EphB4 extracellular domain, showed that it could antagonise both 
EphB4 and ephrin-B2 signalling and that sEphB4 injected into mice could decrease tumour 
growth in mouse tumour xenografts (Figure 2.6C). This study also determined that sEphB4 
could inhibit angiogenesis of HUVEC in vitro (Kertesz et al., 2006).  Further studies by the 
same group also determined that sEphB4 stabilised through a C-terminal fusion to human 
serum albumin (sEphB4-HSA) could inhibit migration and limit invasion of Kaposi sarcoma 
cells even in the presence of chemo attractants such as fibroblast growth factor (FGF), vascular 
endothelial growth factor (VEGF), epidermal growth factor (EGF), and platelet-derived growth 
factor (PDGF) (Figure 2.6 C). 
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Figure 2-6: The EphB4 extracellular domain can modulate signalling.  
 
(A)An EphB4-GFP fusion protein with a deletion of EphB4’s cytoplasmic domain (EphB4ΔC-
EGFP) can induce angiogenesis through stimulation of ephrin-B2 reverse signalling. (B) The 
extracellular domain of EphB4 fused with the Fc region of human IgG (EphB4-Fc), which can 
dimerize and be artificially clustered (using an anti-Fc antibody) for signalling, can also induce 
angiogenesis. (C) Bi-directional signalling between EphB4 and ephrin-B2 can be prevented by 
soluble monomeric EphB4 extracellular domain (sEphB4) with or without a serum albumin 
carrier (sEphB4-HSA) which results in diminished angiogenesis and tumour growth. 
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The effect of the sEphB4-HAS fusion was also tested in vivo using a murine tumour xenograft 
model in which Kaposi sarcoma cells were injected into the flank of mice along with either 
sEphB4-HSA or Avastin (a VEGF monoclonal antibody) or both in combination. The 
combination of both sEphB4-HSA and Avastin significantly reduced tumour volume when 
compared to either treatment alone or control untreated tumours (Scehnet et al., 2009). The 
clinical potential of soluble EphB4 ecd is further evidenced by another study combining a 
Dll4/Notch inhibitor (sDll4) and sEphB4-HSA for treatment of insulinoma. The use of both 
inhibitors in RIP1-Tag2 (RT2) mice, a genetically engineered mouse model of pancreatic 
neuroendocrine cancer that can re-initiate tumour angiogenesis after angiogenic blockade, 
resulted in reduced tumour volumes. Interestingly treatment of these mice with sEphB4-HSA 
alone resulted in an increase of the PSENEN gene, the catalytic domain of γ-secretase which 
we have shown can further cleave EphB4 (Djokovic et al., 2010). In Malignant Pleural 
Mesothelioma, xenograft studies have shown that combined treatment with  bevacizumab (a 
VEGF monoclonal antibody) and sEphB4-HAS leads to cell death and complete tumour 
regression through decreased tumour angiogenesis  (Liu et al., 2013a). The role of sEphB4 in 
reducing tumour angiogenesis was also explored in studies of Dll4-mediated Avastin resistance 
highlighting the complex roles EphB4 signalling may have in angiogenesis (Li et al., 2011). In 
summary, the signalling response of ephrin-B2 to EphB4 binding is dependent on the level of 
multimerization of the extracellular domain of EphB4.  
 
2.3.7 Proteases can modify signalling and regulate the interaction between Ephs and 
ephrins 
Proteolytic cleavage has been reported previously for other members of the Eph/ephrin 
family and occurs both in normal and pathological processes and is reported to be another 
regulatory mechanism that includes extracellular and/or intracellular proteolysis of either 
receptor or ligand to terminate the interaction and thus signalling or to influence and elicit a 
different cellular response.  The most well characterised example of this is the interaction 
between A Disintegrin And Metalloproteinase 10 (ADAM10) and EphA3 (Janes et al., 2005). 
When EphA3 and its ligand ephrin-A5 interact on opposing cells, ADAM10 is 
conformationally changed and activated to recognise an ADAM10 cleavage site in ephrin-A5, 
resulting in cleavage of ephrin-A5 from the surface of the ephrin expressing cell. Cleavage of 
ephrin-A5 leads to endocytosis of the remaining EphA3-ephrin-A5 complex into the EphA3-
expressing cell, and subsequent repulsion between the two cells and cessation of ligand 
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signalling (Janes et al., 2005). Another study showed that when the kinase domain of EphA3 
is inactive it sterically hinders effective ADAM10 activity but once EphA3 is stimulated, it 
causes a conformational change that increases ADAM10 activity (Janes et al., 2009). Recently, 
the interaction between ADAM10 and EphA3 has been targeted with blocking monoclonal 
antibodies which bind the cysteine rich domain of ADAM10 and prevent ephrin-A5 cleavage 
(Atapattu et al., 2012). This offers a promising new avenue for inhibiting ADAM10 activity 
which is often associated with cancer and is currently a druggable target (Crawford et al., 2009; 
Duffy et al., 2011). ADAM10 has also been shown to initiate axon withdrawal by cleaving 
ephrin-A2 when it binds to EphA3 allowing the cells to disengage  and is implicated in 
Eph/ephrin signalling in the development of the cranial neural crest (CNC) (Hattori et al., 
2000). ADAM10 terminates the interaction between EphB receptors and ephrin-B1 and B2 that 
stimulates Wnt signalling, elevates SNAI2 expression and induces development of the CNC 
(Wei et al., 2010).  In Xenopus ephrin-B2 is cleaved by ADAM10 and this regulates its protein 
expression (Ji et al., 2014a). These studies demonstrate the highly regulated way that cell 
repulsion or adhesion is achieved by modulation of Eph/ephrin interaction by proteases. 
Studies of cleavage of ephrin ligands have recently centred on how the released 
extracellular domain protein can modulate the activity of its cognate receptor both in normal 
cells and in cancer. Wykosky et al. (2008) showed that soluble monomeric ephrin-A1 was 
released into the medium of both glioblastoma multiforme and breast cancer cell lines after 
cleavage by a metalloprotease (Wykosky et al., 2008). This form of the ligand was still 
functional as it could induce EphA2 internalisation and subsequent down regulation of EphA2 
protein levels (Wykosky et al., 2008). Recently the same group further characterised this by 
discovering that MMPs-1, -2, -9, and -13 could all cleave ephrin-A1 potentially releasing three 
distinct cleavage fragments (Beauchamp et al., 2012). EphA2, which is normally over-
expressed in this type of cancer, is degraded because of the released ephrin-A1 (Wykosky et 
al., 2005). The consequence of this cleavage in a cancer context is unclear as a possible result 
would be loss of EphA2’s tumour promoting properties. Recently, a study by Ieguchi et al. 
(2014), found that ADAM12 could cleave ephrin-A1 and release it into the medium (Ieguchi 
et al., 2014). The study did not indicate where in the amino acid sequence of ephrin-A1 the 
protease actually cleaved but the data seemed to indicate that the complete extracellular portion 
of ephrin-A1 was released into the medium. This study also reported that the soluble ephrin-
A1 might induce lung metastasis in mice injected with Lewis Lung Carcinoma cells. Although 
they did not explore the effect on metastasis directly, they did show that the blood vessels of 
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the lung became leakier after treatment of recombinant ephrin-A1-Fc (Ieguchi et al., 2014).  
They also indicated this could be abrogated by treatment with EphA2-Fc which traps the 
soluble ephrin-A1.  This response is likely to be cell-context or possibly cancer cell-specific 
because an earlier study indicated that EphA2-Fc treatment results in the release of ephrin-A1 
from human embryonic kidney HEK293 cells (Finne et al., 2004).  Another example of cancer 
related cleavage of ephrin ligands involves binding of ephrin-B1 to EphB2 which results in 
ephrin-B1’s cleavage by MMP-8.  This in turn leads to a feedback loop whereby MMP-8 
secretion is increased facilitating tumour migration and invasion (Tanaka et al., 2007). Other 
proteases that can cleave ephrin ligands include the human rhomboid family proteases and γ-
secretase (Georgakopoulos et al., 2006; Georgakopoulos et al., 2011; Pascall et al., 2004; 
Tomita et al., 2006). 
More relevant to this project is the notion that EphRs can also be cleaved by proteases to 
directly modulate their signalling functions. In response to stress, the ectodomain of EphB2 is 
cleaved by neuropsin (kallikrein 8) in the amygdala which causes it to dissociate from the N-
Methyl-D-aspartic acid receptor, activate Fkbp5 gene expression and this correlated with an 
induction of anxiety (Attwood et al., 2011). Treatment of both HEK293 and the bone marrow 
neuroblast cell line SH-SY5Y with recombinant neuropsin resulted in a cleavage event towards 
the C-terminus of the second fibronectin type III repeat of EphB2 and released a 70 kDa protein 
fragment corresponding to almost the entire ecd into the medium.  In neuropsin knockout mice, 
there was no cleavage event and a muted stress response (Attwood et al., 2011).  Along a 
neuron’s dendrite residues there are small protrusions called dendritic spines which can connect 
excitatory synapses and axons and regulate synaptic plasticity (Ethell et al., 2005). In the 
formation of dendritic spines the ectodomain of EphA4 is cleaved by MMPs, independently of 
its ligand, and this is followed by subsequent cleavage by γ-secretase (Inoue et al., 2009). This 
was blocked using the general MMP inhibitor GM6001 which resulted in a decrease of EphA4 
cleavage. Use of the γ-secretase inhibitor Compound E resulted in the accumulation of the 
intermediate C-terminal fragment.  After the second cleavage event by γ-secretase, the 
intracellular domain (ICD) of EphA4 translocates to the nucleus where it enhances the 
formation of lamellipodia and dendritic spines through activation of the Rac signalling pathway 
(Inoue et al., 2009). This regulation was further shown to be attenuated in Alzheimer’s disease 
where there was significantly less ICD of EphA4 in these patients and dendritic spines could 
not be formed (Matsui et al., 2012).  EphA4 cleavage has also been shown to promote repulsion 
between two spinal motor axons and is important for the availability of its ephrin ligand in the 
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developing embryo (Gatto et al., 2014). This cleavage event allows efficient detachment of 
EphA4 expressing motor axons from other axons which express ephrin-A1 and mice that have 
cleavage resistant EphA4 display defects in motor axon guidance (Gatto et al., 2014). 
Interestingly cleavage resistant EphA4 can block ephrin-A1 reverse signalling through cis 
signalling as there is more full length EphA4 on the surface (Gatto et al., 2014).  
Cleavage of EphRs can have distinct consequences which are dependent on where the 
cleavage occurs and also the stimulus that initiates it. Litterst et al. (2007) showed that calcium 
influx stimulated by ionomycin, results in cleavage of EphB2 at the cell membrane by 
ADAM10 and production of an N-terminal fragment of EphB2, which is secreted into the 
medium, and a C-terminal fragment initially still tethered to the cytoplasmic side of the 
membrane but then further cleaved by γ-secretase and released into the cytosol (Litterst et al., 
2007). Distinctly, ligand binding mediated cleavage occurs after internalisation of the 
signalling complex and occurs in the endosome. The cleavage is firstly mediated by β-secretase 
which results in degradation of the EphB2 N-terminal fragment and is followed by γ-secretase 
cleavage of the remaining C-terminal fragment which is then ubiquitinated and degraded in the 
proteasome (Litterst et al., 2007) .This group then showed that if the C-terminal fragment 
escapes degradation it can retain tyrosine kinase activity and can directly phosphorylate 
NMDAR subunits at tyrosine residues independent of Src kinases leading to cell surface 
localisation of the NMDAR (Xu et al., 2009). In contrast to the previous two studies another 
group found that ligand binding induced EphB2 cleavage by MMP-2/MMP-9 at the surface of 
HEK293 cells which resulted in a stable ICD and cellular repulsion through RhoA (Lin et al., 
2008).  These cleavage events can also be independent of the interaction between the Eph 
receptor and ephrin ligand. EphA2 has been shown to be regulated by MT1-MMP in breast 
cancer (Sugiyama et al., 2013). It was found that MT1- MMP and EphA2 were co-expressed 
in the more invasive breast cancer cell lines and that MT1-MMP could cleave EphA2 in the 
first fibronectin type III repeat. Cleavage by MT1-MMP led to intracellular localisation of 
EphA2 and activated RhoA which led to cellular repulsion and single cell invasion. 
Interestingly EphA2 silencing led to decreased MT1-MMP at both the mRNA and protein level 
that indicates that the receptor may be co-regulated with the protease that cleaves it. 
Furthermore, in patients with more invasive tumours and lymph node metastasis there was a 
correlation between high intracellular protein expression of EphA2 and high levels of MT1-
MMP indicating that this also occurred in vivo (Sugiyama et al., 2013). Further to this, another 
study showed that EphA2 cleavage by MT1-MMP occurred in the ligand binding domain of 
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EphA2. Interestingly it was found that ligand independent phosphorylation was the catalyst for 
cleavage by MT1-MMP and this event lead to increased cell migration and anchorage-
independent growth. In vivo xenograft studies revealed that proteolysis of EphA2 increased 
metastasis and that expression of a mutant EphA2 protein that couldn’t be cleaved in these 
mice lead to decreased tumourigenic potential (Koshikawa et al., 2015). Proteases such as those 
involved in the coagulation cascade, that haven’t previously been associated with Eph receptor 
cleavage, have been recently identified as candidate proteases. EphB2 and EphA2 have been 
identified as substrates of the serine protease factor VII (FVII), which when bound by its 
receptor partner tissue factor (TF)  and  is activated (FVIIa), form part of the coagulation 
cascade. In breast cancer cells both EphA2 and EphB2 were directly cleaved in their 
extracellular domains, independently of PAR2, and this lead to cell repulsion after ligand 
stimulation (Eriksson et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2: Literature Review  65
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 2: Literature Review 66                
 
Chapter 3: Studies exploring ephrin-B2 
cleavage by the serine protease 
Kallikrein-4  
 
 
 MURINE, BUT NOT HUMAN, EPHRIN-B2 CAN BE EFFICIENTLY CLEAVED BY 
THE SERINE PROTEASE KALLIKREIN-4: IMPLICATIONS FOR XENOGRAFT 
MODELS OF HUMAN PROSTATE CANCER 
 
 
Jessica Lisle, Inga Mertens-Walker, Carson Stephens, Scott Stansfield, Judith Clements, 
Adrian Herington & Sally-Anne Stephenson 
 
Published in Experimental Cell Research, Volume: 333, Pages 136-146. 
 
Statement of Contribution of Co-Authors for Thesis by Published Paper  
 
 
Contributor  
 
Statement of contribution 
Jessica Lisle   
 
Involved in experimental design, performing the 
laboratory experiments, data analysis and writing the 
manuscript 
  
Inga Mertens-Walker 
Involved in data analysis and editing the manuscript 
for submission 
Carson Stephens Involved in making the recombinant KLK4 
Scott Stansfield  Performed the in silico experiments  
Judith Clements 
 
Involved with experimental design and reviewing the 
manuscript 
Adrian Herington 
 
Involved with experimental design and reviewing the 
manuscript 
Sally-Anne Stephenson 
Involved in the conception and design of the project, 
performing the laboratory experiments and editing 
document drafts 
 Chapter 3: Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications 
for xenograft models of human prostate cancer 68                
 
 
 
 
The authors listed below have certified that:  
 
1. They meet the criteria for authorship in that they have participated in the conception, 
execution, or interpretation, of at least that part of the publication in their field of expertise;  
2. They take public responsibility for their part of the publication, except for the responsible 
author who accepts overall responsibility for the publication;  
3. There are no other authors of the publication according to these criteria;  
4. Potential conflicts of interest have been disclosed to (a) granting bodies, (b) the editor or 
publisher of journals or other publications, and (c) the head of the responsible academic unit, 
and  
5. They agree to the use of the publication in the student’s thesis and its publication on the 
Australasian Research Online database consistent with any limitations set by publisher 
requirements. 
 
Principal Supervisor Confirmation  
 
 
I have sighted email or other correspondence from all Co-authors confirming their certifying 
authorship.  
 
 
 
 
 
 
Sally-Anne Stephenson                    3/11/2016             
______________________      ______________  
 
Name     Signature    Date 
 
 
 
QUT Verified Signature
 Chapter 3 : Murine, but not human, ephrin B2 can be efficiently cleaved by the serine protease kallikrein-4: implications 
for xenograft models of human prostate cancer 
  69
 
3.1 GENERAL INTRODUCTION 
The research described in Chapter 3 was published in Experimental Cell Research, 333 
(2015): 136-146 as “Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine 
protease kallikrein-4: Implications for xenograft models of human prostate cancer” by J.E. 
Lisle, I. Mertens-Walker, C.R. Stephens, S.H. Stanfield, J.A. Clements, A.C. Herington and 
S.-A. Stephenson. 
This journal article describes experiments that identify and test ephrin-B2 as a substrate of the 
prostate cancer relevant protease KLK4. Initially, ephrin-B2 was predicted to be a potential 
KLK4 substrate using in silico methods.  Cleavage of ephrin-B2 by KLK4 was proven using 
recombinant proteins and the cleavage site identified using N-terminal sequencing.  
Interestingly human KLK4 specifically and efficiently cleaved the ectodomain of mouse 
ephrin-B2 but was less efficient in cleaving human ephrin-B2. This would suggest that 
KLK4/ephrin-B2 function will differ in murine xenografts vs human prostate cancer and 
should be considered when studying human prostate cancer murine xenografts. 
3.2 ABSTRACT 
Background: Ephrin-B2 is the sole physiologically-relevant ligand of the receptor tyrosine 
kinase EphB4, which is over-expressed in many epithelial cancers, including 66% of prostate 
cancers, and contributes to cancer cell survival, invasion and migration. Crucially, however, 
the cancer-promoting EphB4 signalling pathways are independent of interaction with its 
ligand ephrin-B2, as activation of ligand-dependent signalling causes tumour suppression. 
Ephrin-B2, however, is often found on the surface of endothelial cells of the tumour 
vasculature, where it can regulate angiogenesis to support tumour growth. Proteolytic 
cleavage of endothelial cell ephrin-B2 has previously been suggested as one mechanism 
whereby the interaction between tumour cell-expressed EphB4 and endothelial cell ephrin-
B2 is regulated to support both cancer promotion and angiogenesis. 
Methods: An in silico approach was used to search accessible surfaces of 3D protein models 
for cleavage sites for the key prostate cancer serine protease, KLK4, and this identified murine 
ephrin-B2 as a potential KLK4 substrate. Mouse ephrin-B2 was then confirmed as a KLK4 
substrate by in vitro incubation of recombinant mouse ephrin-B2 with active recombinant 
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human KLK4. Cleavage products were visualised by SDS-PAGE, silver staining and Western 
blot and confirmed by N-terminal sequencing. 
Results: At low molar ratios, KLK4 cleaved murine ephrin-B2 but other prostate-specific 
KLK family members (KLK2 and KLK3/PSA) were less efficient, suggesting cleavage was 
KLK4-selective. The primary KLK4 cleavage site in murine ephrin-B2 was verified and 
shown to correspond to one of the in silico predicted sites between extracellular domain 
residues arginine 178 and asparagine 179. Surprisingly, the highly homologous human ephrin-
B2 was poorly cleaved by KLK4 at these low molar ratios, likely due to the 3 amino acid 
differences at this primary cleavage site. 
Conclusion: These data suggest that in in vivo mouse xenograft models, endogenous mouse 
ephrin-B2, but not human tumour ephrin-B2, may be a downstream target of cancer cell 
secreted human KLK4. This is a critical consideration when interpreting data from murine 
explants of human EphB4+/KLK4+ cancer cells, such as prostate cancer cells, where 
differential effects may be seen in mouse models as opposed to human clinical situations. 
3.3 INTRODUCTION 
EphB4 is a member of the large Eph family of type 1 transmembrane receptor tyrosine 
kinases (RTKs) (Arvanitis et al., 2008; Pasquale, 2008), but unlike other Eph family members 
has only a single physiologically relevant ligand, ephrin-B2 (Sakano et al., 1996). In a 
mechanism exclusive to the Eph family, Eph receptors expressed on the plasma membrane of 
epithelial cells interact with their ephrin ligands which are also membrane-anchored on a 
neighbouring cell, commonly an endothelial cell, to activate bidirectional signalling pathways 
- forward into the Eph receptor expressing cell and reverse into the ligand expressing cell 
(Pasquale, 2008). EphB4 and ephrin-B2 are both critical in development and for the formation 
of the cardiovascular system and are particularly important in demarcating arterial (ephrin-
B2) from venous (EphB4) endothelial cells which is critical for formation of the capillary 
plexus (Adams et al., 1999; Gale et al., 2001; Gerety et al., 1999; Wang et al., 1998).    
The expression of several Eph receptors is significantly dysregulated in cancer and 
EphB4 in particular is commonly over-expressed in many epithelial cancers, including 66% 
of prostate cancers (PCa) (Lee et al., 2005; Xia et al., 2005b). Knockdown experiments using 
PCa cell lines have shown that EphB4 is a key regulator of PCa cell survival, invasion and 
migration (Xia et al., 2005b). Recent in vitro studies indicate that these cancer-promoting 
EphB4 signalling pathways are mostly independent of ephrin-B2 interaction, as addition of 
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excess clustered soluble ephrin-B2 ectodomain to cancer cells over-expressing EphB4 
activates/phosphorylates the EphB4 kinase domain and can cause growth suppression in vitro 
(Barneh et al., 2013; Hu et al., 2014; Rutkowski et al., 2012). However, ephrin-B2 is also 
present in tumours, expressed primarily on the endothelial cells of the tumour vasculature and 
by fibroblasts in the surrounding prostate tumour stroma (Astin et al., 2010; Noren et al., 
2004). Several groups have shown that endothelial cell ephrin-B2 plays a key role in 
regulating angiogenesis and lymphangiogenesis, an important element in supporting tumour 
growth and for arresting cells during site-specific metastatic dissemination (Héroult et al., 
2010; Sawamiphak et al., 2010; Wang et al., 2010b). Thus, collectively these studies suggest 
a fine balance and tight regulation of EphB4-ephrin-B2 interaction exists that is critical to the 
promotion or suppression of tumour growth and spread.  
Recent evidence has shown that this balance can be altered through cleavage of the 
ectodomain of ephrin-B2 by metalloproteinases (MMPs), γ-secretase and A Disintegrin and 
Metalloproteases (ADAMs) 8, 10 and 13 (Georgakopoulos et al., 2006; Guaiquil et al., 2010a; 
Ji et al., 2014b; Tomita et al., 2006; Wei et al., 2010). This results in activation of ephrin-B2 
and Src signalling pathways and upregulation of its angiogenic properties (Guaiquil et al., 
2010a). Other ephrin proteins have also been shown to be susceptible to protease cleavage 
(Hattori et al., 2000; Ieguchi et al., 2014; Janes et al., 2005; Pascall et al., 2004; Tanaka et 
al., 2007; Tomita et al., 2006). We therefore hypothesised that ephrin-B2 may be susceptible 
to proteolytic cleavage by proteases that are relevant in PCa. 
The serine protease kallikrein related peptidase 4 (KLK4) is over-expressed and 
secreted from PCa cells and plays an increasingly recognised key role in PCa cell biology, 
cleaving a number of known tumour modulators and extracellular matrix proteins (Avgeris et 
al., 2011; Clements et al., 2014; Klokk et al., 2007; Seiz et al., 2010; Veveris-Lowe et al., 
2005; Wang et al., 2010a). Increased expression of KLK4 in 60 PCa patient samples when 
compared with 59 benign prostatic hyperplasia (BPH) samples positively correlated with PCa 
stage and pre-operative PSA serum concentration (Avgeris et al., 2011). Accordingly, when 
compared with normal prostate epithelia KLK4 protein was over-expressed in malignant 
prostate and predominantly in the nucleus of basal cells (Klokk et al., 2007). KLK4 over-
expression has been linked to increases in proliferation, migration and epithelial to 
mesenchymal transition although this may be cell context dependent (Klokk et al., 2007; 
Veveris-Lowe et al., 2005). More recently, Seiz et al. (2010) developed two KLK4-specific 
antibodies for an immunohistochemical study of PCa samples and reported that KLK4 is 
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upregulated in cancerous glandular epithelial cells from early-stage but not late-stage PCas 
(Seiz et al., 2010). Although the full biological contribution of KLK4 to PCa is not known, 
Wang et al (2010) have described an interesting feedback mechanism where KLK4 released 
from PCa cells activates PAR-1 expressed by surrounding stromal cells and this, in turn, 
releases cytokines (IL-6) that stimulate cancer cell proliferation and increased production of 
KLK4 (Wang et al., 2010a). 
Using an in silico approach, 3D protein models in the UniProt database were searched 
for protein crystal structures which presented potential KLK4 consensus cleavage sites on 
their surfaces, sites which are therefore accessible to the protease.  Mouse ephrin-B2 was one 
of the proteins for which potential KLK4 cleavage sites were identified.  Here we report 
biochemical validation of the in silico prediction and show that KLK4 is able to specifically 
cleave murine ephrin-B2. However, surprisingly it has a much reduced efficacy in cleaving 
human ephrin-B2. This is an important distinction and has potentially major implications for 
the interpretation of data from murine explants of human EphB4+/KLK4+ cancer cells where 
differential effects may be seen in mouse models as opposed to human clinical situations.  
 
3.4 MATERIALS AND METHODS 
3.4.1 Recombinant Proteins and Antibodies 
Recombinant auto-activating KLK4 was prepared in-house using Splicing by Overlap 
Extension PCR to couple the coding sequence of mature KLK4 coupled to the pro-domain of 
prostate specific antigen (PSA/ KLK3) (at the 5’end) and V5 and poly-histidine encoding 
sequences at the 3’end in the pIB plasmid (Horton et al., 1989). Recombinant KLK4 is 
produced as an inactive zymogen, but has the capacity to self-cleave and remove the PSA pro-
domain and this results in release of an auto-activated form of the KLK4 enzyme. The KLK4-
pIB plasmid was used to transfect cells of the insect cell line Sf9 using a previously described 
method (Ramsay et al., 2008). Production of proteolytically active KLK4 was confirmed by 
titrating against α1-antichymotrypsin, an inhibitor of KLK4, using 100 μM D-Val-Leu-Arg 
7-Amindo-4-trifluoromethylcoumarin (Sigma-Aldrich Corporation, NSW, Australia) as the 
substrate in 100 μl assay buffer (50 mM Tris, 50 mM NaCl, pH 8.8, 0.01% Tween-20) (Mukai 
et al., 2008). Kallikreins KLK2 and KLK3/PSA, produced in a similar manner, were already 
available in the laboratory. Recombinant murine ephrin-B2-Fc and recombinant human 
ephrin-B2-Fc were purchased from R&D Systems (Minneapolis, Minnesota, USA). The less-
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selective serine proteases trypsin (Sigma), chymotrypsin (Sigma) and GluC (New England 
Biolabs, Ipswich, Massachusetts, USA), and the subtilisin-like proprotein convertase Furin 
(New England Biolabs) were used as positive (trypsin, chymotrypsin and GluC) and negative 
controls (Furin) for cleavage. Two ephrin-B2 polyclonal antibodies raised against distinct 
extracellular domain epitopes were purchased from Santa Cruz Biotechnology (Santa Cruz, 
California, USA) – the rabbit anti-ephrin-B2 (P-20) raised against a common (but not 
disclosed) human/mouse extracellular domain epitope and the rabbit anti-ephrin-B2 (H-83) 
raised against the human/mouse sequence, amino acids 168-235.  
3.4.2 Ephrin-B2-Fc digestion with KLK4 and other proteases 
Recombinant murine ephrin-B2-Fc protein was diluted and incubated overnight at 37ºC with  
the proteases KLK4, the closely related kallikreins KLK2 or KLK3/PSA, the less-selective 
serine proteases trypsin, chymotrypsin and GluC, or the subtilisin-like proprotein convertase 
Furin. Incubations were either in the supplier’s recommended 1 x reaction buffer or 
phosphate-buffered saline. KLK4 reactions were performed in a reaction buffer containing 50 
mM Tris-HCl and 50 mM NaCl, pH 8.5. To find the optimum molar ratio for ephrin-B2 
cleavage, the KLK4 digestion experiment was performed with a fixed amount of ephrin-B2 
and decreasing amounts of active KLK4 from a 1:1 ephrin-B2 to KLK4 molar ratio (100 ng 
ephrin-B2 + 41 ng KLK4) to a 1:1/1000 ephrin-B2 to KLK4  ratio (100 ng ephrin-B2 + 41 pg 
KLK4).  For the other proteases, reactions contained 100 ng of ephrin-B2 and 1 ng of the 
protease in either the supplied buffer or in PBS. The reactions were terminated by adding 
SDS-loading buffer (0.01 M Trizma, 40% Glycerol, 4% SDS, 0.006% Bromophenol Blue, 
5% β-mercaptoethanol, pH 6.8) and boiled at 95ºC for 5 minutes to denature the proteins. 
Samples were electrophoresed into 10% separating SDS-PAGE gels through a 4% stacking 
gel and individual proteins visualized by silver staining or Western blotting. De-glycosylation 
was performed using PNGase F (New England Biolabs). KLK4 activity in the PNGase F 
reaction buffer was confirmed. 
3.4.3 Western Blot Analysis 
Separated proteins were transferred by electroblotting onto BioTrace™ NT 
nitrocellulose membrane (Pall, Pensacola, Florida, USA). The membranes were blocked with 
Western blocking reagent (Roche, Indianapolis, Indiana, USA) before incubation with the 
primary antibodies - rabbit anti-mouse ephrin-B2 (P-20; 1:1000) or rabbit anti-mouse ephrin-
B2 (H-83; 1:500) followed by peroxidase-conjugated goat anti-mouse secondary antibodies 
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(Pierce, from Thermo Fisher Scientific, Scoresby VIC, Australia) (used at a 1:30,000 
dilution). Immunoreactivity was detected using the Amersham™ ECL Plus 
Chemiluminescence kit (GE Healthcare, Rydalmere, NSW, Australia). 
3.4.4 Silver staining 
After electrophoresis, gels were fixed in 40% methanol/10% acetic acid for at least 30 
min and rinsed briefly before addition of K3Fe(CN)6 /Na2S2O3(5H2O) solution for 5 min. 
After rinsing, 12 mM AgNO3 was added for 20 min and the gel washed briefly before the 
protein bands were developed using formaldehyde/2.9% sodium carbonate. The reaction was 
stopped with 5% acetic acid when the bands were clearly visible.  
3.4.5 N-terminal sequencing 
Protein fragments generated by cleavage reactions were separated on a 10% SDS-PAGE gel 
(with a 4% stack) and transferred onto Immobilon-FL Polyvinylidene fluoride (PVDF) 
membrane (Millipore, Billerica, Minnesota, USA). The membrane was then stained with 
0.25% Coomassie Blue R-250 in 40% methanol/10% acetic acid and destained with 5% 
methanol/7.5% acetic acid. The protein bands that corresponded with ephrin-B2 cleavage 
fragments were excised and sent for N-terminal sequencing at the Australian Proteome 
Analysis Facility (Sydney, NSW, Australia).  
 
3.5 RESULTS 
3.5.1 In silico identification of the EphB4 ligand, ephrin-B2, as a potential substrate of 
KLK4 
An in silico approach, enhanced Proteomic Identification of Cleavage Sites (ePICS) 
[Stansfield, Stephens, Clements, manuscript in preparation] was used to identify potential 
KLK4 consensus cleavage sites in proteins in the UniProt database for which crystal structures 
were available. This included the extracellular receptor binding domain of mouse ephrin-B2 
(Figure 3.1A). This approach is an extension to the PICS methodology reported by Schilling 
et al. 2011 and is designed to identify those potential substrates where the cleavage sites map 
to the surface of the protein and would therefore be accessible to the protease(Schilling et al., 
2011). 
The KLK4 consensus cleavage sites examined were predicted by comparison of 
experimentally validated cleavage sites in known substrate proteins including pro-KLK3, pro-
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KLK11, prostatic acid phosphatase, urokinase receptor, pro-urokinase, pro-meprin, enamelin, 
amelogenin, parathyroid hormone-related peptide (PTHrP) and members of the insulin-like 
growth factor (IGF) and IGF binding protein (IGFBP) family members (Debela et al., 2006; 
Matsumura et al., 2005). A high ePICS score (Figure 3.1B and 3.1C, red boxes) identifies that 
part of the protein as a potential target for KLK4 cleavage.  
PBD model 1IKO (Figure 1B and 2B) corresponds to the crystal structure of murine 
ephrin-B2 amino acids 30-207 produced by the yeast P. pastoris and analysed by X-ray 
diffraction with a resolution of 1.92 Ǻ (Toth et al., 2001). Structure was determined for amino 
acids 30-170 only, because the remaining 37 amino acids form a flexible structure, completely 
disordered in the electron density map and for which no coordinates could be determined 
(Toth et al., 2001). Flexible structures may still be accessible to proteases, however, and so 
this sequence was included in the ePICS analysis. Human ephrin-B2 was modelled on the 
structure of mouse ephrin-B2 to produce PBD entry 2HLE (Figure 3.1C), however a mistake 
in the sequence at residue 106 (green square; Figure 3.2A) (where lysine in the human ephrin-
B2 sequence replaces arginine in the mouse) was corrected in a more recent entry 3GXU (as 
used in Figure 3.2B). As illustrated in Figures 3.1A and 3.1B (red boxes), the ePICS approach 
identified both murine and human ephrin-B2 as potential targets for KLK4 cleavage. Five 
different potential cleavage sites were identified at the same positions in each sequence 
(Figure 3.2A – red arrows). One site (#1, blue box), identical between murine and human 
ephrin-B2 sequences, was identified in the modelled part of the mouse and human proteins 
between Arg (R)159 and Ala (A)160 of murine ephrin-B2 and this site does indeed map to 
the surface of the folded proteins (Figure 3.2B – blue boxes). The other four predicted sites 
(#2-5) (Figure 3.2A) were within the undetermined flexible sequence from amino acids 171 
to 207. Despite the high level of homology overall between the two ephrin-B2 sequences, 
there were three amino acid differences within the P4-P4’ sequence at predicted cleavage site 
#2 (Figure 3.2A – red boxed sequence). Sites #3, 4 and 5 were identical in both sequences.  
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Figure 3-1: Identification of ephrin-B2 as a potential substrate of KLK4. 
(A) Model of ephrin-B2 within the plasma membrane showing the crystal structure of the 
extracellular Eph receptor binding domain (PBD 2HLE) (blue), a single transmembrane helix 
(red) and the unresolved intracellular domain (dark red) that includes a PDZ domain at the C-
terminal end (dark blue). (B) An in silico approach (enhanced Proteomic Identification of 
Cleavage Sites (ePICS) – Stansfield, Stephens, Clements; manuscript in preparation) was used 
to identify potential KLK4 consensus cleavage sites in proteins for which crystal structures 
were available. (B) High ePICS scores (>4, red boxes) identify murine ephrin-B2 as a 
potential target for KLK4 cleavage. Cleavage sites are within the extracellular domain of the 
protein (UniPROT Annotations – top green bar). The yellow UniPROT modifications bar 
identifies the positions of amino acids that may be glycosylated (red spot tags) and 
phosphorylated (yellow spot tags) and disulfide bridges (black brackets). (C) ePICS scores 
also suggest KLK4 may cleave human ephrin-B2.  
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Figure 3-2: Position of predicted KLK4 cleavage sites within the sequence and the folded 
protein. 
(A)Amino acid sequence alignment of partial extracellular domains of the human 
ephrin-B2 (Human) and mouse ephrin-B2 (Mouse) proteins. The sequences of the 
extracellular domains are shown in black, the transmembrane sequence is green and the 
intracellular portion is blue. Amino acids showing identity between the two sequences are 
indicated by the asterisk (*) below the alignment, a colon (:) indicates the amino acids are 
conserved, a full stop (.) indicates a semi-conserved substitution and a blank space indicates 
amino acids that are non-conserved. An error in the PBD entry 2HLE (used for modelling in 
Figure 1C), at residue 106 (identified by the green square; Figure 3) (where lysine in the 
human ephrin-B2 sequence replaces arginine in the mouse) was corrected in a more recent 
PBD entry 3GXU (as used in (B)). The predicted potential KLK4 cleavage sites in mouse 
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ephrin-B2 and the corresponding sequences in human ephrin-B2 are indicated by the red 
arrowheads and are numbered from 1 to 5. The confirmed KLK4 cleavage site in mouse 
ephrin-B2 and the corresponding sequence in human ephrin-B2 are boxed in red.  The number 
of the amino acid within each sequence is shown to the right for each line of the aligned 
sequences. 
__________________________________________________________________________ 
 
3.5.2 Biochemical confirmation of ephrin-B2 cleavage by KLK4 
To confirm that the in silico approach for the identification of KLK4 cleavage sites was 
successful, we next determined in vitro whether KLK4 could indeed cleave the extracellular 
domain of murine ephrin-B2. The entire extracellular domain of recombinant mouse ephrin-
B2 (NCBI reference sequence NP_034241.2), from Arg 27 to Ala 227 fused to the Fc region 
of human IgG1 via a flexible linker sequence at the C-terminus (eB2-Fc), was incubated with 
auto-activated recombinant KLK4. The recombinant murine eB2-Fc protein migrates at 60-
65 kDa in SDS-PAGE under reducing conditions and was visualized by silver staining (Figure 
3.3A). Progressive cleavage of murine eB2-Fc was seen as the ratio of KLK4 to eB2-Fc 
increased, with complete fragmentation at a 1 EphB4:1 KLK4 molar ratio (lane 2). Specific 
fragments were seen in the sample to which the lowest amounts of KLK4 (1 EphB4:1/100 
and 1: 1/1000 KLK4) were added, although full-length eB2-Fc was still present (lanes 5 & 6). 
The major band in all lanes at 37 kDa was shown to be an Fc fragment (see below).  
The three most strongly silver stained bands in lane 5 - peptides 1-3 in Figure 3.3B - 
were excised and the N-terminal amino acid sequence of each was determined (Figure 3.3B). 
As expected, the largest band with the N-terminus at Arg 27 corresponded to the entire eB2-
Fc parent peptide (Band 1 in Figure 3.3B, Figure 3.3C). The second largest band (approx 50 
kDa) matched an epitope in the mouse ephrin-B2 extracellular domain sequence that would 
be produced by cleavage after Arg 178 (Figure 3.3C. This is site #2 (Figure 3.2A), which falls 
within the ephrin-B2 sequence for which the 3-dimensional structure could not be determined. 
The second shorter sequence (approx 37 kDa) matched a site within the Fc sequence of the 
recombinant eB2-Fc protein showing that band 3 contains most of the Fc tag (Figure 3.3B 
and 3.3C). 
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Figure 3-3: KLK4 cleavage of murine ephrin-B2.  
 
(A) A fixed amount of murine ephrin-B2-Fc (100 ng; lanes marked with + eB2-Fc) was 
incubated with decreasing amounts of active KLK4 from a 1:1 ephrin-B2 to KLK4 molar ratio 
(100 ng ephrin-B2 + 41 ng KLK4) to a 1:1/1000 ephrin-B2 to KLK4 ratio. Fragments were 
separated by SDS-PAGE and visualised using silver staining.  KLK4, full length eB2-Fc, 
eB2-Fc fragments and the Fc fragment are indicated by arrows. Molecular weight markers 
(M) are shown on the left. A representative example of three independent experiments is 
shown. (B) Fragment bands (labelled Peptides 1-3) from lane 5 of the silver-stained gel 
(indicated by blue box in A) were extracted and subjected to N-terminal sequencing to identify 
the KLK4 cleavage sites in the mouse ephrin-B2 protein.  (C) The N-terminal sequences are 
shown and are illustrated diagrammatically. The N-terminal end of full length ephrin-B2-Fc 
begins with R27.  The primary cleavage site (Peptide 2) occurs after R178 within the ephrin-
B2 extracellular domain (ephrin-B2 ecd; RNHGPTR). A second significant cleavage site 
(Peptide 3) was identified within the human IgG Fc fragment (RSCDKTH). (D) Human 
ephrin-B2 is cleaved less efficiently with KLK4 and is unlikely to be a biological substrate. 
Mouse ephrin-B2-Fc (mouse eB2-Fc) and human ephrin-B2-Fc (Human eB2-Fc) were 
cleaved with KLK4 at molar ratios of 1 ephrin:1 KLK4, 1 ephrin:1/10 KLK4 and 1 
ephrin:1/100 KLK4. Proteins were separated by SDS-PAGE and visualized by silver staining. 
Uncleaved ephrin-B2-Fc proteins were used as controls for the full length proteins (indicated 
by the eB2-Fc arrows). Cleavage fragments of several sizes are indicated by the bracket 
arrows (eB2-Fc cleavage fragments). A representative example of two independent 
experiments is shown. (E) A heat map showing the KLK4 preferred amino acids in the 
substrate P and P’ positions. Amino acids are shown in single letter code on the left of the 
heat map. More intense yellow indicates this amino acid is more preferred in this position, 
more blue indicates less preferred. Boxes indicate the amino acids found specifically in the 
validated KLK4 cleavage site in mouse ephrin-B2 (white boxes), amino acids common to this 
sequence in both human and mouse ephrin-B2 extracellular domain (red boxes), and found 
specifically in human ephrin-B2 (green boxes). 
____________________________________________________________________________________ 
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The identities of the other two fragments of approximately 25 and 20 kDa were not 
determined but are presumed to be fragments of ephrin-B2 that result from additional and 
perhaps less efficient, cleavage events, as they are detected by an N-terminal ephrin-B2 
antibody (see below and Fig 3.5C). Discrepancies in the predicted sizes of fragments, as based 
on amino acid sequence, and the size of these fragments may be explained by potential post-
translational modifications.  The NetNGlyc 1.0 Server was used to interrogate the ephrin-B2 
Arg 27-Arg 178 sequence for potential N-glycosylation sites and two were identified within 
the extracellular domain, one at Asn 11 (site NSSN) and one at Asn 114 (site NGSL)  (Figure 
3.4A).  To confirm that the ephrin-B2 recombinant protein we used is glycosylated, a 
deglycosylation reaction using PNGase F was performed. A decrease in the molecular weight 
of the ephrin-B2 band was visualised using silver staining (Figure 3.4B, compare lanes 2 and 
3).  We then tested whether de-glycosylated ephrin-B2 can be cleaved by KLK4 and found 
that this was the case and interestingly, a new fragment was identified suggesting there is a 
further KLK4 cleavage site in the extracellular domain of ephrin-B2 that is blocked by 
glycosylation (Figure 3.4B, lane 5).   
 
To determine whether KLK4 could also cleave the extracellular domain of human 
ephrin-B2, a recombinant human ephrin-B2-Fc protein (NCBI reference sequence 
NP_004084.1), corresponding to Lys 26 to Ala 229 also fused to the Fc region of human IgG1 
by a 6 amino acid linker at the C-terminus (eB2-Fc), was also incubated with auto-activated 
recombinant KLK4. Cleavage of human ephrin-B2 by KLK4, however, was much less 
efficient (Figure 3.3D, lanes 5-7) than cleavage of mouse ephrin-B2 (Figure 3.3D, lanes 2-4). 
Significantly reduced cleavage products were seen for human ephrin-B2 in the 1ephrin:1/100 
KLK4 lane when compared (Figure 3.3D, lane 7 vs 4) with the same ratio using the murine 
ephrin-B2. This suggests that human ephrin-B2 is a less likely biological substrate for KLK4. 
The primary KLK4 cleavage site in murine ephrin-B2 is between Arg 178 and Asn 179, 
precisely where there are three differences in the P4-P4’ sequences between mouse and human 
ephrin-B2. Two of the amino acids that vary between the sequences are at the validated KLK4 
cleavage site in the P2’ and P3’ positions in mouse ephrin-B2 (HG vs KD) and the third is at 
P2 (A vs T) (Figure 3.2A). Comparison of these sequences using the heat map used to predict 
the KLK4 consensus cleavage site (Figure 3E) showed that there were only subtle differences 
in the preference for amino acids at these differing positions, but suggests that a glycine (G) 
at position P3’, as in mouse ephrin-B2,  
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Figure 3-4: Murine ephrin-B2 is glycosylated and this post-translational modification 
may regulate KLK4 cleavage.  
(A) NetNGlyc 1.0 was used to predict potential N-glycosylation sites within the extracellular 
domain sequence (R27 – R178) of ephrin-B2.  Two sites were identified – one at asparagine 
N11 (site NSSN) and at asparagine N114 (site NGSL). (B)  Ephrin-B2-Fc (eB2-Fc) was 
treated with PNGase F (PF) or KLK4 (K4) or both enzymes together. Efficient KLK4 
cleavage of ephrin-B2-Fc in the PNGase F buffer (eB2-Fc + K4 in PF buffer) was confirmed. 
Human IgG Fc fragment (Fc) +/- KLK4 was used as a control. Proteins were separated by 
SDS-PAGE and visualized by silver staining. A representative example of two independent 
experiments is shown.  The positions of the molecular weight markers (M) are indicated.  The 
boxed region highlights lower molecular weight bands that correspond to the N-terminal ends 
of the ephrin-B2 protein. The red box identifies the 16.9 kDa de-glycosylated fragment R27-
R178.  The white asterisk identified a new ephrin-B2 fragment only seen after deglycosylation 
prior to KLK4 digestion. 
__________________________________________________________________________ 
may be more favourable for KLK4 cleavage than the corresponding aspartic acid (D) in 
human ephrin-B2. These changes are sufficient to reduce KLK4 cleavage and therefore 
further define the consensus KLK4 cleavage site. 
To determine the specificity of the murine ephrin-B2 KLK4 interaction several other 
proteases, including the closely related kallikreins KLK2 and KLK3/PSA, the less-selective 
serine proteases trypsin, chymotrypsin and GluC, and the subtilisin-like proprotein 
convertase, Furin, were also incubated with recombinant mouse eB2-Fc, and fragmentation 
detected by silver staining (Figure 3.5A). As expected, due to their lower selectivity, major 
cleavage products were present in the trypsin, chymotrypsin and GluC samples, although 
these were clearly different fragments than the KLK4 fragments (Figure 3.5A, lanes T, G, C,). 
The primary < 50 kDa KLK4 cleavage fragment (red box, Figure 3.5A) was not seen with the 
other proteases. Cleavage fragments were not seen in the sample to which Furin was added, 
which was expected as the mature extracellular domain of ephrin-B2 does not contain an Arg-
X-Arg/Lys-Arg motif recognised by this protease (Lai et al., 2009). There were no significant 
cleavage fragments in the samples to which KLK2 and KLK3/PSA had been added suggesting 
that cleavage of murine ephrin-B2 was a highly KLK4-selective event and not a general 
kallikrein cleavage event.  
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Figure 3-5: Murine ephrin-B2 can be cleaved by KLK4 but not closely related 
kallikreins KLK2 and KLK3. 
(A) Murine ephrin-B2-Fc was cleaved with various proteases including KLK2 (K2), 
KLK3/PSA (K3), KLK4 (K4), Trypsin (T), Furin (F), GluC (G) and Chymotrypsin (C). 
Proteins were separated by SDS-PAGE and visualized by silver staining.  The positions of 
the molecular weight markers (M) are indicated. Full length ephrin-B2-Fc protein and ephrin-
B2-Fc cleavage fragments are indicated, with the primary KLK4-generated cleavage fragment 
shown by the red box. This fragment matches fragment 2 seen in Figure 3B. A representative 
example of three independent experiments is shown.  (B) Diagrammatic model of mouse 
ephrin-B2 structural domains and the extracellular domain epitopes recognized by two ephrin-
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B2 polyclonal antibodies used for Western blot detection of cleaved extracellular domain 
fragments. (C and D) Duplicate samples from the protease screen shown in (A) were analysed 
by Western blot analysis using antibodies raised to two distinct N-terminal extracellular 
sequences of ephrin-B2 as indicated. Ephrin-B2 cleavage fragments were identified in 
samples to which KLK4, trypsin, GluC and chymotrypsin had been added but not in the 
samples to which KLK2 or KLK3 had been added. The positions of the molecular weight 
markers are indicated. A representative example of three independent experiments is shown. 
__________________________________________________________________________ 
 
Western blotting using two different mouse ephrin-B2 specific antibodies (Figure 3.5B) 
was used to identify ephrin-B2 containing fragments. Similar fragmentation specificity as that 
seen on silver staining was observed following Western blot analysis, with the primary 
fragment again being the < 50 kDa protein (red box, Figure 3.5B and 3.5C). The N-terminal 
polyclonal antibody, designed to an undisclosed sequence of ephrin-B2, recognised several 
small fragments (20-25 kDa), as also seen in the silver stain (Fig 3.5A and 3.3A), in addition 
to the primary cleaved fragment that also includes the Fc fragment (Figure 3.5C). These 
smaller fragments are not detected with the H83 antibody that recognises sequences between 
amino acid 168 and 235 (Figure 3.5D), confirming that these are N-terminal ephrin-B2 
fragments. This suggests that once the primary cleavage event has occurred, the released 
ephrin-B2 N-terminal fragment can be unwound exposing additional KLK4 sites (e.g. site #1 
in Figure 3.2A) that are subsequently cleaved.   
 
3.6 DISCUSSION 
Bi-directional signalling that is induced by interactions between Eph receptors 
expressed on one cell and their ligands, the ephrins, anchored to the surface of another cell, is 
critical in mediating signals important to several fundamental biological processes (Mellitzer 
et al., 1999; Pasquale, 2008). Dysregulation of Eph-ephrin interactions, for example through 
low ephrin expression, high Eph expression, Eph mutations and/or differential cellular 
compartmentation, leads to modulation of the forward and/or reverse signalling pathways and 
disruption of the normal Eph-ephrin functions. This can lead to several developmental 
disorders and cancers (Pasquale, 2008).  
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Evidence now also strongly suggests that another potential mechanism for 
dysregulating Eph-ephrin interactions is the proteolytic cleavage of either receptor or ligand 
from the membrane of the expressing cells (Arvanitis et al., 2008). Protease-mediated 
cleavage of some Ephs or ephrins has been shown to modify cell-cell adhesion and signalling 
(Hattori et al., 2000).  
The EphB4-ephrin-B2 interaction, in particular, is recognised as being important in 
cancer as it determines whether EphB4 may be tumour promoting or tumour suppressive - in 
prostate (Rutkowski et al., 2012), breast (Barneh et al., 2013; Noren et al., 2006) and 
oesophageal cancers (Hu et al., 2014). Thus, we hypothesised that proteases secreted by PCa 
cells or adjacent normal stromal cells with which they interact, may modulate EphB4-
ephrinB2 interactions by cleaving ephrin-B2 and preventing activation of EphB4, which 
would normally result in tumour suppression. Instead, such cleavage could facilitate tumour 
cell migration and invasion and tumour angiogenesis via ligand-independent mechanisms. 
Using a bioinformatics screen, we identified murine ephrin-B2 as a likely proteolytic target 
for the serine protease kallikrein-like peptidase 4 (KLK4). As increased expression of KLK4 
in prostate and other epithelial cancers correlates with cancer progression (Lawrence et al., 
2010), and over-expression of KLK4 in PC3 PCa cells induces epithelial to mesenchymal 
transition and increased migration/invasion (Lawrence et al., 2007), we hypothesised that at 
least part of the tumour promoting role of KLK4 may be through cleavage of ephrin-B2 and 
subsequent dysregulation of EphB4-ephrin-B2 interactions. We tested this prediction using 
recombinant murine ephrin-B2-Fc and human KLK4 proteins and confirmed that a KLK4 
cleavage site was present in murine ephrin-B2 by N-terminal sequencing. However, when 
similar cleavage experiments were performed using human ephrin-B2, cleavage was only 
detected when a high molar ratio of KLK4: ephrin-B2 was used and we conclude from this 
result that human ephrin-B2 is a less likely/relevant biological substrate for KLK4. There is 
significant amino acid sequence variance (3/8 residues) within the identified P4-P4’cleavage 
site that is likely the basis for the differential cleavage efficiency. 
The implication of this finding may be profound when considering mechanisms at play 
in the human clinical situation and needs to be considered when interpreting the results of 
studies using EphB4 and KLK4 positive human prostate tumours in murine xenografts. 
Increased ephrin (reverse) signalling and increased tumour-promoting angiogenesis has been 
previously linked to cleavage of the ectodomain by proteases including matrix 
metalloproteinases MMP-8, -9 and -12, and ADAM8, ADAM10 and ADAM13 (Guaiquil et 
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al., 2010a; Ji et al., 2014b; Wei et al., 2010). Removal of the ectodomain of ephrin-B2 is 
followed by release of an intracellular C-terminal fragment (CTF) by action of Presenilin-1/γ-
secretase (Georgakopoulos et al., 2006). The CTF then regulates intracellular ephrin-B2 
signalling pathways involving c-Src and leads to increased angiogenesis (Georgakopoulos et 
al., 2006). Further, the CTF of ephrin-B1, when over-expressed in COS cells can translocate 
to the nucleus suggesting that, like other intracellular cleavage fragments of type 1 single-
span transmembrane proteins such as the key cell differentiation molecule Notch (Jarriault et 
al., 1995), this intracellular fragment could act as a transcriptional regulator (Tomita et al., 
2006).  
Alternatively, an additional but contrasting impact of cleavage and release of the ephrin-
B2 ectodomain is via its potential interaction with, and possible activation of, its EphB 
receptors (EphB2, EphB4) expressed on PCa cells. In vitro studies have shown that soluble, 
but clustered ephrin-B2 ectodomain, can activate the kinase activity of EphB4 in cancer cells 
and initiate tumour suppressive effects (Noren et al., 2004; Rutkowski et al., 2012). Non-
clustered (monomeric) soluble ephrin-B2 ectodomain can bind Eph receptors but this results 
in different biological responses to those effected by clustered soluble ephrin-B2-Fc 
(Arvanitis et al., 2008; Pasquale, 2008). Further studies are required to examine the structural 
nature of the KLK4-cleaved ectodomain – monomeric or clustered – and the potential 
functional impact of ephrin-B2 cleavage. 
 
3.7 CONCLUSION 
 
Implicitly, these data suggest that ectodomain cleavage of ephrin-B2 may be a significant 
mechanism that regulates the migration and metastasis of PCa cells in vivo. However, in 
presenting the first evidence that the key PCa serine protease, KLK4, can specifically and 
efficiently cleave the ectodomain of mouse ephrin-B2, KLK4 appears not to similarly 
efficiently cleave human ephrin-B2. Therefore, one may see differential effects of KLK4 on 
regulation of human PCa cells in mouse xenografts as opposed to tumours in situ in human 
tissues (Figure 3.6). We suggest that differences in protease action against human and mouse 
target proteins should be taken into consideration when performing xenograft experiments.  
In the mouse, xenografts of EphB4 over-expressing human PCa cells, which also over-express 
and secrete KLK4, provide a scenario in which the KLK4 may cleave ephrin-B2 expressed 
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by host mouse endothelial and fibroblast cells. This can result in increased angiogenesis due 
to activated ephrin-B2 reverse signalling, prevention of normal interaction with PCa cell 
EphB4 and therefore inhibition of ligand-dependent tumour suppressive signalling. These 
outcomes would lead to alteration of the behaviour of the PCa cells in vivo and enhanced 
tumour progression. In contrast, the same response, at least mediated by KLK4, is not likely 
to occur with prostate tumours in man as human KLK4 is less able to cleave human ephrin-
B2. This does not rule out processing of ephrin-B2 in the human circumstance by other 
proteases, such as ADAMs, which may therefore have a similar effect in promoting 
angiogenesis, but it does suggest that the known prostate tumour promoting role of KLK4 in 
the human is not via ephrin-B2 cleavage.  Nonetheless, these data provide a model for further 
exploration of possible protease-mediated control mechanisms underlying the complex 
tumour-suppressive and tumour-promoting effects of EphB4-ephrin-B2 signalling. 
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Figure 3-6:  Model of the proposed differential effect of KLK4 cleavage of ephrin-B2 in mouse xenograft 
versus human prostate cancer endothelial cells.   
 
In a mouse xenograft model (left panels), KLK4 released by human prostate cancer cells can interact with and 
cleave ephrin-B2 expressed on host (murine) endothelial cells, thereby triggering reverse signalling mechanisms 
and stimulating angiogenesis. Interaction of the cleaved ephrin-B2 ectodomain with the prostate cancer cell 
EphB4 is dysregulated. In contrast, in the human clinical situation released KLK4 is unable to efficiently cleave 
host (human) ephrin-B2, cleavage-derived angiogenesis pathways are inactive and potentially normal ephrin-
B2/ephB4 interaction can occur. 
 
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 91
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 92                
 
 
Chapter 4: Kallikrein-related Peptidase 4 
Initiates Cleavage of the Tumour-
promoting Receptor Tyrosine 
Kinase, EphB4, at the Surface of 
Prostate Cancer Cells  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 93
 
 
KALLIKREIN-RELATED PEPTIDASE 4 INITIATES CLEAVAGE OF THE 
TUMOUR-PROMOTING RECEPTOR TYROSINE KINASE, EPHB4, AT THE 
SURFACE OF PROSTATE CANCER CELLS 
 
Jessica E. Lisle, Inga Mertens-Walker, Carson Stephens, Scott H Stansfield, Judith A 
Clements, Adrian C Herington & Sally-Anne Stephenson 
 
Manuscript in Preparation  
 
Statement of Contribution of Co-Authors for Thesis by Published Paper  
 
 
Contributor  
 
Statement of contribution 
Jessica Lisle   
 
Involved in experimental design, performing the 
laboratory experiments, data analysis and writing the 
manuscript 
 
Inga Mertens-Walker 
Involved in performing the laboratory experiments 
and in data analysis 
Carson Stephens Involved in making the recombinant KLK4 
Judith A Clements 
 
Involved with experimental design and reviewing the 
manuscript 
Adrian C Herington 
 
Involved with experimental design and reviewing the 
manuscript 
Sally-Anne Stephenson 
Involved in the conception and design of the project 
and editing document drafts. 
 
 
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 94                
 
The authors listed below have certified* that:  
 
1.They meet the criteria for authorship in that they have participated in the conception, 
execution, or interpretation, of at least that part of the publication in their field of expertise;  
2. They take public responsibility for their part of the publication, except for the responsible 
author who accepts overall responsibility for the publication;  
3. There are no other authors of the publication according to these criteria;  
4. Potential conflicts of interest have been disclosed to (a) granting bodies, (b) the editor or 
publisher of journals or other publications, and (c) the head of the responsible academic unit, 
and  
5. They agree to the use of the publication in the student’s thesis and its publication on the 
Australasian Research Online database consistent with any limitations set by publisher 
requirements. 
 
Principal Supervisor Confirmation  
 
 
I have sighted email or other correspondence from all Co-authors confirming their certifying 
authorship.  
 
 
 
 
 
 
Sally-Anne Stephenson                     3/11/2016             
______________________     ______________  
 
Name     Signature    Date 
 
 
 
 
 
 
QUT Verified Signature
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 95
4.1 GENERAL INTRODUCTION  
The research described in Chapter 4 is a manuscript in preparation entitled “Kallikrein-
related Peptidase 4 Initiates Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, 
EphB4, at the Surface of Prostate Cancer Cells” by Jessica E. Lisle, Inga Mertens-Walker, 
Carson Stephens, Judith A Clements, Adrian C Herington & Sally-Anne Stephenson. 
This manuscript describes the identification of protein fragments of EphB4 in prostate 
cancer cells that result from proteolysis. It also builds on the observation that as the ligand for 
EphB4 is a substrate for KLK4, EphB4 may also be a substrate for this prostate cancer 
associated protease, as well as a substrate for other proteases.   
4.2 ABSTRACT  
EphB4, a member of the largest family of receptor tyrosine kinases, is commonly over-
expressed in epithelial cancers including 66% of prostate cancers where it promotes tumour 
angiogenesis, increases cancer cell survival and facilitates invasion and migration. How EphB4 
contributes to cancer has not been completely determined, but mechanisms that disrupt the 
balance between the EphB4 receptor and its ligand, ephrin-B2, to allow tumour promotion 
through ligand-independent EphB4 forward signalling, are implicated. Such mechanisms may 
include proteolytic cleavage, and supporting this hypothesis is our identification that EphB4 is 
a substrate of kallikrein-related peptidase 4 (KLK4). KLK4 is a serine protease that is also 
commonly elevated in prostate cancers, with particularly strong expression in tumours that 
have metastasized to bone, and is reported to have significant functional roles in prostate cancer 
progression. The ability of KLK4 to cleave EphB4 was initially tested using recombinant 
proteins. We then demonstrated that KLK4 could cleave EphB4 from the surface of prostate 
cancer cells. Cleavage of EphB4 by KLK4 resulted in fragments of 70 kDa and 50 kDa and N-
terminal sequencing was used to show that KLK4 cleaves EphB4 after arginine-508.  A second 
C-terminal, and therefore intracellular, fragment of 47 kDa was generated by the action of the 
intracellular protease γ-secretase, possibly as a consequence of ectodomain shedding. This 
study has not only revealed a new substrate for the important prostate cancer protease KLK4, 
but has also provided, to our knowledge, the first direct evidence for serine protease-mediated 
cleavage of the EphB4 receptor, with significant implications for the mechanism of action for 
the known tumour progression and angiogenic effects of EphB4.  
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4.3 INTRODUCTION 
EphB4 is a receptor tyrosine kinase (RTK) that is a member of the B subclass of the Eph 
receptor (EphR) family (Bennett et al., 1995). EphB4 and its sole ligand, ephrin-B2, are both 
type 1 transmembrane proteins, anchored within the plasma membrane of neighbouring cells. 
Cell to cell contact allows the formation of a heterotetramer comprised of two receptors 
expressed on the surface of one cell, with two ligands expressed on the surface of another, and 
this is the minimum requirement for activation of signalling (Himanen et al., 2007). In a manner 
unique to the Eph-ephrin system, signalling is propagated through both cells, forward into the 
receptor expressing cell and reverse into the ligand expressing cell, in what is termed bi-
directional signalling (Pasquale, 2008). These signalling pathways regulate a variety of normal 
biological processes including vascular and  neuronal development in the embryo (Gerety et 
al., 1999). 
EphB4 is commonly over-expressed in many epithelial cancers including 66% of prostate 
cancers where increased expression may be an early event in tumourigenesis (Lee et al., 2005; 
Xia et al., 2005b). EphB4 contributes to tumour progression by aiding angiogenesis in tumour 
xenografts through reverse signalling of ephrin-B2 expressed on endothelial cells (Noren, 
2004) and promoting tumour cell survival, migration and invasion (Xia et al., 2005b). As others 
and we have found, the tumourigenic function is most likely a ligand-independent process as 
normal EphB4-ephrin-B2 signalling is tumour suppressive (Chen et al., 2008; Pasquale, 2010; 
Rutkowski et al., 2012). Over-expression experiments have confirmed that increasing EphB4 
on the surface of a non-transformed breast cell (MCF10A) confers a transformed phenotype 
while similar over-expression on a prostate cancer cell (22Rv1) promotes a metastatic 
phenotype (Rutkowski et al., 2012). Given that EphB4 activation of reverse ephrin-B2 
signalling aids angiogenesis, yet ligand stimulation of forward EphB4 signalling is tumour 
suppressive the interaction between EphB4 and ephrin-B2 must be managed to allow both of 
these signalling pathways to occur at the same time. 
Studies of several EphR-ephrin interactions have shown that attenuation of signalling can 
be achieved by two key mechanisms. In the first of these, the whole receptor-ligand complex 
is endocytosed into either cell via a mechanism that is dependent on Rac signalling and may 
include “pinching off” part of the plasma membrane of the opposite cell (Zimmer et al., 2003). 
The second mechanism involves protease cleavage of the ligand or the EphR after formation 
of the receptor-ligand complex. Proteases linked to Eph receptor and ephrin proteins include 
RHBDL2, a rhomboid transmembrane serine protease that cleaves ephrin-B3, several matrix 
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metalloproteinases and A Disintegrin and Metalloproteases (ADAMs) that have been reported 
to cleave both Eph receptors and ephrins including ephrin-A2 and ephrin-B1 (Hattori et al., 
2000; Inoue et al., 2009; Lin et al., 2008; Litterst et al., 2007; Pascall et al., 2004; Tanaka et 
al., 2007). EphB4 has been implicated as a potential substrate for ADAM-8, -9 and -17 by 
using an indirect “gain of function” approach (Guaiquil et al., 2009; Guaiquil et al., 2010b; 
Mendelson et al., 2010; Weskamp et al., 2010).   
In this Chapter, in silico data suggesting that EphB4 is a target for the serine protease 
kallikrein-related peptidase 4 (KLK4) is explored using biochemical and cell-based assays. 
Elevated expression of KLK4 is common in prostate cancers, with strong expression found in 
tumours that have metastasized to bone (Avgeris et al., 2011; Klokk et al., 2007; Seiz et al., 
2010; Veveris-Lowe et al., 2005; Wang et al., 2010a). Although the full mechanistic 
contribution of KLK4 to prostate cancer remains to be elucidated, it has been shown that KLK4 
secreted from prostate cancer cells may contribute to tumour progression through degradation 
of matrix proteins, thereby facilitating invasion and migration. KLK4 also activates signalling 
pathways of the protease-activated receptor (PAR) sub-family of G protein-coupled receptors. 
KLK4 releases an N-terminal ectodomain of PAR-2 allowing a conformational change in the 
remaining N-terminal sequence which activates the PAR-2 receptor (Ramsay et al., 2008). To 
our knowledge, to date, no serine protease-based mechanism for regulation of EphB4 has been 
reported, therefore we sought to determine whether KLK4 can cleave EphB4. 
4.4 MATERIALS AND METHODS 
4.4.1 Cell lines and Cell Culture  
The cell lines used in this study were obtained from the American Type Cell Culture 
Collection (ATCC) (Manassas, Virginia, USA). The prostate cancer lines 22Rv1, and the 
derivative cell lines 22Rv1-B4 (22Rv1 over-expressing EphB4) and 22Rv1-VO (containing 
the empty expression vector) as well as the spontaneously immortalized non-transformed breast 
line MCF-10A and the derivative cell lines MCF10A-B4 (MCF10A over-expressing EphB4) 
and MCF10A-VO (containing the empty expression vector) were made and cultured as 
previously described (Rutkowski et al., 2012). The prostate cancer lines PC3, DU145 and 
LNCaP were all cultured in RPMI containing 10 % FCS.  
4.4.2 Recombinant Proteins, Antibodies and Reagents 
Recombinant human EphB4-Fc, which comprises the extracellular domain of EphB4 
fused to the Fc region of human IgG1, was purchased from Sino Biologicals (Beijing, China). 
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Mature auto-active KLK4 (individual preparations were between 50% and 80% active) was 
produced in house and confirmed proteolytically active as previously described (Lisle et al., 
2015; Ramsay et al., 2008). Compound E (γ-Secretase Inhibitor XXI) and MG132 were 
purchased from Merck Millipore (Darmstadt, Germany). EphB4 antibodies include 3 
commercially available antibodies comprising an anti-human EphB4 C-terminal specific 
murine monoclonal antibody (Zymed, Invitrogen; 1:1000 dilution), anti-human EphB4 C-
terminal specific rabbit polyclonal antibody ( Novus; 1:1000 dilution) and an anti-human N-
terminal specific  rabbit polyclonal antibody (H-200, Santa Cruz Biotechnology; 1:500 
dilution) (Figure 4.1A). Monoclonal antibodies (13A7) targeting an epitope in the extracellular 
domain of EphB4 were a gift from BenEphex Biotechnologies Pty Ltd (Adelaide, Australia) 
(Stephenson et al., 2015). Anti-human GAPDH murine monoclonal antibody was purchased 
from Abcam (Cambridge, UK; 1:10,000 dilution). The HRP-conjugated anti-mouse and anti-
rabbit secondary antibodies were purchased from Pierce Biotechnology (Rockford, IL, USA; 
1:10,000 dilution). 
4.4.3 SDS-PAGE and Western Blotting 
Protein lysates were prepared using  RadioImmuno-Precipitation Assay (RIPA) buffer. 
Protein concentrations were determined with the Pierce BCA Protein Assay Kit (Pierce, 
Thermo, Rockford, IL) and 30 µg of protein,  separated using 10% SDS–PAGE gels, were then 
transferred onto BioTrace™ NT nitrocellulose membrane (Pall, Pensacola, FL). Membranes 
were blocked with Western blocking reagent (Roche, Indianapolis, Indiana) before incubation 
with primary antibodies and peroxidase-conjugated secondary antibodies with 
immunoreactivity detected using SuperRX X-ray film (Fuji Film Corporation, Japan) with the 
Amersham™ ECL Plus Chemiluminescence kit (GE Healthcare, Rydalmere, NSW).  
4.4.4 EphB4-Fc digestion with KLK4 
Recombinant human EphB4-Fc and active KLK4 were incubated overnight at 37ºC with 
reactions performed in a buffer containing 50 mM Tris-HCl and 50 mM NaCl, pH 8.5. To find 
the optimum molar ratio for EphB4 cleavage, the digestion experiment was performed with 
decreasing amounts of active KLK4 from a 1:1 EphB4 to KLK4 molar ratio (100 ng EphB4 + 
41 ng KLK4 ) to a 1:1/5000 EphB4 to KLK4  ratio (100 ng EphB4 + 8.2 pg KLK4). The 
reactions were terminated by adding SDS-loading buffer, electrophoresed and silver stained as 
previously described (Lisle et al., 2015). 
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4.4.5 N-terminal sequencing 
The protein bands, which corresponded with EphB4 cleavage fragments, were 
electrophoresed, transferred, stained and excised as previously described (Lisle et al., 2015). 
Fragments were sent to the Australian Proteome Analysis Facility (Sydney, NSW, Australia) 
for N-terminal sequencing by six cycles of Edman degradation (Chapter 3, Section 3.4.5).  
4.4.6 In vitro KLK4 digestion of EphB4 
The cell lines 22Rv1-VO and 22Rv1-B4, were grown to >90% confluence in T25 flasks 
(Nunc, Victoria, Australia). Cell monolayers were washed three times with PBS, then treated 
with the indicated concentration of KLK4 in serum free medium at 37ºC. Cells were lysed in 
RIPA buffer and lysates used in Western analysis to detect full-length EphB4 and cleavage 
fragments with the antibodies described above. A total protein lysate, made by directly adding 
RIPA buffer to a monolayer of 22Rv1-B4 cells in a flask, was used as a positive control for 
endogenous cleavage of the EphB4 protein. 
4.4.7 Protease inhibition experiments 
The effect of inhibiting KLK4 activity was tested using both the general serine protease 
inhibitor aprotinin and a specific KLK4 inhibitor SFTI-FCQR (Swedberg et al., 2009).  Cells 
were treated for 2 h at 37ºC (cell culture incubator) in the presence of two different 
concentrations of KLK4 (20 nM or 80 nM) with or without inhibitor added at a five-fold excess. 
In similar experiments, γ-secretase activity was blocked using different concentrations of 
Compound E (Gamma Secretase Inhibitor XXI). Proteasome activity was inhibited by 
treatment with 10 µM of the compound MG132 for 8 h at 37ºC. Cells were lysed in RIPA 
buffer and lysates used in Western blot analysis to detect full-length EphB4 and cleavage 
fragments as described above. 
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4.5 RESULTS 
4.5.1 Identification of EphB4 cleavage products in both endogenously EphB4 expressing 
prostate cancer cell lines and engineered cells  
Previously, we had generated two cell lines in which EphB4 was artificially over-
expressed, using the prostate cancer cell line 22Rv1 and the mammary epithelial cell line MCF-
10A as the parental lines (Rutkowski et al., 2012).  Western analysis with a validated EphB4 
N-terminal specific monoclonal antibody (13A7) (Figure 4.1A) confirmed over-expression of 
EphB4 (120 kDa), in both of the resultant polyclonal lines, but in the 22Rv1-B4 cells 
specifically, a second immunoreactive band of approximately 70 kDa was also seen (Figure 
4.1B). This was presumed to be a cleavage product representing an N-terminal fragment of 
EphB4 and this was then confirmed by identifying the corresponding C-terminal fragment 
using a C-terminal specific EphB4 antibody (Figure 4.1C).  In both EphB4 over-expressing 
cell lines an immunoreactive band that corresponded with the predicted size of full-length 
EphB4 was detected as expected and additionally 22Rv1-B4 cells displayed two bands of 
approximately 50 kDa and 47 kDa (Figure 4.1C).  This observation supported the previous 
result using the N-terminal antibody which visualized a 70 kDa fragment (Figure 4.1B) and 
suggested that EphB4 is specifically cleaved in 22Rv1-B4 prostate cancer cells, but not 
MCF10A-B4 breast cells, implying therefore that a protease specifically expressed in the 
22Rv1 prostate cancer cell line and not the MCF10A breast cell line was processing the EphB4.  
The presence of two C-terminal fragments (CTFs), however, also implied that there are two 
separate C-terminal cleavage events and that the 47 kDa may be a result of further processing 
of the 50 kDa fragment (Figure 4.1C). 
 To determine whether EphB4 is cleaved in other prostate cancer cell lines, lysates were 
prepared from LNCaP, DU145 and PC3 cells for Western blot analysis using the EphB4 
specific antibodies. Several potential cleavage fragments were detected and, although less well 
detected in these lines when compared with the over-expressing 22Rv1-B4 cells, the 50 kDa 
fragment could be seen in all lines (Figure 4.1D). In all the PCa cell lines examined there is a 
70 kDa band detected with the C-terminal antibody. This band has been shown to be a non-
specific band (data not shown).  The presence of other potential cleavage fragments that vary 
between cell lines suggests that EphB4 is a target for protease activity in prostate cancer cells 
and that different proteases may be involved. 
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Figure 4-1: Identification of EphB4 fragments in 22Rv1 cells over-expressing EphB4 
(22Rv1-B4) using Western analysis and EphB4-specific antibodies.  
 
(A) Model of the EphB4 protein showing domains including the globular domain (blue), 
cysteine-rich domain (yellow), two fibronectin type III repeats (green), the transmembrane 
domain (brown), the kinase domain (orange), and the SAM domain with a C-terminal PDZ 
domain (buff).  The predicted epitopes recognized by four different EphB4-specific antibodies 
are aligned to the approximate position of the amino acid sequence of EphB4. (B) Total protein 
lysates (~30 g) from MCF-10A cells over-expressing EphB4 (Lane 1 – MCF-10A-B4) and 
22Rv1 cells over-expressing EphB4 (Lane 3 – 22Rv1-B4) were analysed by Western blotting 
with an antibody that recognizes the N-terminal cysteine-rich domain epitope of EphB4. An 
immunoreactive band corresponding to the predicted size of full length EphB4 was seen in 
samples from both MCF-10A-B4 and 22Rv1-B4.  A second immunoreactive band at 
approximately 70 kDa was also seen in the 22Rv1-B4 sample only.  An antibody recognizing 
GAPDH (37 kDa) was used as a loading control. (C) Total protein lysates (30 g) from MCF-
10A cells over-expressing EphB4 (Lane 1 – MCF-10A-B4) and 22Rv1 cells over-expressing 
EphB4 (Lane 2 – 22Rv1-B4) were analysed by Western blotting with an antibody that 
recognizes the C-terminus of EphB4. An immunoreactive band corresponding to the predicted 
size of full length EphB4 was again seen in samples from both MCF-10A-B4 and 22Rv1-B4.  
Two immunoreactive bands at approximately 50 kDa and 47 kDa were also seen in the 22Rv1-
B4 sample.  An antibody recognizing GAPDH (37 kDa) was again used as a loading control. 
(D) Western blot analysis of EphB4 in prostate cancer cell lines using the C-terminal antibody 
identifies several potential EphB4 cleavage fragments. The antibody recognizing GAPDH (37 
kDa) was used as a loading control. 
_________________________________________________________________________ 
4.5.2 Recombinant EphB4-Fc can be cleaved by active KLK4 
As previously reported in Chapter 3, the ligand for EphB4, ephrin-B2, is cleaved by the 
prostate cancer associated serine protease KLK4 and KLK4 was therefore considered a 
possible candidate protease for the generation of EphB4 cleavage fragments (Lisle et al., 2015). 
In support of this, others report that KLK4 is expressed by the 22Rv1 cell line but not by 
MCF10A cells (Lai et al., 2009), To determine whether KLK4 could indeed cleave the 
extracellular domain of EphB4, recombinant human EphB4-Fc (EB4-Fc) was incubated with 
auto-activating recombinant KLK4 prepared in-house (Lai et al., 2009; Lisle et al., 2015). The 
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commercially obtained EphB4-Fc protein includes the entire extracellular domain of human 
EphB4 (NP_004435.3) from Met 1 to Ala 539 fused to the N-terminus of the Fc region of 
human IgG1 (Figure 4.2A). Recombinant human EphB4-Fc protein substrate was incubated 
overnight with increasing amounts of active KLK4 from a 1:1/5000 substrate (EphB4-Fc) to 
enzyme (KLK4) molar ratio to a 1:1 molar ratio (Figure 4.2B). The recombinant human 
EphB4-Fc protein is a disulfide-linked homodimeric protein and as a result of glycosylation 
migrates as a 105-110 kDa protein in SDS-PAGE under reducing conditions (Figure 4.2B, lane 
8, EphB4 only).  Although full-length EphB4 was also present in the samples containing low 
amounts of KLK4 (lanes 5-7), at the high molar ratios this band was almost completely absent 
and instead a single band of approximately 30 kDa appeared (Lanes 2 – 4, Figure 4.2B).  This 
was identified as a fragment of the Fc domain and is consistent in size with the Fc only control 
used for this experiment (Figure 4.2B, lane 10, Fc only) (Lisle et al., 2015). The absence of 
any other cleavage fragments suggested that the EphB4 extracellular domain is completely 
degraded by high amounts of KLK4 (lanes 2-4, Figure 2B). Clear evidence of partial KLK4 
cleavage of the EphB4 protein was seen in samples where the amount of KLK4 added was 
lower (Figure 4.2B, lanes 5-6). In these samples, a band of ~35 kDa was clearly visible (Figure 
4.2 B – red boxes).  
 
4.5.3 Identification of the KLK4 cleavage site in the EphB4 extracellular domain using 
N-terminal sequencing  
To identify the amino acid sequence of the KLK4 cleavage site in EphB4, the ~ 35 kDa 
fragment band produced as the initial KLK4 cleavage event (Figure 4.2B – red boxes) was 
subjected to N-terminal sequencing using six cycles of Edman degradation. Using only the 
major signal option the N-terminal sequence of the fragment was determined to be ARSEAG 
(Figure 4.3A – red boxes) as this corresponded to the sequence in the EphB4 extracellular 
domain at Ala 509 – Gln 514 (Figure 4.3B).  The presence of an arginine residue at residue 508 
and immediately N-terminal to this sequence supports the hypothesis that this is a KLK4 
cleavage site, as KLK4 is well documented to cleave after either an arginine or a lysine.  This 
sequence also matches the predicted consensus KLK4 cleavage sites, as defined by both 
Matsumura et al. (2005) and Debela et al. (2006) (Debela et al., 2006; Matsumura et al., 2005). 
The molecular weight of the fragment, that includes the C-terminal fragment of the EphB4 
extracellular domain, the human IgG1 Fc (Pro100 to Lys330 = 26 kDa), the 6-  
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Figure 4-2: Recombinant EphB4-Fc can be cleaved by KLK4.  
(A) Schematic of the Recombinant EphB4-Fc protein. (B) Recombinant human EphB4-Fc 
(EB4-Fc) was incubated with decreasing amounts of active KLK4 (KLK4) from a 1:1 KLK4 
to EphB4 ratio (1) to a 1/5000:1 KLK4 to EphB4 ratio (0.005). Full length proteins and 
cleavage products were visualised by silver staining. The full-length EphB4-Fc protein (EB4-
Fc) and KLK4 and a cleavage fragment corresponding to the C-terminal sequence of the human 
IgG1 Fc protein are indicated by arrows on the right. The cleavage product isolated Histidine 
tag (841 Da) and the linker sequence (835 Da) is predicted to be ~ 34 kDa, and this is consistent 
with the predicted molecular weight of the cleavage fragment generated (Figure 3C).for N-
terminal sequencing is indicated by the red box. The molecular weight marker used was 
Precision Plus Protein™ Dual Color Standard (Bio-Rad) and the protein bands with their 
corresponding molecular weights in kilodaltons (kDa) are shown on the left. 
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Histidine tag (841 Da) and the linker sequence (835 Da) is predicted to be ~ 34 kDa, and 
this is consistent with the predicted molecular weight of the cleavage fragment generated 
(Figure 4.3C).Cleavage at this sequence would release almost the complete extracellular 
domain of EphB4 (Figure 4.3D), estimated to be ~ 70 kDa, and entirely consistent with the N-
terminal cleavage fragment identified by Western analysis (Figure 4.1B) The second major 
signal generated from the Edman degradation was TPPVLD (Figure 4.3A – green boxes) which 
corresponded to a sequence in the human IgG1 Fc portion of the recombinant EphB4-Fc protein 
at Thr277-Asp282. This fragment must have been co-purified with the EphB4 cleavage 
fragment and its identification confirms that the Fc region can also be cleaved by KLK4. Given 
that the EphB4 fragment is not seen on further KLK4 digestion it is likely that further sites are 
exposed after cleavage at RARSEAG. 
4.5.4 Exogenous KLK4 can cleave EphB4 from the surface of prostate cancer cells  
The results presented above showed that recombinant KLK4 can cleave the extracellular 
domain of recombinant EphB4 but to determine whether KLK4 could cleave EphB4 protein 
when it is expressed on the surface of prostate cancer cells, 22Rv1-B4 cells were treated with 
either recombinant KLK4 or KLK4 with aprotinin and after 2 h, protein lysates were prepared 
for Western blot analysis using the C-terminal EphB4-specific antibody (Figure 4.4A). In all 
lanes a band corresponding to full length EphB4 was seen and in the KLK4-treated cells, 
smaller bands of ~50 kDa and ~47 kDa were consistent with those seen previously (Compare 
Figure 4.4A with Figure 4.1C). This cleavage was seen to be concentration dependent, as 
increasing concentrations of KLK4 added to the cells resulted in the production of more of 
these fragments (Figure 4.4A). These smaller bands were less apparent in the untreated sample 
showing that the generation of these two fragments correlates with the increased presence of 
active KLK4. Also, with addition of higher concentrations of KLK4, there is the appearance of 
further bands at ~ 53 kDa and ~100 kDa which are not observed in the lane with lower 
concentrations which suggests further cleavage events may be occurring at higher 
concentrations of KLK4.  The cleavage fragments were also less apparent (to a similar level as 
seen in the untreated cells) when aprotinin, a general and reversible, serine protease inhibitor 
was added to the cells at the same time as the KLK4.   
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Figure 4-3: Identification of the KLK4 cleavage site in the extracellular domain of human 
EphB4.  
(A) N-terminal sequencing identified two major signal sequences - ARSEAG (boxed in red) 
and TPPLVD (boxed in green). (B) The ARSEAG sequence identified as the KLK4 cleavage 
site corresponds to position 509-514 in the human EphB4 protein sequence. The red arrow 
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indicates the site immediately after R508. (C) Diagrammatic representation of the recombinant 
EphB4-Fc fusion protein identifying the KLK4 cleavage site and the origin of the human IgG1 
Fc fragment with the identified cleavage site. (D) A diagrammatic representation of the 
predicted effect of KLK4 cleavage of EphB4 at this site.  Most of the extracellular domain 
would be removed including the ligand binding domain (blue), the cysteine-rich region 
(yellow), and the two fibronectin type III repeats (green).  The intracellular portion including 
the tyrosine kinase domain (orange) and the SAM and PDZ domains (buff) would remain 
attached to the inside of the cell membrane via the transmembrane sequence.  
___________________________________________________________________________ 
 
4.5.5 Specific inhibition of KLK4 diminishes EphB4 cleavage 
 
A specific inhibitor for KLK4, the cyclic peptide SFTI-FCQR (Swedberg et al., 2009), was 
then used to confirm that the EphB4 cleavage fragments generated by KLK4 were KLK4-
specific cleavage fragments. Using the C-terminal antibody, in untreated cells (Figure 4.5 – 
Lane 1) the appearance of the 50 and 47 kDa bands indicates their presence in cell lysates, 
consistent with previous experiments. It should be noted that 22Rv1 cells are known to express 
endogenous KLK4 (Lai et al., 2009). Following addition of KLK4, these bands were more 
intense as expected (Figure 4.5, lanes 2 & 5), but were diminished when the SFTI-FCQR 
inhibitor was added (Figure 4.5, lanes 3 & 6), indicating that these fragments are most likely 
generated as a consequence of the initial KLK4 extracellular cleavage event. Even less of these 
cleavage fragments were seen in the presence of aprotinin proving that these fragments are 
generated by the activity of serine proteases, but suggests that other serine proteases may also 
be active here.  Interestingly, in the cells treated with KLK4, the lower ~47 kDa cleavage 
fragment appeared more intense than in the sample from cells treated with KLK4 and both 
aprotinin and the SFTI-FCQR inhibitor which suggests that this may be generated as a 
consequence of KLK4 cleavage and perhaps not by it. 
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Figure 4-4: Western analysis comparing the molecular weights of EphB4 cleavage 
proteins produced both endogenously in 22Rv1-B4 cells and through the proteolytic 
function of exogenous KLK4. 
The 22Rv1-B4 cells were treated with 20 nM, 80 nM, 120 nM recombinant KLK4 (or vehicle) 
and then analysed using the C-terminal EphB4-specific antibody. The 50 and 47 kDa fragments 
are enhanced with addition of KLK4, with the 47 kDa band being more prominent. The EphB4 
fragments are produced in a dose-dependent manner. Loading control was provided using an 
antibody specific to GAPDH. The molecular weight marker used was Precision Plus Protein™ 
Dual Color Standard (Bio-Rad) and the protein bands with their corresponding molecular 
weights in kilodaltons (kDa) are shown on the left.   
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Figure 4-5: Western analysis comparing the molecular weights of EphB4 cleavage 
proteins produced after incubation of 22Rv1-B4 cells with exogenous KLK4, the specific 
KLK4 inhibitor SFTI-FCQR and the serine protease inhibitor aprotinin. 
 
The 22Rv1-B4 cells were treated with 20 nM or 80 nM recombinant KLK4 (or vehicle – 
untreated cells) in the presence or absence of the specific KLK4 inhibitor SFTI-FCQR and the 
serine protease inhibitor aprotinin and then analysed using the C-terminal EphB4-specific 
antibody. The 50 and 47 kDa fragments are enhanced with addition of KLK4, with the 47 kDa 
band being more prominent with an increased concentration of KLK4. Cleavage fragments of 
several sizes are indicated. Loading control was provided using an antibody specific to 
GAPDH. The molecular weight marker used was Precision Plus Protein™ Dual Color Standard 
(Bio-Rad) and the protein bands with their corresponding molecular weights in kilodaltons 
(kDa) are shown on the left.  
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4.5.6 Inhibition of γ-secretase activity blocks further cleavage of the 50 kDa C-terminal 
fragment 
Initial ectodomain cleavage of receptor proteins is often followed by further cleavage 
events by intracellular and intramembrane proteases (Lal et al., 2011; Lee et al., 2002; Pascall 
et al., 2004; Tomita et al., 2006). Because of the small difference in size between the C-terminal 
50 kDa and 47 kDa fragments, it was predicted that the initial 50 kDa fragment released by the 
cleavage of the ectodomain was followed by a second cleavage event that was most likely 
occurring within the transmembrane domain and that this was possibly by the action of γ-
secretase, a multi-subunit intramembrane protease known to cleave various type I 
transmembrane proteins within their transmembrane domains (Lal et al., 2011; McCarthy et 
al., 2009; Steiner et al., 2008).This can often result in the release of an intracellular fragment 
(ICD) of the targeted protein that then has a unique biological function within the cell (De 
Strooper et al., 1999).  
To determine whether γ-secretase further processes the 50 kDa C-terminal fragment 
(CTF) of EphB4 that remains after KLK4-cleavage of the extracellular domain, 22Rv1-B4 cells 
were treated for 2 h with the γ-secretase inhibitor Compound E with concentrations increasing 
from 0.01 M to 10 M. At the lowest concentration of Compound E (0.01 M), the 47 kDa 
band was no longer detected and as the concentration of Compound E increased, the 50 kDa 
CTF increased in intensity suggesting that the further processing of this cleavage fragment was 
being prevented (Figure 4.6A). A ~53 kDa band seen previously with high concentrations of 
KLK4 (Figure 4.5) also increased in intensity as the concentration of Compound E increased.   
To determine whether γ-secretase processing of CTF fragments of EphB4 occurs after 
cleavage of the extracellular domain and regardless of the protease involved, PC3 cells were 
treated for 2 h with Compound E and the presence of EphB4 cleavage fragments identified 
using Western blot analysis (Figure 4.6B). PC3 cells were chosen for this experiment because 
they endogenously express high levels of EphB4, but we have subsequently reported that most 
of this protein is retained in the endoplasmic reticulum with only a small proportion localised 
to the plasma membrane (Stephenson et al, 2015). Furthermore, the PC3 cells used here did 
not express KLK4 and this is therefore not the protease responsible for the cleaved fragments 
of EphB4 seen in PC3 cells (Figure 4.1D).  Functional γ-secretase complexes have been 
reported to be retained in the ER membranes (Capell et al., 2005; Ohta et al., 2011). 
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Figure 4-6: Inhibition of KLK4 cleavage of EphB4 using two different inhibitors. 
 (A) Western blot analysis of EphB4 proteins and fragments after γ-secretase activity in 22Rv1-
B4 cells was inhibited by the addition of Compound E in four different concentrations ranging 
from 10 nM to 10 M.  At the lowest concentration of Compound E (10 nM), the 47 kDa band 
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was no longer detected and as the concentration of Compound E increased, the intensity of the 
50 kDa band also increased. An antibody to GAPDH was used as a loading control. (B) PC3 
cells were also treated with 100 nM of compound E. A γ-secretase targeted fragment is clearly 
seen at ~75 kDa. In this sample there also appeared to be more of the 50 kDa cleavage 
fragments retained with less processing to 47 kDa.   
PC3 cells were treated with 100 nM Compound E for 24 h and then lysates were examined for 
EphB4 fragments and compared with untreated and vehicle only treated cells.  In untreated and 
vehicle only treated PC3 cells, both the 50 kDa CTF and the 47 kDa ICD are only faintly 
detected (a sample of 22Rv1-B4 lysate was used as a positive control and to assist with 
identification of the CTF and ICD products).  Consistent with the lack of surface expression of 
EphB4 in these cells, treatment with exogenous KLK4, the KLK4 inhibitor and aprotinin, 
resulted in no change to the level of fragments detected (Figure 4.6B).  Treatment with 
Compound E however did appear to increase the amount of the 50 kDa band, as this was 
detected more strongly in this sample. This suggests that this fragment is produced by an initial 
protease cleavage event and the product is then a target for γ-secretase processing but although 
unlikely to be at the same site as KLK4.  Interestingly, another higher molecular weight band 
at ~80 kDa in size was seen very clearly in the PC3 Compound E treated sample. The presence 
of this band identifies another cleavage event that generates a product that is likely to be further 
processed either by γ-secretase or a γ-secretase-mediated process (Figure 4.6B). 
 
4.5.7 Inhibition of the proteasome reveals that C-terminal fragments are stable  
Activity of γ-secretase can generate a functional intracellular fragment (ICD) of the target 
protein and to provide an indication of the potential stability of the EphB4 ICD or whether the 
fragment is degraded by the proteasome, 22Rv1 cells were treated with the proteasome 
inhibitor MG132. If the ICD is degraded by the proteasome, inhibition of this should result in 
an increased amount of ICD compared to that in untreated cells. After 8 h treatment with a high 
dose of MG132 very little of the CTF or ICD increased which suggests that they are not sent 
to proteasome (Figure 4.7). When both the proteasome and the -secretase were inhibited only 
a slight increase of the CTF was seen and there were no new intermediate fragments apparent 
which suggests that there are only two cleavage events occurring endogenously in these cells.  
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Figure 4-7: Effect of inhibition of the proteasome on levels of EphB4 cleavage fragments 
in cells in which γ-secretase is also inhibited. 
 
Western blot analysis of EphB4 proteins and fragments in 22Rv1-B4 cells after inhibition of 
the proteasome using MG132, γ-secretase activity using Compound E and addition of both 
inhibitors together. Vehicle is 0.1% DMSO. An antibody to GAPDH was used as a loading 
control. 
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4.5.8 Mutation of the KLK4 cleavage site of EphB4 leads to production of alternative 
fragments. 
KLK4 cleavage of target proteins is predicted to occur after recognition of specific amino 
acids in the P and P’sites (Figure 4.8A). The preference for certain amino acids at the P and P’ 
positions was determined using a heat map where a more intense yellow signal indicates this 
amino acid is more preferred in this position, and more blue indicates less preferred (Figure 
4.8A).  A site-directed mutagenesis approach was used to change the Arginine 508 in the P1 
position of the identified KLK4 cleavage site of EphB4 to an Alanine, an amino acid that is 
much less favoured at this position for KLK4 interaction (Figure 4.8A). R508A EphB4 was 
over-expressed in 22Rv1-B4 cells (22Rv1-B4) and protein lysates examined by Western 
analysis for the presence of EphB4 cleavage fragments.  Two bands were identified as potential 
cleavage fragments of the mutant EphB4 protein but these were smaller than the 50 kDa and 
47 kDa fragments seen in the samples from wild type EphB4 (22Rv1-B4) and wild type EphB4 
with a C-terminal V5 His tag (22Rv1-B4-V5 His).  This would suggest that although KLK4 
can no longer cleave at the R508 site anymore, an alternative protease cleavage site is now 
being used. This may be because the mutant protein has not folded correctly and protease 
cleavage sites that were once buried are now exposed to protease action. To determine whether 
these fragments are generated by serine protease activity and whether they are further processed 
by γ-secretase, cells were treated with aprotinin, Compound E and a combination of both 
inhibitors.  For this experiment the Novus polyclonal antibody which was raised to a 
recombinant fragment corresponding to a region within amino acids 565 and 919 of EphB4 
was used in an attempt to identify further cleavage fragments that the C-terminal monoclonal 
antibody may miss. In control cells expressing the wild type EphB4 protein, the intensity of 
the 50 kDa fragment increased in the samples from cells that had been treated with Compound 
E as expected (Figure 4.8C – red box). One of the lower molecular weight bands is also 
identified with this polyclonal antibody in all samples from the 22Rv1-B4 cells.  When γ-
secretase is inhibited using Compound E though two further bands of between 50 and 55 kDa 
are then seen (purple boxes) clearly showing that γ-secretase is further processing two other 
fragments.  Inhibition of serine protease activity using aprotinin does not alter the levels of 
these γ-secretase cleaved products suggesting that they must be generated through the activity 
of a different class of protease but the identity of this has not been explored further at this time. 
 
 
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 115
 
 
 
 
 
 
 
 Chapter 4: Cleavage of the Tumour-promoting Receptor Tyrosine Kinase, EphB4, in Prostate Cancer 116                
 
Figure 4-8: Mutation of the KLK4 cleavage site in EphB4 
 
(A) A heat map showing the KLK4 preferred amino acids in the substrate P and P’ positions. 
Amino acids are shown in single letter code on the left of the heat map. More intense yellow 
indicates this amino acid is more preferred in this position, more blue indicates less preferred. 
Boxes indicate the amino acids found specifically in the validated KLK4 cleavage site in 
EphB4.  (B) Western blot analysis comparing the production of EphB4 cleavage fragments in 
22Rv1-B4 cells (Vector only - 22Rv1-VO, wild type over expressing 22Rv1-B4 and 22Rv1 
over-expressing wild type EphB4 with a C-terminal V5 His tag – 22Rv1-B4-V5 His) with 
KLK4 site R508A EphB4 expressing 22Rv1 cells (22Rv1-B4). The presence of two smaller 
cleavage fragments identified specifically in the K4 site mutant 22Rv1-B4 cells is indicated 
by the red box. An antibody to GAPDH was used as a loading control. (C) Western blot analysis 
of EphB4 proteins and fragments in 22Rv1-B4 cells after inhibition of general serine protease 
activity using aprotinin, γ-secretase activity using Compound E and after addition of both 
inhibitors together. Two bands between 50 and 55 kDa retained in the Compound E treated 
samples are indicated by the purple boxes. Two non-specific bands identified using the Novus 
polyclonal antibody are indicated. Vehicle is 0.1% DMSO. An antibody to GAPDH was used 
as a loading control 
__________________________________________________________________________ 
 
 
4.6 DISCUSSION 
Protease regulation of members of the Eph family and their ephrin ligands has been 
reported, but until this study, no proteases had been directly linked to EphB4, a receptor 
tyrosine kinase often over-expressed in prostate cancer (Figure 4.9(1)). In exploring the 
consequence of over-expression of EphB4  on the surface of prostate cancer cells, a 70 kDa 
fragment of EphB4 present in the cell lysates of the 22Rv1-B4 prostate cancer cells (Figure 4.9 
(a and b), but not the breast MCF10A-B4 cell line, was identified using an N-terminal specific 
antibody. This suggested that EphB4 cleavage may occur in a cell context dependent-manner 
and a prostate cancer specific protease, like KLK4, might be involved (Figure 4.9(2)). This 
result was then verified using an antibody raised to the C-terminal end of EphB4 and 
interestingly this identified two fragments – one of ~50 kDa which is consistent with the 
expected size of the C-terminal portion, and another slightly smaller which was considered to 
be potential evidence of a further cleavage event.  To our knowledge these experiments provide 
the first evidence that EphB4 is a target for protease activity and identify two potentially 
biologically active fragments.  
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The in silico prediction that EphB4 was a potential substrate of KLK4 was then tested 
using recombinant EphB4 and active KLK4 proteins in a biochemical approach. A recombinant 
protein corresponding to the extracellular domain of EphB4 was cleaved by KLK4 at an 
EphB4: KLK4 molar ratio of 1:1/1000. Given that an established substrate of KLK4, the pro 
form of urokinase-type plasminogen activator (uPA), is reportedly cleaved at a higher enzyme 
to substrate ratio of 1:100 (Beaufort et al., 2006), this low ratio would suggest EphB4 is a good 
candidate substrate for KLK4.   
N-terminal sequencing of the resulting primary cleavage fragment identified the 
sequence ARSEAG which corresponded to residues 509-514 of EphB4.  Immediately upstream 
of this sequence in the EphB4 extracellular domain is an arginine (R508) and together this 
sequence is consistent with a KLK4 consensus site (Matsumura et al 2005; Debela et al, 2006). 
Cleavage at this site would separate the EphB4 protein into two fragments predicted to be of 
70 kDa and 50 kDa, consistent with the Western blot analysis that identified the fragments.   
The identified KLK4 cleavage site is located proximal to the transmembrane domain. 
Cleavage would release almost the entire ectodomain potentially, a fragment with an important 
biological function. Some clues to this function are already provided by the large number of 
studies that have used recombinant human EphB4 ectodomain proteins in both in vitro and in 
vivo experiments. Reverse signalling is commonly reconstructed using soluble EphB4-Fc 
proteins that are artificially clustered using anti-Fc antibodies (Füller et al., 2003; Hamada et 
al., 2003; Pennisi et al., 2009). A pro-tumourigenic function for the EphB4 ectodomain is 
suggested by experiments using such clustered EphB4-Fc proteins and expression of truncation 
mutants (Héroult et al., 2010; Kaenel et al., 2011). Activation of ephrin-B2 reverse signalling 
of endothelial cells by tumour cells engineered to over-express a truncated EphB4 receptor, in 
which the intracellular domains including the kinase domain have been replaced with EGFP, 
resulted in increased angiogenesis as indicated by a higher blood content (haemoglobin level) 
and larger blood vessels compared to control EphB4 positive tumours (Noren et al., 2004). 
Alternatively, soluble monomeric EphB4 ectodomain has been reported as an antagonist of 
EphB4/ephrinB2 signalling and suppresses endothelial cell migration, adhesion, and tube 
formation in vitro by blocking activation of EphB4 and  
ephrin-B2 (Kertesz et al., 2006). In the experiments described here, the 70 kDa fragment of the 
EphB4 ectodomain is easily detected using Western blot analysis of total protein lysates, which 
suggests that much of the ectodomain remains attached to the cell surface, presumably through 
interactions with full length protein and most likely via the two fibronectin type III repeats and 
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the cysteine-rich domain all believed to be involved in stabilizing Eph receptor dimers. 
Continued KLK4 activity could eventually release multimers of EphB4 ectodomains from the 
surface of prostate cancer cells in a biological equivalent of the signalling experiments using 
clustered EphB4-Fc proteins described above .Interaction between the 70 kDa ectodomain and 
full length EphB4 would also restrict the forward activation of EphB4 signalling, and will 
thereby limit the tumour suppression that is a normal consequence of ligand binding.  
The cellular consequences of generating an intracellular fragment may also be 
significant. Cleavage of cell membrane-expressed EphB2 by ADAM10 releases the 
ectodomain of EphB2 after residue 543 (Litterst et al., 2007). Two C-terminal fragments were 
also identified in this and a further study  and it was shown that the lower of the two bands 
resulted from further processing of the higher molecular weight C-terminal band by 𝛾-secretase 
which cleaved just inside the transmembrane domain and this is where EphB4 is predicted to 
be cleaved gamma secretase suggesting this could be a common mechanism in the Eph family 
(Litterst et al., 2007; Xu et al., 2009). Similarly, ADAM10 can also cleave cell membrane 
expressed EGF receptor, Erb-B4, and 𝛾-secretase then releases an 80 kDa soluble intracellular 
fragment (s80) that is translocated to the nucleus (Komuro et al., 2003; Ni et al., 2001; Williams 
et al., 2004). Nuclear translocation of both full-length and fragments of receptor tyrosine 
kinases has been reported and linked to both normal and cancer cell functions (Stephenson et 
al., 2012). The 50 kDa fragment appeared to be stable as it was not inhibited by MG132 
treatment, however the 47 kDa fragment did appear to diminish after treatment. This is due to 
the fact that at the concetration used γ-secretases is also inhibited by MG132 (Okamoto et al., 
2001). It will be interesting to determine the fate and function of the intracellular C-terminal 
fragment of EphB4 and this is the aim of experiments described in Chapter 5. 
Several members of the kallikrein family are increased in prostate cancer including 
prostate specific antigen, or kallikrein 3 (KLK3), the current biological marker for clinical 
prostate cancer; KLK2 which is also over-expressed in prostate cancer and can activate PSA; 
and KLK4 which is also up-regulated in prostate cancer and correlates with advanced disease 
making this family of serine proteases attractive candidates for cleavage of EphB4 (Lawrence 
et al., 2010). Lawrence et al. (2010) identified KLK4 as the most highly expressed KLK gene 
in 22Rv1 cells (Lawrence et al., 2010). KLK4 is only expressed in breast and prostate cancers 
that express the progesterone receptor (PR) or androgen receptor (AR), respectively (Lai et al., 
2009). MCF10A are both PR and AR negative (Subik et al., 2010) and do not express the KLK4 
gene - all reasons that made KLK4 a good candidate for the protease that cleaves EphB4 but it 
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is clearly not the only protease that might be involved in EphB4 regulation as PC3 cells which 
are KLK4 negative also have the C-terminal fragments and it will be interesting to identify 
other proteases that are important in various cancer cells. 
This study has identified a completely novel mechanism for proteolytic regulation of 
EphB4. The results reported here, that identify a process for release of the EphB4 ectodomain, 
with the subsequent generation of an intracellular fragment, further add to the functional and 
mechanistic complexity of the Eph/ephrin system and provide novel insights into potential 
explanations for the contrasting ligand-dependent tumour suppressive effects and the ligand-
independent tumour promoting effects of EphB4 (Rutkowski et al., 2012).  
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Figure 4-9: Model of possible consequences of protease cleavage of EphB4 expressed on 
the surface of prostate cancer cells.  
 
(1) EphB4 clustered on the surface of prostate cancer cells stimulates tumour growth through 
ligand-independent pathways. Cleavage by KLK4 releases the ectodomain which then either 
stimulates or inhibits angiogenesis through ephrin-B2 ligands expressed on endothelial cells 
depending on whether it is released as dimers/multimers (2a) or as monomers (2b). (3) 
Continued interaction between the ectodomain and full length EphB4 may prevent ligand-
induced tumour-suppressive EphB4 signalling and, instead, promote a ligand-independent 
signalling pathway whilst also stimulating reverse signalling required for angiogenesis, both of 
which will lead to stimulation of tumour cell growth. (4) The second cleavage event by a second 
protease – most likely γ-secretase - releases the intracellular fragment, which either may 
directly stimulate tumour growth from the cytosol or be translocated to the nucleus where it 
could activate expression of tumour promoting genes.   
__________________________________________________________________________ 
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Figure 4-10: Model of process of protease cleavage of EphB4.   
Action of an extracellular shedding protease generates a C-terminal fragment (CTF) of cell 
membrane expressed EphB4 that is then further processed by γ-secretase to release a soluble 
intracellular domain (ICD) into the cytoplasm.  The biological function of this ICD is explored 
in Chapter 5. 
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5.1 GENERAL INTRODUCTION  
 
The research described in Chapter 5 is entitled “Localisation and functions of the intracellular 
domain fragment of EphB4 in prostate cancer” and is a manuscript in preparation. Results in 
the previous chapter describe the production of an intracellular domain (ICD) fragment of 
EphB4 resulting from a proteolytic mechanism. This manuscript describes how ectopic 
expression of this ICD fragment causes increased proliferation and migration as well as 
changes in the expression of genes involved in epithelial to mesenchymal transition. Together 
these results begin the characterisation of a new, previously unexplored function for the 
biological fragments of the EphB4 protein in prostate cancer.  
 
5.2 ABSTRACT 
EphB4 is a receptor tyrosine kinase that is implicated in the formation and progression 
of many epithelial cancers. However, surprisingly interaction with its ligand in a cancer context 
is tumour suppressive, whilst overexpression and absence of the ligand leads to ligand 
independent tumour promotion. Previously, we provided evidence for proteolysis of EphB4, 
which could regulate this interaction. In addition, we showed that after an initial cleavage event 
there is a second cleavage event, which produces a smaller C-terminal fragment of EphB4 of 
approximately 47 kDa termed the intracellular domain fragment (ICD). This study describes 
how the ectopic expression of this fragment in PC3 and DU145 prostate cancer cells resulted 
in increased proliferation and increased migration of these cells. This fragment also has a 
functional nuclear localisation signal and was found to be required for the translocation of the 
ICD to the nucleus in these cells.  Over expression of this fragment correlated with an alteration 
in the morphology of the cells, and as the fragment could localise to the nucleus, was 
investigated as having a possible impact on gene regulation and possibly genes involved in the 
epithelial to mesenchymal transition. PC3 and DU145 cells that had ectopic overexpression of 
the ICD had increased mRNA levels of LEF1 – a key transcription factor in the Wnt-β Catenin 
pathway that is linked to EMT in androgen independent prostate cancer. This data suggests that 
the ICD fragment may have differential roles in prostate cancer compared to full length EphB4 
and could also be contributing to prostate cancer.  
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5.3 INTRODUCTION 
Classically, RTKs are tethered in the plasma membrane and transduce signals from the 
extracellular matrix into the cell stimulated by interaction with their cognate ligands. It is only 
in recent years that signalling mechanisms beyond this have been elucidated whereby full 
length or proteolytic fragments of these receptors can have additional functions both inside the 
cell, in other cell compartments, or outside the cell (Lemmon et al., 2010). Regulated 
intramembrane proteolysis (RIP) is a process by which an RTK is initially cleaved within its 
extracellular domain by a protease, and this is followed by a second cleavage event of the 
remaining C-terminal fragment, to release a functional intracellular fragment into the 
cytoplasm of cell.  Data from studies exploring proteolytic processing of RTKs in cancer have 
shown that proteases can cleave and liberate the ectodomain of these receptors and in some 
cases the extracellular domain retains its ability to bind ligands (Sanderson et al., 2008). Many 
of these RTKs can then undergo a second intracellular cleavage event mediated by γ-secretase 
(Blobel et al., 2009; Higashiyama et al., 2011; Lee et al., 2002; Na et al., 2012; Rio et al., 
2000). For example, efficient Notch signalling requires both of these cleavage events (Brou et 
al., 2000; De Strooper et al., 1999; Taniguchi et al., 2002). Interaction of the Notch receptor 
with its ligand induces a conformational change that results in a cleavage site becoming 
available for ADAM17, which then cleaves the extracellular domain close to the cell membrane 
(Brou et al., 2000). This subsequently allows for an intracellular cleavage of the Notch receptor 
in the juxtamembrane region by the presenilin/γ-secretase complex and results in release of a 
C-terminal fragment (De Strooper et al., 1999). The C-terminal is transported to the nucleus 
where it influences the expression of several target genes including CSL (Jarriault et al., 1995). 
Another well-characterised cancer related type I transmembrane receptor that undergoes 
ectodomain shedding is ErbB4/HER4 into an ErbB4 isoform that contains a specific protease 
binding site for ADAM17 (Vidal et al., 2005). ADAM17 cleavage releases an 80 kDa 
membrane-associated ErbB4 C-terminal fragment which then undergoes γ-secretase 
intramembrane cleavage (Linggi et al., 2005; Vidal et al., 2005). This fragment, termed 4ICD, 
translocates into the nucleus where, through cross talk with the oestrogen receptor, promotes 
oestrogen regulated proliferation even in the absence of exogenous ErbB4 ligand in breast 
cancer (Rokicki et al., 2010; Williams et al., 2004). 
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EphB4 is a member of the Eph family of receptor tyrosine kinases, which are type 1 
transmembrane proteins often involved in embryogenesis and development (Pasquale, 2010). 
They interact with cell membrane tethered ligands called ephrins and this then elicits responses 
in both the receptor and ligand-expressing cells called ligand-dependent bi-directional 
signalling (Pasquale, 2010). Evidence that this interaction is dysregulated in cancer and that 
ligand-independent signalling may be tumourigenic has been demonstrated by our laboratory 
(Rutkowski et al., 2012). Recently our laboratory has identified both full length EphB4 in the 
nucleus of the prostate cancer cells which suggests EphB4 may regulate genes after nuclear 
translocation (Mertens-Walker et al., 2015b). In Chapter 4 of this thesis it was demonstrated 
that EphB4 undergoes proteolysis in PCa and that this may produce bioactive C-terminal 
cleavage fragments that could contribute to the function of EphB4 in PCa. This study aimed to 
determine the contribution of this intracellular domain fragment of EphB4 to PCa, through 
over-expression studies and in vitro assays of cell behaviour. 
5.4 MATERIALS AND METHODS 
5.4.1 Reagents and Antibodies 
Antibodies used in this study include two commercially available antibodies directed 
towards epitopes in the C-terminus of EphB4 and termed Zymed (Invitrogen) and Novus 
(Novus Biologicals). Ivermectin was a kind gift from Professor David Jans (Monash, 
Melbourne). Recombinant KLK4 was made in-house according to previously published 
methods (Lisle et al., 2015).  
5.4.2 Cell lines and Cell Culture  
The cell lines used in this study were obtained from the American Type Cell Culture 
Collection (ATCC) (Manassas, Virginia, USA). The prostate cancer lines PC3, DU145, 
LNCaP, 22Rv1 and the derivative lines (VO, B4) were all cultured in RPMI medium containing 
10 % FCS. The non-transformed breast line MCF-10A and the derivative cell lines MCF10A-
B4 (MCF10A over-expressing EphB4) and MCF10A-VO (containing the empty expression 
vector) were cultured as previously described (Rutkowski et al., 2012).  
5.4.3 Cloning  
Previously, our laboratory has generated an expression vector containing the full length 
coding sequence of human EphB4 (Genbank accession number NM_004444) in the pIRES-
neo2 vector (Clontech, Mountainview, CA) (pIRES-EphB4) (Rutkowski et al., 2012).The 
intracellular sequence of EphB4, which corresponds to amino acids 561- 987 of EphB4, was 
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PCR amplified and cloned into the pIRES-neo2 vector using the restriction enzyme sites Nhe1 
and Age1 (NEB, Ipswich, MA, USA) to produce the expression vector pIRES-ICD. The 
sequence was verified as mutation free by Sanger DNA sequencing performed by Australian 
Genome Research Facility (AGRF).  
5.4.4 Transfection 
For the production of polyclonal derivative cell lines that stably overexpressed EphB4 
and the intracellular domain of EphB4, 2 µg of the expression vectors containing the full length 
coding sequence of human EphB4 and the intracellular sequence of EphB4 were linearized 
with Nru1, combined with 6 µL Lipofectamine 2000 (Invitrogen) and transfected according to 
the manufacturer’s instructions into the PCa cell lines DU145 and PC3. Transfected cells were 
cultured for 48 h before stably transfected cells were selected for 2 weeks using a pre-optimized 
dose of 400 µg/mL of G418 (Invitrogen) for DU145 and PC3 cells.  As a control for the pIRES-
neo2 empty vector  was also transfected into the cell lines and selected with G418 as above 
according to the manufacturer’s instructions (Life Technologies).  
5.4.5 RNA isolation and Real Time PCR 
RNA was isolated from cell lines using Trizol™ solution according to the manufacturer's 
recommendations (Life Technologies). RNA was reverse transcribed into cDNA using 
Superscript III reverse transcriptase (Life Technologies). The SYBR Master Mix (Life 
Technologies) was used for gene expression analysis on the ViiA™ Real Time PCR system 
(Applied Biosystems). 
5.4.6 Western Blotting 
Protein lysates were prepared using  RadioImmuno-Precipitation Assay (RIPA) buffer 
and protein concentrations were determined with the Pierce BCA Protein Assay Kit (Pierce, 
Thermo, Rockford, IL). Western blotting analysis was performed as per Section 3.4.3. 
5.4.7 Subcellular Fractionation 
22Rv1-VO and 22Rv1-B4 cells were grown to 90 % confluence and serum starved for 
12 h. One T175 flask (Nunc) was left untreated whilst another was treated with 200 nM of 
active KLK4 for 1 h. Cells were then lifted with Versene (Invitrogen) and collected by 
centrifugation into ice cold PBS.  Fractionation was then performed according to the 
manufacturer’s instructions using the Subcellular Protein Fractionation Kit for Cultured Cells 
(Pierce). For fractionation of LNCaP and MCF10A-B4 cells were grown to 90 % confluence 
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in a T175 flask (Nunc). Cells were lysed on ice for 15 min in 500 µl lysis buffer (10 mM 
HEPES pH 7.5, 5 mM MgCl2, 10 mM KCl, 5 mM EDTA, protease inhibitors). After cells were 
removed from the bottom of the flask using a cell scraper, 0.7% Igepal (Sigma-Aldrich New 
South Wales, Australia) was added and the cells were further incubated for 5 min on ice. Cell 
lysates were then centrifuged at 4 °C for 5 min at 14,000g. Supernatants contained the cytosolic 
fraction and were collected into a fresh 1.5 mL eppendorf. The remaining pelleted fraction 
which contained the nuclei were resuspended in 50 µl nuclear buffer (25 mM HEPES pH 7.5, 
5 mM NaCl, 0.2% Igepal, 10% glycerol (v/v)) and vortexed for 30 s at the highest setting before 
another incubation on ice for 15 min. After this incubation, nuclear lysates were centrifuged at 
14,000g for 15 min at 4 °C to remove debris and the supernatant transferred into a fresh tube 
as the “nuclear fraction”. 
5.4.8 Immunofluorescence 
Cells were seeded onto poly-L-Lysine coated glass coverslips and allowed to attach and 
grow in normal growth conditions overnight. Cells were then washed in PBS and fixed using 
4% paraformaldehyde/PBS (Sigma-Aldrich) for 15 min at RT. Cells were then permeabilised 
with PBS/ 0.1% Triton X-100 for 3 mins and blocked in 10 % goat serum PBS/ 0.1% Triton-
X100 for 1 h at room temperature. Primary antibodies were incubated in 10 % goat serum 
overnight at 4 °C. Primary antibody was then detected by incubation for 1 h at RT with an 
Alexa Fluor 488-conjugated secondary antibody (1/1000 dilution) (Invitrogen) after washing 
unbound antibody with PBS. Slides were mounted in ProLong® Gold Antifade containing 4',6-
diamidino-2-phenylindole dihydrochloride (DAPI) (Life Technologies) for visualisation of the 
nuclei. Images were collected using a Leica SP5 spectral scanning microscope (Leica, Freiburg, 
Germany) at 63x magnification using immersion oil.  
5.4.9 Scratch wound Assay 
Cells were seeded into 24 well plates and grown until they formed a monolayer. Cells 
were then serum starved for 6 h before the monolayer was then scratched using a sterile 200 µl 
pipette tip and the cells washed carefully with PBS to remove cell debris and detached cells. 
Images were taken at 0 h and 18 h using a Nikon Eclipse microscope at 10 x magnification and 
the wound areas were measured using Tscratch (Gebäck et al., 2009). 
5.4.10  Boyden Chamber Transwell Assay 
The Boyden Chamber assays were performed in 24-well plates with transwell cell culture 
inserts with 8 μm pores (Falcon; BD Biosciences, NSW, Australia). Cells were seeded into the 
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top chamber of a transwell in RPM1 medium with 0.1%  FCS at a density of 5 x 103 cells per 
well. The bottom chamber contained 10% FCS medium that was used as a chemo-attractant. 
Cells were allowed to migrate for 18 h before fixing with cold 100%  methanol. The transwell 
inserts were then washed with PBS and stained with DAPI. Membranes were excised from the 
Boyden chamber inserts using a sterile scalpel blade, mounted on slides and viewed with Nikon 
Eclipse at 10 x magnification.  
5.4.11  Proliferation  
Cells were seeded into 96 well plates at a density of 1 x 103 cells per well in quadruplicate 
samples. Proliferation was examined using CellTiter Aqueous One solution (Promega, Sydney 
Australia) at 0 h, 24 h, 48 h and 72 h in a Multiskan™ GO Microplate Spectrophotometer at 
490 nM according to the manufacturer’s instructions.    
5.4.12  Ivermectin Treatments  
Cells were treated with 1 µM of Ivermectin (the stock solution of 10 mM was solubilised 
in 100 % DMSO) for 2 h at 37 °C.  A 0.01% DMSO vehicle control was also performed. Cells 
were then fixed in 4% PFA for 15 mins at RT and immunofluorescence was performed. 
5.4.13  Statistics 
Data are presented as mean ± SEM unless stated otherwise. Statistical differences were 
assessed using either Student’s t test or one-way ANOVA followed by Fisher’s least significant 
difference post hoc test with significance set at P<0.05. For the proliferation experiments a two 
way ANOVA with Tukey’s multiple comparisons test was performed.   The number of 
replicates and/or repeat experiments is indicated in the appropriate figure legends. 
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5.5 RESULTS  
5.5.1 The intracellular domain fragment can localise to the nucleus of prostate cancer 
cells 
Previously our laboratory has identified two nuclear localisations signals (NLS) in 
EphB4 and found them both to be functional through mutation of the key amino acid residues 
involved in importin mediated transport (Figure 5.1A) (Mertens-Walker et al., 2015b). Often, 
cleaved ICD fragments of type I transmembrane receptors can be transported to the nucleus to 
have a function (Linggi et al., 2005) (Figure 5.1A).  To explore the fate and function of the 
EphB4 ICD, the cellular localisation of this fragment was determined. Firstly, Subcellular 
fractionation was performed to enrich the proteins of several different compartments of the cell 
into different fractions and the presence of the fragment in these fractions determined using 
Western blot analysis with an EphB4 specific C-terminal antibody. The breast cell line 
MCF10A-B4, which has been engineered to over-express EphB4, was used as positive control 
for nuclear localisation as our laboratory has found full length EphB4 goes to the nucleus in 
these cells (Personal communication, Inga Mertens-Walker). In the KLK4 positive PCa cell 
line LNCaP, the ~ 47 kDa ICD fragment of EphB4 was found endogenously in the nuclear 
enriched fraction (Figure 5.1B). A whole cell lysate of MCF10A-B4 cells was used to confirm 
the presence and size of full length EphB4 in the nuclear fractions. A band corresponding to 
full length EphB4 was seen at 120 kDa in the nuclear fraction of the MCF10A-B4 cells, 
however this band was not seen in the LNCaP nuclear fraction suggesting that the main form 
of EphB4 in the nucleus of LNCaP cells is the ICD fragment (Figure 5.1 B).  This was an 
expected result because this cleavage fragment was not present in the MCF10A-B4 cells 
(Chapter 4, Figure 4.1B & C). GAPDH, which is a cytosolic marker, was not found in the 
nucleus of either nuclear sample confirming the purity of the fractions (Figure 5.1B).  
To confirm whether the fragment was in the nucleus of 22Rv1-VO and 22Rv1-B4 cells these 
cells were subjected to a subcellular fractionation using a subcellular fractionation kit (Pierce) 
(Figure 5.1C-F). These cells also had recombinant KLK4 added to determine the localisation 
of the KLK4-initiated fragments.  The purity of the fractions was assessed by Western blot 
analysis with proteins, which are not normally located in the fraction of interest (Figure 5.1 C-
F).  
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Figure 5-1: The intracellular domain fragment can localise to the nucleus of prostate 
cancer cells.  
(A) Diagrammatic depiction of regulated intramembrane proteolysis. Firstly, the type 1 
transmembrane protein is processed by a shedding protease in the extracellular domain. A 
complex of proteins known as γ-secretase cleaves the protein either in its transmembrane 
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domain or juxtamembrane region. The intracellular domain (ICD) is released into the cytosol. 
The ICD is then either functional within the cytoplasm, degraded in the proteasome or 
translocated into the nucleus where it can regulate transcription of target genes. (B) Subcellular 
fractionation was performed on LNCaP and MCF10A-B4 cells and Western blot analysis was 
performed with an EphB4 specific C-terminal antibody. An antibody to GAPDH was used to 
show purity of nuclear fractions (absence of immunoreactivity). (C-F) Western-blot analysis 
of subcellular fractions of EphB4 using the C-terminal EphB4 specific antibody. Fractions and 
lysates from 22Rv1-VO (VO) and 22Rv1-B4 (B4) cells were compared either with exogenous 
addition of KLK4 (+ KLK4) or without (- KLK4) (C) Membrane fraction reprobed with EEA1 
(early endosome marker), Calnexin (endoplasmic reticulum marker) and GAPDH (cytoplasmic 
marker. (D) Chromatin bound fraction reprobed with EEA1 (early endosome marker), GAPDH 
(cytoplasmic marker) and MDC-1 (nuclear marker). (E) Cytoplasmic fraction reprobed with 
EEA1 (early endosome marker), γH2AX (nuclear marker) and GAPDH (cytoplasmic marker). 
(F) The Soluble nuclear fraction was reprobed with EEA1 (early endosome marker), GAPDH 
(cytoplasmic marker) and MDC-1 (nuclear marker) as controls for purity and loading. For all 
Western blots the molecular weight marker used was Precision Plus Protein™ Dual Color 
Standard (Bio-Rad) and the protein bands with their corresponding molecular weights in 
kilodaltons (kDa) are shown on the left. 
__________________________________________________________________________________________ 
 
All fractions contained full length EphB4 in both 22Rv1-VO and 22Rv1-B4 cells with 
the fractions containing the most being the membrane (Figure 5.1C) and interestingly the 
soluble nuclear fraction (Figure 5.1F). Accordingly, after addition of KLK4 there appeared to 
be both the 47 kDa and 50 kDa fragments in the soluble nuclear fraction (Figure 5.1F). After 
treatment with KLK4 in the 22Rv1-B4 cells the apparent amount of full length EphB4 was 
reduced in the chromatin bound fraction, however the 47 kDa fragment appeared increased 
(Figure 5.1D). The membrane fraction contained both C-terminal fragments the 47 kDa and 
the 50 kDa in the 22Rv1-B4 and both of these became more prominent after addition of KLK4 
(Figure 5.1C).In the cytoplasmic enriched fraction of the 22Rv1-B4 cells, the untreated cells 
have a 47 kDa fragment and upon KLK4 treatment there is an increase in the amount of this 
fragment detected as well as the appearance of the 50 kDa fragment (Figure 5.1E). A summary 
of these findings is included in Table 5.1.  
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Table 5-1: Summary of EphB4 and ICD fragment Subcellular fractionation results 
 
 
 
5.5.2 Exogenously overexpressed full length EphB4 and intracellular domain of EphB4 
cause morphology changes in cells 
Since the γ-secretase site which produces the intracellular fragment has not yet been mapped 
and it was predicted that this might be difficult by N-terminal sequencing given the small 
amount present in the cells, it was decided to clone the entire intracellular domain (ICD) of 
EphB4 from amino acids 561-987 into the mammalian expression vector pIRES-neo2 as this 
is reported to be where γ-secretase can cleave other Eph receptors including EphB2 and EphA4  
(Inoue et al., 2009; Litterst et al., 2007). These constructs were stably expressed in DU145 and 
PC3 cells and a polyclonal population of cells was selected using G418 resistance to determine 
the effect of expression of this fragment on growth characteristics of the stably transfected 
cells. PC3 and DU145 cells, which were made to exogenously over-express full length EphB4 
(B4) were also made and the expression of ICD or  EphB4 confirmed by Western analysis 
using a C-terminal specific antibody (Figure 5.2A). A lysate of 22Rv1-B4 cells was included 
to compare the correct size of the full length EphB4 and ICD fragment of the engineered cells. 
Full length EphB4 is shown at 150 kDa consistent with the 22Rv1-B4 positive control sample 
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on this gel in the DU145-B4 and PC3-B4 cells and as expected  there is higher expression in 
the DU145-B4 and PC3-B4 cells compared to the empty vector cells (Figure 5.2A). The ICD 
fragment in the 22Rv1-B4 cells is at 47 kDa and there is a band of comparable size in the 
DU145-ICD and PC3-ICD cells engineered to over express the ICD fragment, suggesting that 
cloning and protein expression of the ICD fragment was successful (Figure 5.2A). 
Interestingly, after G418 selection the ICD cells of both cell lines had a different morphology 
compared to the vector only cells.  (Figure 5.2B-C). The DU145-VO cells typically had a round 
shape whereas the DU145-ICD cells appeared more elongated and mesenchymal (Figure 5.2B). 
The PC3-ICD cells appeared larger and were more rounded than the PC3-VO cells (Figure 
5.2C).  
 
 Chapter 5: Localisation and functions of the intracellular domain fragment of EphB4 in prostate cancer 138                
 
 
 
Figure 5-2: Exogenously overexpressed full length EphB4 and intracellular domain of 
EphB4 causes changes in morphology of B4 and ICD cells.  
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(A) Western blot analysis of DU145 and PC3 cells stably expressing the pIRES-neo2 vector 
(VO), full length EphB4 (B4) and intracellular domain (ICD) using the C-terminal EphB4 
antibody.  Full length EphB4 is 150 kDa and the ICD fragment is 47 kDa. An antibody to 
GAPDH was used as a loading control for all blots and appears at 37 kDa.  (B) DU145 cells 
were transfected with vectors for over-expression of full length EphB4 (B4) or the intracellular 
domains only (ICD). The empty vector was used as a control (VO). Morphology of the cells 
was compared using light microscopy at 20 X magnification.(C) Light microscopy of PC3-V0, 
PC3-B4, PC3-ICD cells also compared at 20 X magnification. The scale bar represents 50 µM.   
___________________________________________________________________________ 
 
5.5.3 Exogenously overexpressed full length EphB4 and intracellular domain of EphB4 
localise to the nucleus of PC3 and DU145 cells and this nuclear import is through 
importins 
 
To determine whether the ICD fragment could go the nucleus in the cells which over express 
the ICD, the cells were examined using immunofluorescence with EphB4 specific C-terminal 
antibodies. Over-expression of EphB4 in PC3-B4 cells was confirmed and in these cells the 
EphB4 was mostly localised to the cytoplasm and endoplasmic reticulum with some surface 
and nuclear expression consistent with the localisation of exogenous EphB4 expressed by these 
cells (Figure 5.3A) (Stephenson et al., 2015). Over-expression of the ICD fragment was also 
confirmed and as expected, given that it is the C-terminal end and lacks a signal sequence for 
secretion, the protein was mainly cytoplasmic with some staining seen in the nucleus (Figure 
5.3A). Interestingly, these PC3-ICD cells were much larger than the PC3-B4 and PC3-VO 
cells. Similarly, the exogenously over-expressed EphB4 in the DU145-B4 cells displayed a 
mostly surface and cytoplasmic expression with some staining in the nucleus when probed with 
the C-terminal antibody (Figure 5.3B). Conversely, staining in DU145-ICD cells appeared to 
be more peri-nuclear and nuclear (Figure 5.3B). Controls were also performed where irrelevant 
IgG antibody was used with appropriate secondary to show whether there was non-specific 
antibody binding to cells and these showed little signal demonstrating specificity of antibody 
(Figure 5.3A&B).  
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Figure 5-3: Exogenously overexpressed full length EphB4 and intracellular domain of 
EphB4 localise to the nucleus of PC3 and DU145 cells and this nuclear import may be 
through importins. 
 
(A) Immunofluorescence analyses of PC3-VO, PC3-B4 and PC3-ICD cells using the Novus 
C-terminal to detect EphB4 (green) in the nucleus (DAPI, blue). Shown here is the overlay 
between both channels as well as separate channels. (B) Immunofluorescence analyses of 
DU145-VO, DU145-B4 and DU145-ICD cells using the Novus antibody. Shown here is the 
overlay between both channels as well as separate channels. An IgG control with secondary 
antibody is also shown to demonstrate specific staining. The scale bar represents 20 µM.   
___________________________________________________________________________ 
 
Nuclear import of proteins can occur when NLS motifs are recognised by members of the 
importin family of proteins which transport their cargo proteins through the nuclear pore 
complex and into the nucleus (Stewart, 2007). Importin proteins can be inhibited by small 
molecule inhibitors including the anti-parasitic drug Ivermectin (Wagstaff et al., 2012). 
Previously our laboratory used both immunoprecipitation and immunofluorescence to show 
that full length EphB4 could associate with importin-α and that this could translocate EphB4 
into the nucleus (Mertens-Walker et al., 2015b). The ICD sequence retains one of the functional 
NLS sequences so to determine if the ICD fragment was transported to the nucleus by importin 
proteins, Ivermectin was used to block importin transport and the localisation of the EphB4 
ICD was then examined again using immunofluorescence (Figure 5.4A-B). After 2 h treatment 
with Ivermectin there appeared to be less EphB4 ICD in the nucleus of the DU145-ICD cells 
when compared with vehicle control (Figure 5.4A). As expected there was also a reduction in 
the apparent levels of nuclear EphB4 in DU145-B4 cells but this was less pronounced (Figure 
5.4A). The same trend was also seen with the PC3 cells where after treatment with Ivermectin 
the PC3-B4 and ICD cells lost some nuclear staining however this was a less pronounced 
change than that see with the DU145 cells (Figure 5.4B).  
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Figure 5-4: EphB4 localise to the nucleus of PC3 and DU145 cells and this nuclear import 
may be through importins 
 
 (A) DU145-B4 and ICD cells were treated with either vehicle or 1 µM Ivermectin for 2 h, then 
immunofluorescence performed with the Novus EphB4-specific polyclonal antibody (Green). 
Insert: Shown here is the overlay of the EphB4 (green) staining with the nucleus (DAPI, blue). 
(B) PC3-B4 and ICD cells were treated with either vehicle or 1 µM Ivermectin for 2 h, then 
immunofluorescence performed with Novus EphB4-specific polyclonal antibody. Insert: 
Shown here is the overlay of the EphB4 (green) staining with the nucleus (DAPI, blue). 
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5.5.4 Over-expression of the intracellular domain fragment increases proliferation in 
PC3 cells but not DU145 cells 
To investigate further the function of the EphB4 ICD an MTS assay which measures 
proliferation was carried out on the full length EphB4 and ICD over expressing cells. The PC3-
B4 and PC3-ICD cells both showed a statistically significant increase in proliferation when 
compared with cells containing the empty vector (PC3-VO) (P<0.01) with the PC3-ICD cells 
also having a slight increase in proliferation over the full-length EphB4 cells after 24 h (Figure 
5.5A). At 48 h, both the PC3-B4 and PC3-ICD cells also had a statistically significant increase 
in proliferation when compared with the empty vector control (P<0.01) (Figure 5.5A). The 
PC3-B4 and PC3-ICD cells also had a statistically significant increase in proliferation when 
compared with the empty vector control at 72 h with the PC3-B4 cells being very significantly 
increased (P<0.001) (Figure 5.5A). The DU145-B4 and ICD cells did show a slight increase in 
proliferation when compared with the empty vector control cells but this was not statistically 
significant at any of the days of the assay (Figure 5.5B). 
 
5.5.5 Expression of the intracellular domain fragment increases migration in PC3 cells 
To determine whether over-expression of the full-length EphB4 protein or ICD fragment 
could alter the migration of the cells, both a scratch wound assay and a Boyden chamber 
transwell assay were performed. The scratch wound assay, performed over 18 h revealed that 
the PC3-B4 cells had significantly increased migration when compared with the empty vector 
control cells PC3-VO (Figure 5.6A). The PC3-ICD cells did appear to have increased migration 
over the empty vector control cells but this was not significant (Figure 5.6A).  The PC3-B4 
cells also appeared to have a higher percentage wound closure than the PC3-ICD cells however 
again this is was not statistically significant (Figure 5.6A). A Boyden chamber transwell 
migration assay was then used to further assess migration through 8 m pores and towards 
medium containing 10% FCS as a chemo-attractant. The PC3-B4 cells had a statistically 
significant increased fold change in migration that was three times the number when compared 
to the empty vector controls (P<0.01)  and the PC3-ICD cells (P<0.001)   which suggests that 
the PC3-B4 cells had increased migratory capacity but that over-expression of the ICD 
fragment did not influence cell migration in this assay (Figure 5.6B).  
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Figure 5-5: Over-expression of the intracellular domain fragment increases proliferation 
in PC3 cells but not DU145 cells 
 
(A) PC3-VO, PC3-B4 and PC3-ICD cells and (B) DU145-VO, DU145-B4 and DU145-ICD 
cells were seeded into 96 well plates and proliferation determined at 24, 48 and 72 h by 
absorbance at 490 nm with the MTS reagent.  Graphs represent mean absorbance +/- SEM 
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normalised to the VO control and expressed as OD at 490 nM. Statistical significance was 
determined using a two way ANOVA with Tukey’s multiple comparisons test with ** 
indicating a P<0.01 and *** indicating a P<0.001 statistically significant difference compared 
the VO cells.  Experiments were repeated three times (n = 3) with 4 technical replicates per 
experiment. 
________________________________________________________________________ 
 
Figure 5-6: Over-expression of the intracellular domain fragment increases migration in 
PC3 cells 
 
Confluent monolayers of PC3-VO, PC3-B4 and PC3-ICD cells were wounded with a pipette 
tip and images taken at 0 h and 18 h using a Nikon Eclipse light microscope.  (A) 
Representative photomicrographs are shown at 0 and 18 h after wounding.  The wound area 
was quantitated using TScratch and expressed as percent wound closure. Data are represented 
as ±SEM, representing 3 individual biological repeats (n= 3) each with 3 technical replicates. 
* P<0.05 using a Student’s t Test. (B) Transwell assays were carried out over 18 h with PC3-
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VO, PC3-B4 and PC3-ICD cells. Data are represented by fold change in migration through 
Transwell compared to the empty vector control. Data are represented as ±SEM,with 
Statistical significance was determined using a Student’s T test with ** indicating a P<0.01 
and *** indicating a P<0.001 statistically significant difference compared the VO cells.  Data 
represent 3 individual biological repeats (n= 3) each with 3 technical replicates. 
___________________________________________________________________________ 
 
5.5.6 The intracellular domain fragment increases migration in DU145 cells 
The same two migration assays were also performed on the DU145 derivative cells to compare 
their migratory capacities. Similarly to the results seen with PC3-B4 cells, the DU145-B4 cells 
also appeared to have  increased  migration in the wound closure assay when compared with 
the cells containing the empty vector (DU145-VO)  however this did not quite reach 
significance (P=0.050001) (Figure 5.7A). The DU145-ICD cells did have a statistically 
significant increase in the percentage wound closure when compared with the DU145-VO cells 
(P<0.05) (Figure 5.7A). Both the DU145-B4 and DU145-ICD cells had a similar rate of wound 
closure over 18 h (Figure 5.7A). In the Boyden chamber transwell assay, the DU145-B4 cells 
had showed a statistically significant increased fold change in migration when compared with 
the DU145-VO cells (P<0.05) but the DU145-ICD cells showed no advantage with a similar 
number of cells to that of the DU145-VO control migrating through the pores (Figure 5.7B). 
The DU145-B4 cells demonstrated an almost 1.5 fold increase migration of cells compared to 
the DU145-ICD and DU145-VO cells.  This result suggests that over-expression of the ICD 
fragment does not contribute to migration of cells through pores in this assay (Figure 5.7B). 
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Figure 5-7: Over-expression of the intracellular domain fragment increases migration in 
DU145 cells 
 
Confluent monolayers of DU145-VO, DU145-B4 and DU145-ICD cells were wounded with a 
pipette tip and images were taken at 0 h and 18 h with a Nikon Eclipse light microscope.  (A) 
Representative photomicrographs are shown at 0 and 18 h after wounding.  The wound area 
was quantitated using TScratch and expressed as percent wound closure. Data are represented 
as ±SEM, representing 3 individual biological repeats (n= 3) each with 3 technical replicates. 
* P<0.05 using a Student’s t Test. (B) Transwell assays were carried out over 18 h with PC3-
VO, PC3-B4 and PC3-ICD cells. Data are represented by fold change in migration through 
Transwell compared to VO control. Data are represented as ±SEM, representing 3 individual 
biological repeats (n= 3) each with 3 technical replicates. 
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5.5.7 The intracellular domain fragment may regulate expression of EMT genes 
Over-expression of both full length EphB4 and the ICD fragment did appear to alter the 
morphology of both the PC3 and DU145 expressing cells when compared with the VO controls 
(Figure 5.2B & C). Elongation of the DU145-ICD over-expressing cells was particularly 
suggestive of a mesenchymal transition. For this reason alterations to the expression levels of 
genes associated with epithelial to mesenchymal transition (EMT), including EMT markers 
CDH1 (E-cadherin), SNAI1 (Snail 1), CDH2 (N-cadherin), SNAI2 (Slug 1), VIM (vimentin) 
and TWIST1 (Twist) were explored by quantitative RT-PCR.  Furthermore, previous data from 
our laboratory had demonstrated that full length EphB4 could bind DNA including close to the 
promoter of the prostate cancer associated gene LEF1 (Mertens-Walker et al., 2015b). For this 
reason, the LEF1 gene was also investigated to determine if its expression was also modulated 
by the over-expression of either the full length EphB4 protein or the ICD fragment. 
qRT-PCR analysis revealed that overexpression of the ICD fragment in both DU145 and 
PC3 cells increased the expression of LEF1 with PC3-ICD cells increasing by almost  6 fold 
compared to the empty vector cells (Figure 5.8A). The DU145-ICD cells increased LEF1 
expression by 3 fold over their respective empty vector control cells (Figure 5.8A). Both of 
these increases were statistically significant (P<0.01) and (P<0.001). Surprisingly, the 
overexpression of full length EphB4 did not increase LEF1 expression in the PC3 and DU145 
cells (Figure 5.8A). 
The transcription factor TWIST1 was significantly increased in PC3-B4 cells compared 
to PC3-VO cells however, its expression was not changed in the PC3-ICD cells (Figure 5.8B). 
Conversely, TWIST1 was significantly down-regulated in the DU145-B4 cells losing 85% of 
its expression compared to the DU145-VO cells (Figure 5.8B). The DU145-ICD cells also 
significantly down-regulated TWIST1 expression however, this was not as low as the DU145-
B4 cell expression of this gene (Figure 5.8B).  
 During EMT the expression level of CDH1 is expected to decrease due to the transcriptional 
repressors SNAI1 and SNAI2. When normalised to the expression levels of PC3-VO cells, 
CDH1 expression was significantly down-regulated in the PC3-B4 cells with a 98% reduction 
in expression (Figure 5.9A).  Over-expression of the ICD fragment in DU145 cells resulted in 
a significant decrease in CDH1 expression with over 70 % less expression compared to VO 
controls (Figure 5.9A). CDH1 expression in DU145-B4 cells did not significantly change 
compared to VO cells however was almost statistically significantly higher than the DU145-
ICD cells (p=0.0501) (Figure 5.9A). 
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Figure 5-8: qRT-PCR of LEF1 and TWIST1 in DU145 and PC3 cell lines  
 
(A) Relative gene expression of LEF1 normalized to RPL32 and relative to the expression of 
PC3-VO cells or DU145-VO cells in stably over-expressing PC3-B4, PC3-ICD, DU145-B4 
and DU145-ICD cells as determined by qRT-PCR. (B) Relative gene expression of TWIST1 
normalized to RPL32 and relative to the expression of PC3-VO cells and DU145-VO cells in 
stably over-expressing PC3-B4, PC3-ICD, DU145-B4 and DU145-ICD cells as determined by 
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qRT-PCR. Data are represented as ±SEM, with statistical significance determined using a 
Student’s T test with * indicating P<0.05,   ** indicating a P<0.01 and *** indicating a 
P<0.001. Experiments were performed in triplicate with n=3 biological replicates. 
__________________________________________________________________________ 
 
CDH2 expression increased in the PC3-B4 cells however the expression of CDH2 did 
not change in the PC3-ICD cells. Conversely, the DU145-B4 cells lowered their expression of 
CDH2 compared to the DU145-VO cells with the DU134-ICD cells having even less of CDH2 
expression than the DU145-B4 cells and this was statistically significant however expression 
of this gene in all DU145 derivative cell lines was very low (Figure 5.9B).  
None of the cell lines showed statistically significant changes in SNAI1 expression 
(Figure 5.10A). Interestingly both PC3-B4 and ICD cells increased their SNAI2 expression 
however these increases where not statistically significant (Figure 5.10B). The DU145-B4 and 
ICD cells slightly lowered both their SNAI1 and SNAI2 expression compared to the DUI145-
VO cells (Figure 5.10A &B).The VIM gene was increased 4 fold in the PC3-B4 cells compared 
to the VO controls however there were no other trends evident from the qRT-PCR analysis 
(Figure 5.11).  
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Figure 5-9: qRT-PCR of expression of CDH1 and CDH2  in  DU145 and PC3 cell lines  
 
(A) Relative gene expression of CDH1 normalized to RPL32 and relative to the expression of 
PC3-VO cells or DU145-VO cells in stably over-expressing PC3-B4, PC3-ICD, DU145-B4 
and DU145-ICD cells as determined by qRT-PCR. (B) Relative gene expression of CDH2 
normalized to RPL32 and relative to the expression of PC3-VO cells and DU145-VO cells in 
stably over-expressing PC3-B4, PC3-ICD, DU145-B4 and DU145-ICD cells as determined by 
qRT-PCR. . Data are represented as ±SEM, with statistical significance determined using a 
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Student’s T test with * indicating P<0.05,   ** indicating a P<0.01 and *** indicating a 
P<0.001.Experiments were performed in triplicate with n=3 biological replicates.  
___________________________________________________________________________ 
 
 
Figure 5-10: qRT-PCR of expression of SNAI1 and SNAI2 in DU145 and PC3 cell lines  
 
(A) Relative gene expression of SNAI1 normalized to RPL32 and relative to the expression of 
PC3-VO cells or DU145-VO cells in stably over-expressing PC3-B4, PC3-ICD, DU145-B4 
and DU145-ICD cells as determined by qRT-PCR. (B) Relative gene expression of SNAI2 
 Chapter 5: Localisation and functions of the intracellular domain fragment of EphB4 in prostate cancer 153
normalized to RPL32 and relative to the expression of PC3-VO cells and DU145-VO cells in 
stably over-expressing PC3-B4, PC3-ICD, DU145-B4 and DU145-ICD cells as determined by 
qRT-PCR. . Data are represented as ±SEM, with statistical significance determined using a 
Student’s T test with * indicating P<0.05,   ** indicating a P<0.01 and *** indicating a 
P<0.001.Experiments were performed in triplicate with n=3 biological replicates.  
___________________________________________________________________________ 
 
 
 
 
 
Figure 5-11: qRT-PCR of expression of VIM in DU145 and PC3 cell lines 
 
(A) Relative gene expression of VIM normalized to RPL32 and relative to the expression of 
PC3-VO cells or DU145-VO cells in stably over-expressing PC3-B4, PC3-ICD, DU145-B4 
and DU145-ICD cells as determined by qRT-PCR. Experiments were performed in triplicate 
with n=3 biological replicates.  
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5.6 DISCUSSION 
Protease cleavage is an important post-translational modification for many proteins, 
responsible for trafficking of new proteins to the correct cellular compartment, for activation 
of enzymes through removal of pro-domains and for cessation of function by breaking the 
protein target into fragments that are then degraded (Litterst et al., 2007).  In some cases 
however cleavage within the functional protein can in fact generate fragments of the protein 
that have further, and often quite different, functions and cellular localisations to the parent 
protein ((Chen et al., 2015). The research described in this Chapter aimed to characterise the 
function of a fragment of the EphB4 protein released from inside of the plasma membrane by 
the sequential actions of a shedding protease that removes the extracellular domain and γ-
secretase within the plasma membrane. This process is called RIP and is a common mechanism 
for functional activation of several type 1 transmembrane proteins including the Notch 
receptors, where the released intracellular fragments alter transcription of several target genes 
after nuclear translocation (Blobel et al., 2009; Fryer et al., 2002; Higashiyama et al., 2011; 
Junttila et al., 2005; Lee et al., 2002; Lubman et al., 2007; Na et al., 2012; Rio et al., 2000) 
Previous data from our laboratory had identified EphB4 in the nucleus of cells (Mertens-
Walker et al, 2015). In exploring this further, a fragment of EphB4 of the approximate size of 
the 47 kDa ICD had been identified in nuclear protein lysates from the prostate cancer cell line 
LNCaP.  This preliminary data suggested that like Notch receptors, RIP might be responsible 
for generation of the EphB4 ICD sequence and this is then translocated to the nucleus of these 
cells where it may have a possible function in gene regulation.  The localisation of the ICD 
fragment was therefore explored further using Subcellular fractionation experiments. These 
experiments are technically very difficult and it is challenging to separate the very complex 
cells into separate compartments without some contamination from others. For example, the 
ER is contiguous with the outer nuclear membrane and it is expected that there will be some 
membrane contamination within the nuclear fraction. This would be further complicated when 
using an over-expression system of a surface expressed transmembrane protein as this would 
be expected to be present in ER, transport vesicles, the membranes of the golgi apparatus and 
the plasma membrane so would expect to be present in both membrane and cytoplasmic 
fractions. Accordingly, full length EphB4 was identified in all fractions although there did 
appear to be less in the sample enriched for chromatin bound proteins. Similarly, the 50 kDa 
CTF and 47 kDa ICD fragments were also present in each fraction although the levels of this 
increased when the cells were treated with exogenous KLK4. Interestingly, the level of the 47 
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kDa ICD fragment was particularly enriched in the sample of chromatin bound proteins from 
KLK4 treated cells. A possibly cleaner way to do Subcellular fractionation is to do sucrose 
gradients which use the density of sucrose fractions to isolate particular cellular compartments 
(Hayashi et al., 2012; Wang et al., 2015). Another way to prove that the ICD is fragment is 
nuclear is to perform immunofluorescence and co-localise it with nuclear markers such as 
γH2AX, COIL, and PCNA as per Mertens-Walker et al. 2015.  
The ICD fragment contains an NLS sequence that our laboratory has shown to be 
functional (Mertens-Walker et al, 2015) and this is the likely mechanism through which this 
protein fragment is transported to the nucleus. Supporting this hypothesis is the data presented 
here using Ivermetin, a small molecule inhibitor of importin-α which shows less nuclear 
localisation of the over-expressed ICD fragment in treated cells (Wagstaff et al., 2012). The 
DU145-ICD cells treated with the inhibitor showed a clear loss of nuclear EphB4 which 
indicates that the ICD fragment in these cells is reliant on importins for transport into the 
nucleus. A difference was also seen in the Ivermectin-treated PC3-ICD cells but this was not 
as clear and might be explained if the nuclear translocation of the ICD fragments could occur 
via a different mechanism such as retrograde transport (Liao et al., 2007). 
Recent reports of processing of other Eph receptors (EphA2, EphA4, EphB2) and the 
related identification of ICD fragments in the cytoplasm and nucleus of various cancer cells 
would suggest that this is a common mechanism for Eph receptor function (Attwood et al., 
2011; Gatto et al., 2014; Inoue et al., 2009; Lin et al., 2008). The ICD fragment contains the 
complete kinase domain, SAM domain and PDZ domain and each of these could contribute to 
a novel function for this protein fragment. Reports of expression and generation of ICD 
fragments causing cells to increase their proliferation, migration and invasive capacity 
consistent with tumourigenic potential formed a rationale for expressing the EphB4 ICD to 
determine if it also could promote an oncogenic phenotype  (Golubkov et al., 2014b; Junttila 
et al., 2005; Na et al., 2012). Firstly, however, the ectopic expression of the EphB4 ICD in PC3 
and DU145 cells needed to be verified using an approach whereby the whole intracellular 
fragment of EphB4 was cloned into a mammalian expression construct for transfection into 
DU145 and PC3 and selection of stable ICD expressing derivative polyclonal populations. The 
ectopic ICD was consistent with the size of the ICD produced by proteolytic cleavage, and had 
the same Subcellular localisation as the ICD, with ICD over-expressing cells displaying more 
nuclear and cytoplasmic localisation than the full-length EphB4 expressing cells, as expected. 
Robust expression of the ICD was seen in the nucleus of both populations and both ICD 
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expressing cells had a change in morphology. Speculation that if the ICD was in the nucleus 
and affecting gene expression that could explain a change in cell morphology seen in these 
cells. DU145 cells expressing the ICD fragment had a more elongated mesenchymal shape 
when compared with the cells containing the empty vector. The PC3 cells expressing the ICD 
fragment also had a changed appearance, similar to an amoeboid phenotype and often these 
cells were multinucleated (see Supplementary Figure 1-2).  
It has been shown that other ICD fragments can influence migration, invasion and 
proliferation of cancer cells so functional assays of the EphB4 ICD cells were performed to 
determine if the EphB4 ICD could affect cell behaviour of prostate cancer cells (Golubkov et 
al., 2014b; Junttila et al., 2005; Na et al., 2012). EphB4 ICD overexpression increased 
proliferation of PC3 cells, however so did full length EphB4. Previously, EphB4 has been 
shown to have a role in proliferation, cell viability and apoptosis in PC3 cells whereby 
knockdown of EphB4 with siRNA resulted in cell cycle arrest and increased apoptosis 
(Rutkowski et al., 2012; Xia et al., 2005b). It is still unknown how full length EphB4 
contributes to cell growth, but the nuclear translocation of either full length or the ICD fragment 
could be regulating genes involved in the cell cycle, either directly or indirectly and this should 
be further explored with these cells. Interestingly, DU145-B4 and DU145-ICD cells did not 
have a significant increase in proliferation and this could be attributed to many factors such as 
binding partners that may help increase proliferation in conjunction with full length EphB4 or 
the ICD proteins not being present in DU145 cells.  
The ICD cells had a changed cellular morphology compared to the VO or B4 cells and 
due to the fact that the cells looked like they had undergone either an EMT (DU145-ICD) or 
mesenchymal to epithelial transition (MET) (PC3-ICD) several markers of these processes 
were explored at the mRNA level. It was found that consistent with the epithelial morphology 
of the PC3-ICD cells they had slightly increased CHD1 compared to the empty vector cells. 
They also had higher levels of SNAI1 which is the transcriptional repressors of CHD1in tumour 
cells (Batlle et al., 2000; Bolós et al., 2003). This suggests that the PC3-ICD cells could be in 
a state of amoeboid transition or undergoing MET (Paňková et al., 2010). The PC3-B4 cells 
showed the opposite for the expression of CHD1  and were possibly undergoing EMT. This is 
unsurprising as it has been shown that overexpression of full length EphA2 has been shown to 
induce EMT in gastric cancer cells (Huang et al., 2014). To explain this there could be a 
dominant negative effect whereby ICD overexpression antagonises the effects of full length 
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EphB4 allowing the cells to be able to respond to different stages of metastasis such as is the 
case for CD44 (Mellor et al., 2013).  
It was shown that overexpression of the ICD in DU145 cells led to a more mesenchymal 
morphology and this was reflected in the fact that these cells lost their CDH1 expression 
compared to empty vector cells. However, other markers of EMT must be explored such as 
ZEB1 to determine how CDH1 is being down regulated.   
It was demonstrated that LEF1 mRNA increased in both PC3-ICD and DU145-ICD cells. LEF1 
is a transcription factor that is often linked to androgen-independent prostate cancer so there 
could be a link between the EphB4 ICD fragment and prostate cancer progression, however 
this will need to be further assessed with clinical samples (Li et al., 2009). Previously our 
laboratory showed that full length EphB4 could regulate the expression of LEF1, however this 
was not the case for this study (Mertens-Walker et al., 2015b). 
EphB4 has been shown in many cancers including prostate cancer to increase migration 
and this may actually correlate with production of the ICD fragment (Rutkowski et al., 2012; 
Xia et al., 2006; Xia et al., 2005b; Yang et al., 2006).  Studies of the functional cleaved ICD 
of PTK7 provide support for this hypothesis because when overexpressed, the PTK7 ICD was 
shown to influence cell motility and migration in a cancer context (Golubkov et al., 2014a; Na 
et al., 2012). Not surprisingly, full length EphB4 in PC3 cells increased migration significantly 
in both migration assays performed and this is in keeping with data previously published by 
our laboratory that shows the same response when full length EphB4 is overexpressed in 22Rv1 
and MCF10A cells (Rutkowski et al., 2012). This is thought to be due to the absence of the 
ligand ephrin-B2 interacting with EphB4 and producing tumour suppressive forward signals 
into the EphB4 expressing cell, so the cell can freely migrate (Rutkowski et al., 2012). Data 
presented here suggests that production of the ICD fragment may also contribute to increased 
migration. Supporting this hypothesis are reports that EphA2 cleavage by MT1-MMP produces 
an ICD fragment in breast cancer that increased single cell invasion and migration compared 
to collective migration in cells that expressed only the full length EphA2 protein (Koshikawa 
et al., 2015; Sugiyama et al., 2013). Expression of the EphA2 ICD fragment correlated with 
increased phosphorylation of the Src kinase which lead to increased Rho activity, a key driver 
of cellular migration (Sugiyama et al., 2013). It would be interesting to investigate further 
whether this is the case for the PC3 and DU145 ICD cells.  
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The effect of ICD over-expression on migration of cells was also tested using a transwell 
assay and in this case, the PC3-ICD cells did not migrate more than the PC3-VO cells. The 
PC3-ICD cells had a different morphology and were larger in size with a more rounded shape 
than the smaller PC3-VO and more mesenchymal PC3-B4 cells. This could account for the 
difference as the 8 µM size of the pores in the transwell system might have provided more of 
a barrier to the larger cells or the PC3-ICD cells might have not have been able to reorganise 
their cytoskeleton sufficiently to migrate through during the time period for which the assay 
was performed. Assays where single cell migration is quantified might therefore be better 
methods to measure the migratory capacity of these cells. Conversely, both of the generated 
DU145 cells showed a similar trend however the DU145-ICD cells increase in migration was 
statistically significant compared to the DU145-B4 cells. This could be due to the more 
mesenchymal morphology of the DU145-ICD cells that makes them migrate better in the 
scratch wound healing assay than the transwell assay.  
Many groups have used immunohistochemistry approaches to identify EphB4 protein in 
clinical cancer samples and EphB4 is often reported in the cytoplasm of these cells.  In most 
cases, the approach used includes counter-staining of the nuclei and as a consequence it is likely 
that any nuclear localisation of EphB4 has gone un-noticed (Guijarro-Muñoz et al., 2013; Tu 
et al., 2012; Wu et al., 2004). Given the results presented here, that show that these C-terminal 
EphB4 ICDs are both cytoplasmic and nuclear and have functions that contribute to 
proliferation and migration, it will be interesting to see if these ICDs can be found in clinical 
samples of prostate cancers and whether they correlate with prognosis. Understanding these 
events may not only clarify a new mechanism of action for EphB4 in tumour promotion but 
may also lead to novel avenues for cancer treatment. 
 
 
 
 
 
 
 
E.N  
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5.7 SUPPLMENTARY FIGURES  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S 1: PC3-ICD cells are multinucleated  
 
(A) Immunofluorescence analyses of PC3-ICD cells using the Novus C-terminal to detect 
EphB4 (green) in the nucleus (DAPI, blue). Shown here is the overlay between both channels 
as well as separate channels. The scale bar represents 75 µM.   
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Figure S 2: PC3-ICD cells fuse and become multinucleated 
 
(A)  PC3-ICD cells were viewed in the IncuCyte;( ESSEN BioScience Inc) over a period of 3 
days. Images are of 1 cell at the indicated time point. Time is shown with 24 hr time whereby 
day 0, 0:00 was the time of seeding cells.  
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Chapter 6:  General Discussion and Future 
Directions 
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6.1 SUMMARY OF FINDINGS  
 
This thesis has ultimately examined the role that proteases play in the EphB4 - ephrin-
B2 system. Firstly, it was demonstrated through in silico prediction that ephrin-B2 could be a 
substrate of the serine protease KLK4. This was then tested with recombinant proteins and it 
was found that mouse ephrin-B2-Fc was the preferred substrate of KLK4 over human ephrin-
B2-Fc. This was reported to be due to amino acid difference in the protein sequence at the 
KLK4 cleavage site, which changed KLK4’s preference for cleavage at a particular consensus 
sequence. This has implications when using models where mouse ephrin-B2 would be present, 
such as xenograft studies, where there might be different biological responses.  
The second chapter explores protease cleavage of the receptor EphB4 which is the 
binding partner of ephrin-B2. Firstly models where full length EphB4 was over expressed in 
the PCa cell line 22Rv1 (22Rv1-B4) and the breast fibrocystic disease cell line MCF10A 
(MCF10A-B4) were used and it was discovered that, using EphB4 specific antibodies to the 
extracellular domain, not only full length EphB4 was detected but a smaller fragment of ~ 70 
kDa was detected in the PCa cells but not in the breast cells.  Using these same cell models but 
with a C-terminal specific antibody it was found that there were two C-terminal fragments in 
the PCa cells that were not in the breast cells. This was then shown to be from proteolytic 
cleavage, most likely sequential cleavage events, that produced an ICD fragment of ~ 47 kDa. 
KLK4, a PCa associated protease, was identified as possibly the first protease that cleaves 
EphB4 in the extracellular domain whilst γ-secretase was identified as the protease responsible 
for the 2nd cleavage event which produced the ICD fragment. This fragment appeared stable 
indicating that it may be bioactive.  
The third research chapter showed that the ICD fragment described in the previous 
chapter may have a function in PCa. Firstly, PCa cells which endogenously express EphB4 and 
PCa cells where EphB4 was ectopically overexpressed, had the ICD fragment in their nuclear 
enriched fractions which suggested a possible role in gene regulation. This fragment was then 
over expressed in PC3 and DU145 cells and found in the nucleus. Expression of the 
intracellular fragment in PC3 and DU145 cells results in a changed morphology  suggesting a 
role in the transformation of these cells to a different cancer phenotype. PC3 cells which over 
expressed this fragment migrated more than the empty vector cells and they had increased 
proliferation indicating that the ICD may give the cancer cells an advantage. The DU145-ICD 
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cells did not have higher proliferation however they had increased migration. Markers of 
epithelial to mesenchymal plasticity were explored by qRT-PCR due to the changed cellular 
morphology of these cells and these were found to change.  Both cell lines had ICD induced 
increased LEF1 expression that has previously been shown to be regulated by full length 
EphB4. Interestingly, these data suggest that either directly or indirectly the ICD fragment may 
have a role in gene regulation in PCa.   
6.2 DISCUSSION AND FUTURE DIRECTIONS  
 
In Australia, clinically significant aggressive PCa is currently the 2nd leading cause of 
death from cancer for males and it poses a significant burden on our health care system (AIHW, 
2014). PCa is often manageable in early stages; however, treatment options are limited for late-
stage disease. Therefore, it is vital that new options for treatment are developed that can help 
these patients. This study explored EphB4 and ephrin-B2, both proteins that are identified as 
possible targets for new therapies in PCa.  
The receptor tyrosine kinase EphB4 and its ligand ephrin-B2 are important regulators of 
developmental processes through the signalling and repulsive forces they impart when they 
interact (Pitulescu et al., 2010). Ephrin-B2 is the sole physiological ligand of the receptor 
tyrosine kinase EphB4, which is over-expressed in many epithelial cancers, including PCa, and 
is a key regulator of cancer cell survival, invasion and migration of PCa cells (Lee et al., 2005; 
Xia et al., 2005b). There is evidence for a dual role for EphB4 in PCa that depends on the 
presence or absence of its ligand (Rutkowski et al., 2012). EphB4 that is over-expressed leads 
to tumour promotion however when it interacts with ephrin-B2 on the surface of tumour cells, 
this leads to forward signalling into the EphB4 expressing cell and surprisingly tumour 
suppression (Rutkowski et al., 2012). When ephrin-B2, which is expressed primarily on 
endothelial cells, is activated by EphB4 interaction, it increases tumour angiogenesis, a key 
element in supporting tumour growth, (Noren et al., 2004). Therefore, there might be a 
mechanism that regulates the interaction between EphB4 and ephrin-B2 that could lead to 
angiogenic reverse signalling without stimulating tumour suppressive forward signalling. This 
study has identified a potential novel mechanism for regulating the interaction between EphB4 
and ephrin-B2 in PCa through proteolytic cleavage of either ligand or receptor.  
Ephrin-B2 has been previously reported to be first cleaved by metalloproteinases and 
then subsequently γ-secretase which results in a C-terminal fragment of ephrin-B2 
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(Georgakopoulos et al., 2006). This fragment can then phosphorylate Src kinase 
(Georgakopoulos et al., 2006).  My study demonstrated that in vitro, the serine protease KLK4, 
could also be cleaving ephrin-B2, however this cleavage event has not be explored with cell 
lines or animal models. Therefore, there is still the intriguing possibility that KLK4 cleavage 
of ephrin-B2 leads to a γ-secretase dependent C-terminal fragment of ephrin-B2 that may be 
bioactive or can signal and this should be followed up further. 
Interestingly, this cleavage event was only efficient for murine ephrin-B2 because of 
differences in the protein sequences between human and mouse ephrin-B2. It was then 
speculated that KLK4 over-expressed and secreted from PCa cells, could cleave ephrin-B2 
(surface-bound on neighbouring endothelial cells), compromising EphB4-ephrin-B2 
interaction, and thereby potentially modulating the functional impact of both ephrin-B2 itself 
and its receptor EphB4. This however might only be true for murine xenografts where murine 
ephrin-B2 is present that could be cleaved by KLK4. However, as previously reported other 
metalloproteinases might still be able to cleave human ephrin-B2 and this should be explored 
in PCa cells (Georgakopoulos et al., 2006). This could be further tested using protease 
inhibitors to this class of proteases and then looking for the absence of ephrin-B2 cleavage 
fragments in PCa cells using Western analysis. 
This study provides the first evidence of proteolytic regulation of EphB4 in PCa whereby 
the PCa-associated protease KLK4 cleaves the ectodomain of EphB4. Data revealed a fragment 
of ~70 kDa corresponding to the extracellular domain of EphB4 in both lysates and media (data 
not shown) of the 22Rv1–B4 cells. Interestingly, as the 70 kDa fragment was seen in cell lysates 
this indicates that it may still be connected to the cell surface possibly through interaction with 
full length EphB4. This observation however was not followed up in this thesis due to time 
constraints.  The interaction that keeps this fragment connected could be through non-covalent 
interactions of the cysteine rich domain and the fibronectin type III repeats that normally occur 
when EphB4 and other RTKs cluster together for signalling (Nikolov et al., 2013). N-terminal 
sequencing of recombinant EphB4-Fc after incubation with the protease KLK4 showed that 
the primary cleavage site occurred at arginine 508. This occurs in the extracellular domain and 
is proposed to be the site at which the 70 kDa fragment is produced based on molecular weight 
prediction. This however was not formally confirmed in cell lines although it was attempted at 
length throughout the duration of candidature by immunoprecipitation of N-terminal EphB4 
and performing Mass spectrometry on the fragment. Studies have shown that EphB4 on tumour 
cells can stimulate reverse signalling and angiogenesis through ephrin-B2 expressed on 
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neighbouring endothelial cells. This signalling can be stimulated by full length EphB4 on the 
cell membrane, EphB4 that contains only the extracellular domain and has its cytoplasmic 
domain deleted, or recombinant EphB4-Fc proteins which are clustered together (Martiny-
Baron et al., 2004; Noren et al., 2004). However, soluble, monomeric EphB4 extracellular 
domain has been shown to prevent this signalling by blocking binding to ephrin-B2 and 
subsequent reverse signalling (Kertesz et al., 2006). Therefore, the signalling response of 
ephrin-B2 to EphB4 binding is dependent on the level of multimerization of the extracellular 
domain of EphB4. The cleavage of EphB4 from the surface of prostate cancer cells could 
release a 70 kDa extracellular fragment that could either stimulate or inhibit angiogenesis 
depending on the level of multimerization. This study did not explore the EphB4 extracellular 
domain fragment but this could be explored through determining the biological function of the 
released ECD with similar functional studies as where performed in Chapter 5. In addition, 
determining the conformation of this ECD, for example whether it is released as a monomer or 
multimeric form through performing reducing versus non-reducing SDS-PAGE, will be 
invaluable and add further knowledge to the regulation of the EphB4-ephrin-B2 interaction in 
PCa.  
EphB4 is a type 1 transmembrane protein and often, the ICDs of other type 1 
transmembrane proteins, such as Notch receptors, are known to exert biological effects through 
nuclear translocation and the most characterised effect is transcriptional regulation (Blobel et 
al., 2009; Fryer et al., 2002; Higashiyama et al., 2011; Junttila et al., 2005; Lee et al., 2002; 
Lubman et al., 2007; Na et al., 2012; Rio et al., 2000). Likewise, we found that the EphB4 ICD 
is mostly localized in the nucleus and cytoplasm. It has been reported that monoclonal 
antibodies that target the ECD of oncogenic RTK’s such as HER2 are ineffective as often the 
antibody can’t bind as the ECD is not there and the ICD can still signal, independently of ligand 
stimulation, inside the cell (Kho et al., 2013; Panis et al., 2015; Tural et al., 2014). EphB4 
monoclonal antibodies which stimulate EphB4 forward signalling and thus initiate tumour 
suppression are currently being developed as a way to target surface EphB4 in cancer 
(Stephenson et al., 2015). However, cleavage of the ECD of EphB4 might render these 
antibodies ineffective. KLK4 was identified as a mediator of the first cleavage event in this 
study and subsequently initiated the production of the ICD. If this KLK4-inititated cleavage 
event could be blocked this could be another avenue for targeting EphB4 that would circumvent 
the issues with the antibodies. There are inhibitors of KLK4 that are showing promise in 
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blocking KLK4 associated cleavage and these would be invaluable to delineate these cleavage 
events further and could be possible therapeutics (Swedberg et al., 2009).  
This study identified that KLK4 could cleave EphB4; however the KLK4 negative PCa 
cell line PC3 endogenously had the presence of other protease fragments (approximately 62 
kDa) suggesting that other proteases may also cleave EphB4 when KLK4 is not present (Lai et 
al., 2009). EphB4 is also mostly found intracellularly in these cells, it would be interesting to 
further explore which proteases cleave EphB4 in these cells. KLK4 was explored as the model 
protease in this study however this does not discount the possibility of other proteases cleaving 
EphB4 such as MT1-MMP which cleaves EphA2 or MMP-2 which cleaves EphB2 (Lin et al., 
2008; Litterst et al., 2007; Sugiyama et al., 2013). PC3 cells have active MT1-MMP and MMP-
2 so it could be speculated that these proteases could cleave EphB4 in these cells (Nemeth et 
al., 2002). This cleavage product was not explored in this study but subsequent studies where 
various proteases are silenced with siRNA or shRNA or inhibited with small molecules could 
reveal other possible mediators of EphB4 cleavage. The insight gained might produce new 
ways to target EphB4 and the production of the ICD through inhibition of these other cancer-
associated proteases.  
In this study, it was shown that EphB4 is a substrate of γ-secretase through inhibition 
studies, but it should also be noted that it shares common attributes with other γ-secretase 
substrates. Most often γ-secretase targets proteins that have hydrophobic transmembrane 
domains and localise to lipid rafts (Haapasalo et al., 2011; Lal et al., 2011). As a type 1 
transmembrane protein, EphB4 has a single hydrophobic transmembrane domain and our group 
has reported that EphB4 over-expressed in 22Rv1 cells localises to lipid rafts (Rutkowski et 
al., 2012). Other Eph receptors, including EphA4 and EphB2 are also targets of γ-secretase and 
we showed that EphB4 could also be a substrate (Inoue et al., 2009; Litterst et al., 2007).  This 
is an interesting observation as γ-secretase inhibitors are in clinical trials for treatment of solid 
tumours and together with standard chemotherapies are showing promise as cancer therapeutics 
(Krop et al., 2012; Mizuma et al., 2012; Papayannidis et al., 2015; Schott et al., 2013). A Phase 
1 study of one such inhibitior, MK-0752, in advanced solid tumours led to decreased Notch 
signalling and showed some efficacy in patients with glioblastoma and complete response in a 
patient with anaplastic astrocytoma (Krop et al., 2012). It showed low toxicity if given weekly 
however there were side effects, mostly gastrointestinal events such as nausea and diarrhea due 
to impaired notch signalling in the gut (Krop et al., 2012). Recently this oral inhibitor was 
trialled on children with CNS malignancies in which 71 % of patients lowered their expression 
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of the Notch ICD within 8 hrs of treatment (Hoffman et al., 2015).  This inhibitor has also 
shown promise against solid tumours when combined with other agents such as ridaforolimus, 
which is an mTOR inhibitor, however there were increased toxicities with this combined 
therapy (Diaz-Padilla et al., 2015). Another small molecule that targets γ-secretase is 
R04929097, however this molecule is not as successful as single agent therapy (Diaz-Padilla 
et al., 2015). Another promising avenue with γ-secretase inhibition is that it leads to the 
sensitisation of solid tumours to chemotherapies both in vitro and in vivo (Schott et al., 2013). 
I have shown that the EphB4 ICD could be tumour promoting and if we could block the 
formation of this fragment thorough γ-secretase inhibition this could be another method to 
target EphB4 in PCa.       
  The production of nuclear and cytoplasmic ICD forms of other RTK have been linked 
to poor prognosis of cancer patients whereas membrane localisation can indicate a favourable 
prognosis (Thor et al., 2009). Eph Receptors have also been shown to localise to other 
compartments of the cell (Attwood et al., 2011; Gatto et al., 2014; Inoue et al., 2009; Lin et 
al., 2008). Recently EphB2 was shown in breast cancer clinical samples to localise to both the 
membrane and cytoplasm (Husa et al., 2016). Survival analysis revealed that membranous 
EphB2 was an independent prognostic factor for longer survival whilst cytoplasmic localisation 
led to a poor prognosis and shorter survival (Husa et al., 2016).  In clinical samples, EphB4 is 
often found in the cytoplasm, with a study showing that EphB4 positive cells at the invasive 
front had mainly cytoplasmic EphB4 staining in breast cancer (Guijarro-Muñoz et al., 2013; 
Tu et al., 2012; Wu et al., 2004). The above findings that these C-terminal EphB4 ICDs were 
cytoplasmic and nuclear are exciting and it would be interesting to see if these ICDs could be 
found in PCa clinical samples, as well as whether they correlate with prognosis. However, more 
discriminating markers/antibodies that detect the ICD of EphB4 but not full length EphB4 are 
needed to facilitate this. To determine if these cleavage fragments of EphB4 are firstly present 
in PCa clinical samples and secondly have prognostic value, Western analysis of lysates from 
primary tumours could be performed with both C-terminal and N-terminal antibodies. Recently 
a study into EphA2 cleavage by MT1-MMP in cutaneous SCC showed that IHC  of clinical 
samples of these tumours had lower levels of  the N-terminus of EphA2 than the C-terminus 
suggesting that cleavage had occurred in these samples (Tatsukawa et al., 2016). This was 
confirmed with Western analysis of lysates and revealed C-terminal fragments of EphA2 
(Tatsukawa et al., 2016). An in situ proximity ligation assay (PLA) was performed on these 
samples which revealed that MT1-MMP and EphA2 were co-localised (Tatsukawa et al., 
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2016). These methods could be employed to determine the presence of EphB4 cleavage 
fragments and distinguish between full length EphB4 and the ICD fragment in clinical samples 
and if cleavage fragments of EphB4 are present, histopathological data on the samples could 
be explored to determine whether the presence of fragments correlates with higher and more 
aggressive stages of PCa.  
The exogenous overexpression of ICD cells resulted in increased LEF1, and it can be 
speculated that this is due to the ICD translocating to the nucleus. It can be further speculated 
that the ICD is either binding to transcription factors which then increase the above genes or 
directly bind and influence the expression of these genes uniquely, however this was not 
experimentally determined. CHIP experiments, as performed by Mertens-Walker et al. 2015, 
could be performed to determine whether the ICD of EphB4 can interact with DNA and 
whether there are other genes, it could be influencing. However, this would prove difficult as 
in CHIP assays antibodies are employed to immunoprecipitate the DNA- protein complexes 
and therefore it would prove difficult to distinguish between full length EphB4 or ICD 
fragments binding to the DNA.  Another way to determine whether the ICD is influencing 
genes globally is to perform microarray or RNA-seq analysis on the ICD overexpressing cells 
versus the overexpression of full length EphB4 to discover differentially expressed genes in 
the ICD cells.  
Ivermectin treatment of ICD cells qualitatively lowered the amount of the ICD fragment 
however; this was not quantified and could be by taking sequential confocal Z-stack images of 
the nuclei of these cells and counting the individual fluorescent nuclear foci. To prove that 
nuclear transport of the EphB4 ICD is through importin transport the NLS of the ICD fragment 
could be mutated as per Mertens-Walker et al. 2015  and\ if nuclear transport is importin 
mediated  this will stop nuclear transport of the ICD fragment. 
In conclusion, these studies showed that both ephrin-B2 and EphB4 can be regulated by 
proteases in prostate cancer cells. In the case of ephrin-B2 it was cleaved in its extracellular 
domains by KLK4 however, this cleavage was only efficient for murine ephrin-B2 and not 
human ephrin-B2. EphB4 is also cleaved by KLK4 in prostate cancer, which leads to a second 
cleavage event by the intramembrane protease, γ-secretase, to produce a bioactive cleavage 
fragment. Ectopic expression of the EphB4 ICD increased proliferation and migration as well 
as transcription of markers suggestive of EMT/MET. Thus, EphB4 ICD translocation from the 
plasma membrane to the nucleus likely regulates transcription, thus enhancing tumour 
generation and progression. Ultimately, these data add significantly to the role of EphB4 and 
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ephrin-B2 in PCa through regulation by proteases and this could lead to a better understanding 
of both EphB4 and ephrin-B2 signalling and allowing them to be more effectively targeted in 
cancer.  
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